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Cancer is one of the leading causes of death worldwide. Prostate cancer 
(PC) is the most common male cancer in Western Countries, and second most 
common cause of cancer death in men. The survival rate of cancer patients is 
substantially increased when they are diagnosed at an early stage. There are several 
prostate tumor markers such as human prostatic acid phosphatase, glutathione S-
transferase П, or α-methylacyl coenzyme A racemase. However, prostate specific 
antigen (PSA) is currently considered the best cancer marker available in clinical 
medicine. PSA is protein produced by the cells of prostate gland, is found in the 
blood of healthy men in very low quantities, but the levels of PSA are elevated in 
the presence of prostate cancer or other prostate disorders. For the detection of 
higher PSA levels, antibodies are routinely used. However, the production of 
antibodies requires animals, which are subjected to a number of invasive 
procedures. On the other hand chemically synthesized aptamers with specificity and 
affinity equal to those of antibodies can be an alternative approach how to detect 
PSA. Aptamers offers several advantages over antibodies, including more flexibility 
to different assay formats, which allows them to address the ever-increasing 
requirements of analytical applications. Several facets of aptamers such as their 
stability, ease of immobilization and labelling contribute to this enhanced flexibility 
and present them as attractive candidates for diagnostic and therapeutic 
applications. 
The main objective of the work described in this thesis is the development 
of aptamers against PSA for their potential applications in diagnostics and 
therapeutics. To achieve this objective, several sub objectives such as the 
characterization of PSA, evaluation of different immobilization strategies, 
preparation of oligonucleotide library and single-stranded DNA (ssDNA) were 
performed.  
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This thesis is divided in seven separate chapters. A general introduction 
covering the different topics of the thesis is presented in Chapter 1. Chapter 2 
details the characterization of PSA and the evaluation of different immobilization 
strategies, whilst Chapter 3 discusses the preparation of the oligonucleotide library 
and Chapter 4 compares different methods for generation of ssDNA for use in 
SELEX. Chapters 5 and 6 comprise the studies carried out for the development of 
DNA and RNA based aptamers against PSA.   
In more detail, Chapter 1 provides a general introduction to the state of the 
art of the research area.  This chapter sets out the objectives of the thesis and lists 
the main contributions obtained with the achievement of objectives. 
The selection of aptamers depends highly on the target properties, 
therefore, in Chapter 2, the characterization of PSA obtained from seminal fluid 
was performed using techniques such as SDS-PAGE and Mass spectrometry. 
Target immobilization is one of the efficient partitioning methods used for the 
separation of target bound and non-bound nucleic acids in SELEX process. 
Different immobilization strategies were thus investigated in order to determine the 
best one for immobilization of PSA. Two promising strategies including (i) amine 
coupling using carboxyl modified beads and (ii) the use of the bioaffinity biotin – 
streptavidin system were demonstrated to be optimal for PSA immobilization. 
Chapter 3 focuses on the preparation of an oligonucleotide random library. 
As the oligonucleotide random library consists of a multitude of ssDNA, this 
heterogeneity can cause non-uniform amplification during the polymerase chain 
reaction (PCR). Therefore, a correct choice of library and efficient PCR 
amplification of this selected library can contribute to the success of aptamer 
selection. PCR optimisation of three different libraries was carried out to ensure 
high purity and yield of the amplified libraries. The composition of random libraries 
changes during the SELEX process, and another PCR optimisation of the enriched 
libraries was thus carried out, and it was observed that the addition of several 
additives (dimethyl sulphoxide (DMSO), Betaine, Single Stranded Binding 
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protein) with optimised PCR protocols could prevent the production of undesired 
nonspecific products.  
In Chapter 4, the comparison of different techniques generally used in the 
preparation of ssDNA was carried out. The generation of ss-DNA is a critical step 
in SELEX as the purity and yield can have a significant impact on the successful 
evolution throughout the SELEX process. Several techniques for the generation of 
ss-DNA for SELEX were compared, including the previously reported methods of 
asymmetric PCR, lambda exonuclease digestion and magnetic separation, as well as 
new methods such as the use of T7 Gene 6 exonuclease and the combination of 
asymmetric PCR and exonuclease digestion. The efficiency of each system for the 
generation of ss-DNA was quantitatively evaluated using an enzyme linked 
oligonucleotide assay (ELONA) and the quality of the PCR product was assessed 
using agarose gel electrophoresis. According to the results obtained, all reported 
methods can be used for the generation of ss-DNA, once their disadvantages are 
clearly taken into consideration. Asymmetric PCR followed by T7 Exonuclease 
digestion was clearly demonstrated to have the highest efficiency, achieving a final 
yield of ss-DNA around 85%. Furthermore, we have demonstrated that the yield of 
ss-DNA obtained from unpurified PCR product is comparable to that obtained 
from purified PCR product, overcoming a loss of ds-DNA during the purification 
step, and thus decreasing the time required for each SELEX cycle.  
In Chapter 5, the selection process of DNA based aptamers against PSA is 
described. Variations of protocols were used to identify DNA aptamers, differing in 
the type of partitioning methodology, generation of ss-DNA, starting random 
library and buffer compositions. Several aptamer candidates were selected and 
analysed for their ability to bind to PSA. Two DNA aptamers (I1, I4) with 
dissociation constants in the µM range showed the lowest cross reactivity with 
control proteins such as BSA or streptavidin. For the evaluation of the functionality 
of aptamer I1, competitive Reporter Linked Aptamer Assay (RLAA) with different 
concentrations of PSA was used, achieving the limit of detection 268 nM. 
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Nevertheless, the low specificity of selected aptamer does not permit its use for 
clinical diagnostics. 
Another possibility to select an aptamer against PSA was the selection of an 
RNA aptamer. The variety of conformations achieved by RNA molecules is 
theoretically more diverse, thus increasing the probability of finding an aptamer 
against PSA. RNA aptamers with a dissociation constant in the nM range were 
selected using an automated SELEX process. Moreover, the RNA aptamers were 
demonstrated to be specific and selective. The potential use of the selected 
aptamers for diagnostics was studied using apta-PCR, achieving a limit of detection 
of 11 nM for aptamer S2, demonstrating an improvement on the limit of detection 
achieved by the previously published DNA aptamer for PSA. For the future use of 
selected RNA aptamers in therapeutics, the stability of selected aptamers as well as 
potential effect on the activity of PSA was studied, indicating a high stability and 
moderate inhibitory effect of selected 2´F modified RNA aptamers.  
Chapter 7 presents the main conclusions of the thesis, the principal 
contributions and some future research lines for the continuation of this research. 
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El cáncer es una de las principales causas de muerte en todo el mundo. El 
cáncer de próstata (PC) es el cáncer masculino más común en los países 
occidentales, y la segunda causa de muerte  por cáncer en los hombres. La tasa de 
supervivencia de pacientes con cáncer aumenta sustancialmente cuando se 
diagnostica en una etapa temprana. Hay varios marcadores tumorales de próstata 
tales como la fosfatasa ácida prostática humana, glutatión S-transferasa П, o α-
metilacil coenzima A racemasa, entre otros. Sin embargo, el antígeno prostático 
específico (PSA) es actualmente considerado el mejor marcador del cáncer 
disponible en medicina clínica. PSA es una proteína producida por las células de la 
glándula de la próstata que se encuentra en la sangre de los hombres sanos en 
cantidades muy bajas, pero los niveles se elevan en presencia de cáncer de próstata 
u otros trastornos de la próstata. Para la detección de niveles de PSA se utilizan 
habitualmente anticuerpos. Sin embargo, la producción de anticuerpos requiere 
animales, que están sometidos a una serie de procedimientos invasivos. Por otro 
lado, los aptámeros sintetizados químicamente con especificidad y afinidad iguales a 
los de los anticuerpos pueden ser la alternativa para la detección de PSA. Varias 
características de los aptámeros, tales como la estabilidad, facilidad de 
inmovilización y marcaje, hacen de ellos  candidatos atractivos para aplicaciones 
con fines diagnósticos y terapéuticos. Además, su gran flexibilidad les permite su 
uso en diferentes formatos de ensayo para aplicaciones analíticas.   
El objetivo principal de este trabajo es el desarrollo de aptámeros contra 
PSA para sus posibles aplicaciones en el área terapéutica y de diagnóstico precoz. 
Para completar estos objetivos, varios subobjetivos, como la caracterización del 
PSA, la evaluación de diferentes estrategias de inmovilización, la optimización del 
proceso de amplificación de ADN aleatorio y la comparación de diferentes técnicas 
para la preparación de la cadena sencilla de ADN se han propuesto. 
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Esta tesis se divide en siete capítulos. Una introducción general sobre los 
diferentes temas de la tesis se presenta en el Capítulo 1. El Capítulo 2 está 
relacionado con la caracterización de PSA y la evaluación de diferentes estrategias 
para su inmovilización, mientras que el Capítulo 3 trata de la optimización de la 
amplificación de ADN aleatorio. En el Capítulo 4, se presenta una comparación de 
diversas técnicas para la generación de ADN de cadena sencilla (csADN) para su 
posterior uso en SELEX. Finalmente, los Capítulos 5 y 6 versan sobre la selección 
de aptámeros de ADN y ARN contra el PSA. En último lugar se presentan las 
conclusiones generales. 
El en Capítulo 1 se presenta introducción general, en el que se acotan, 
tanto el ámbito como el alcance del campo de investigación.  En este capítulo, se 
plantean los objetivos de la tesis y se enumeran las principales aportaciones 
obtenidos con la consecución de los objetivos.  
La selección de aptámeros depende en gran medida de las propiedades de 
la diana molecular, por lo tanto en el Capítulo 2, se ha realizado la caracterización 
del PSA utilizando técnicas como la electroforesis en gel de poliacrilamida con 
dodecilsulfato sódico (SDS-PAGE) y la espectrometría de masas. La separación de 
los ácidos nucleicos afines con la diana del resto de la librería es uno de los puntos 
críticos durante la selección in vitro de los aptámeros. En este contexto, la 
inmovilización de dicha diana es una de las metodologías de partición más eficaces 
y generalmente utilizadas. La extrapolación de las estrategias de inmovilización es 
compleja y por lo general resulta ineficaz principalmente debido a las características 
y propiedades específicas de cada diana. Por lo tanto, diferentes estrategias de 
inmovilización  han sido evaluadas con el fin de determinar la mejor para la 
inmovilización del PSA. Dos estrategias prometedoras incluyendo (i) el 
acoplamiento peptídico con partículas magnéticas modificadas  con carbodiimida 
(ii) y la técnica basada en el uso de la diana biotinilada con las partículas magnéticas 
modificadas con estreptavidina mostraron ser óptimas para la inmovilización de 
PSA.  
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El Capítulo 3 se centra en la preparación de la librería aleatoria para su 
posterior uso en el SELEX. Las librerías aleatorias constan de una multitud de 
oligonucleotidos, y esta heterogeneidad puede causar una amplificación no 
uniforme durante la reacción en cadena de la polimerasa (Polymerase Chain 
Reaction - PCR). Por lo tanto, una elección correcta de la librería y su posterior 
optimización de las condiciones de amplificación puede contribuir al éxito de la 
selección del aptámero. Se determinaron las condiciones óptimas para la 
amplificación de tres librerías diferentes, garantizando la pureza de las librerías 
amplificadas. La composición de las librerías cambia durante el proceso de SELEX, 
con lo cual suele ser necesario una optimización adicional de la PCR de las librerías 
enriquecidas. La adición de varias sustancias (dimethyl sulfoxido (DMSO), 
betaina, proteína unida a simple cadena de ADN (SSB) con los protocolos 
optimizados disminuyó la producción de productos no deseados.  
En el Capítulo 4, se lleva a cabo la comparación de diferentes técnicas más 
utilizadas para la preparación de ADN de cadena sencilla. La generación de csADN 
es un paso crítico en SELEX porque la pureza y el rendimiento de diferentes 
técnicas pueden tener un impacto significativo para el éxito del proceso. Varias 
técnicas previamente usadas durante la selección in vitro, incluyendo PCR asimétrica, 
el uso de lambda exonucleasa y separación magnética, así como nuevos métodos 
tales como el uso de T7 Gene 6 exonucleasa y la combinación de la PCR asimétrica 
con la digestión del enzima han sido evaluados. La eficacia de cada sistema de 
preparación de csADN fue determinada cuantitativamente utilizando un ensayo 
especifíco para los oligonucleótidos (Enzyme Linked OligoNucleotide Assay - 
ELONA) y la calidad del csADN obtenido se evaluó mediante electroforesis en gel 
de agarosa. Según los resultados obtenidos, todos los métodos pueden ser utilizados 
para la generación de csADN, una vez tenidos en cuenta sus pros y contras. La 
PCR asimétrica combinada con la digestión con T7 Gene 6 exonucleasa demostró 
tener la mayor eficiencia, logrando rendimientos alrededor del 85%.  
En el Capítulo 5 se describe el proceso de selección de aptámeros de ADN 
contra PSA. Se utilizaron varios protocolos para identificar dichos aptámeros , 
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usando diferentes técnicas de partición, de generación de ADN de cadena sencilla, 
diferentes librerías y composición del tampón. Varios candidatos de aptámeros 
fueron seleccionados y analizados para determinar su afinidad a PSA. Dos 
aptámeros de ADN (I1, I4) con constantes de disociación en el rango µM, 
mostraron la menor interferencia con las proteínas que sirvieron como control 
(BSA y estreptavidina).  La funcionalidad del aptamero I1 fue evaluada mediante un 
ensayo aptamérico específico (Reporter Linked Aptamer Assay - RLAA), 
obteniendo un límite de detección de 268 nM, Sin embargo, el aptámero I1 con 
baja afinidad y especificidad no cumple los requisitos para el uso como elemento de 
reconocimiento molecular en la diagnóstica clínica. 
Otra posibilidad para seleccionar el aptámero contra el PSA consiste en la 
selección de aptámeros de ARN y se describe en el Capítulo 6. La variedad de 
conformaciones alcanzadas por las moléculas de ARN es mayor que las de ADN, 
por lo que existe una probabilidad más alta de seleccionar un aptámero de ARN 
contra el PSA. Diferentes aptámeros de ARN con una constante de disociación en 
el rango nM fueron seleccionados mediante un proceso automatizado de SELEX. 
Además, los aptámeros finales fueron capaces de distinguir entre otras proteínas, 
tales como estreptavidina o BSA. La utilidad de los aptámeros seleccionados de 
ARN en contra de PSA se validó también para su uso potencial en aplicaciones 
diagnósticas utilizando apta-PCR, obteniendo un límite de detección de alrededor 
de 11 nM para el aptámero S2, mejorando el límite de detección alcanzado por el 
aptámero de ADN previamente publicado. Para su uso potencial en la terapéutica, 
la estabilidad de los aptámeros seleccionados, así como los posibles efectos sobre la 
actividad de PSA se han estudiado, indicando una alta estabilidad y un efecto 
ligeramente inhibidor de los aptámeros de ARN modificados. 
En el Capítulo 7 se presentan las conclusiones principales de la tesis 
doctoral, las aportaciones realizadas y algunas líneas de investigación futuras para la 
continuación de este trabajo de investigación.  
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At the beginning of the nineties, three different laboratories [1-3] reported 
their results on the development of an in vitro selection and amplification technique 
for the isolation of specific nucleic acids able to bind to target molecules with high 
affinity and specificity.  The technique was coined SELEX (Systematic Evolution of 
Ligands by EXponentional enrichment) and the resulting oligonucleotides were 
named aptamers, taken from the latin "aptus", to fit. Aptamers are typically 
composed of RNA (RNA aptamers), single-stranded DNA (DNA aptamers) or a 
combination of both with unnatural nucleotides, and range in size from 
approximately 6 to 40 kDa. Due to their three-dimensional structure, characterized 
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by stems, loops, hairpins, bulges, triplexes and quadruplexes, aptamers can bind to a 
wide variety of targets from single molecules to complex target mixtures or a whole 
organism. They bind selectively to their target due to structural compatibility, 
electrostatic and van der Waals interactions, hydrogen bonding, or a combination 
of these effects [4], with dissociation constants (Kd) typically in the low nanomolar 
range, comparable to those observed for monoclonal antibodies. Aptamers are 
more flexible to different assay formats than their antibody counterparts, allowing 
them to address the ever-increasing requirements of analytical applications. Several 
facets of aptamers such as stability, ease of immobilization and labelling contribute 
to this enhanced flexibility and present them as very attractive candidates for 
diagnostic and therapeutic applications. However, aptamers do have drawbacks - 
each aptamer behaves differently and requires a specific set of conditions for 
optimal operation. Furthermore, there are a limited number of aptamers available, 
although an increasing number of aptamers are being reported in the literature.   
 
 
1.1.2 SELEX process 
 
  A typical SELEX procedure begins with a nucleic acid library, generally 
consisting of about 1013 - 1015 different sequences [5], containing a random region 
flanked by two primers used for amplification (Figure 1.1). A randomized single 
stranded DNA (ss-DNA) or RNA pool is incubated directly with the target 
molecule, which is immobilized on a matrix material or is free in solution. 
Following incubation, the bound complexes are separated from the unbound and 
weakly bound oligonucleotides. Target bound oligonucleotides are eluted and 
amplified by polymerase chain reaction (PCR) in the case of DNA or reverse 
transcription PCR (RT-PCR) in the case of RNA. From the resulting double 
stranded DNA (ds-DNA), ss-DNA or transcribed RNA is generated, and this 
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enriched pool of selected oligonucleotides is used in the next SELEX round. 
Generally, 8-15 rounds of SELEX are required in order to obtain a pool of aptamer 
candidates with the highest binding affinity for the target. When affinity saturation 
of the enriched pool of oligonucleotides is achieved, aptamer candidates are cloned 
and sequenced, and individual sequences investigated for their ability to bind to the 
target.   
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  A typical SELEX library consists of a multitude of oligonucleotides 
comprising a central random region of typically 30-60 nt flanked by primer 
sequences of around 20 nt.  In classical SELEX experiments DNA or RNA 
libraries are usually used. DNA has no 2´hydroxyl group, which is highly reactive, 
and accordingly is much more stable to hydrolysis under conditions of higher than 
neutral pH and elevated temperature [6-7].  DNA libraries are thus often used for 
applications requiring increased aptamer stability whilst RNA libraries yield 
aptamers with higher binding affinities due to the ability of RNA to take on a wider 
variety of conformations than DNA [8],  but this is not universally true and indeed 
there is evidence that ssDNA aptamers do not differ in affinity and specificity from 
RNA aptamers [9]. 
  With the goal of increasing the stability of oligonucleotides, modified 
libraries are often used in the selection process. Modifications are introduced into 
the 2´position of the pyrimidines, using 2´-aminopyrimidines [10-11], 
2´fluoropyrimidines [12-13], 2´O-methyl nucleotides [14-15], position 5 of 
pyrimidines [16-17], and 4 of pyrimidines using  thio UTP and CTP [18], amongst 
others. A detailed description of the different modifications can be found in several 
reviews [7, 19-21]. In some experiments structurally constrained libraries are used in 
selection.  In this case, the random region is flanked by fixed sequences able to 
form a particular secondary structure such as a hairpin, G-quartet or pseudoknot [1, 
22-24]. 
  The libraries in genomic SELEX are derived from the genome of the 
organism of interest. To create such libraries, genomic DNA is excised into short 
fragments and appended with the fixed sequences. In all other aspects, genomic 
SELEX is similar to conventional SELEX. This variant of SELEX is used for the 
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identification of important nucleic-acid-protein interactions within any organism 
[25-26]. 
  A variation of the SELEX protocol called tailored-SELEX allows isolation 
of aptamers free of fixed regions with desired properties [27]. In this case, a library 
with 4 or 6 nucleotides on both sides of the random region is used in the SELEX 
process. After each selection round, the primer binding sequences are ligated to the 
library using special adapters and removed before the next round. A very similar 
technique called primer-free genomic SELEX can also avoid the primers’ influence on 
aptamer selection. This method is used to solve a specific problem with genomic 
SELEX, where fixed regions of the library often form complexes with the central 
genomic fragments. Using this method, fixed regions are removed from the 
genomic library before incubation with the target and are subsequently regenerated 
to allow amplification of the selected genomic fragments. An important point in the 
regeneration of primer-annealing sequences is to use thermal cycles of 
hybridization-extension, using sequences from unselected pools as templates [28]. 
More recently, there have been reports of a minimal primer and primer-free SELEX 
protocols for screening of aptamers from random DNA libraries [29-30]. 
 
 
1.1.4 Target molecules  
 
 The evidence that aptamers can be generated against small ions, such as Zn2+ 
[31], Ni2+ [32], to nucleotides such as ATP [33-34], oligopeptides [35], and large 
glycoproteins such CD4 [36], with the size range 65Da – 150kDa, demonstrates 
their tremendous flexibility. The smallest molecular target to date is ethanolamine 
[37], and furthermore, the classes of targets are diverse, including organic dyes [3, 
38], neutral disaccharides [39],  antibiotics [40], neurotransmitters [41], pigments [42] 
and vitamins [43].  
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 However, SELEX has been most often exploited for the generation of 
aptamers against proteins [44].  When the aptamer-binding sites (aptatopes) on 
large molecules are mapped, it is usually found that they are coincident, even if the 
aptamers fall into unrelated sequence families, signifying that only a small 
proportion of the surface of the macromolecule is accessible to aptamers - most 
probably regions of high solvent exposure where positively charged residues 
provide a degree of electrostatic steerage towards the aptatope [5].  
           SELEX has also been applied towards complex cellular targets – cell 
SELEX [45-51]. In the case of cancer cells, aptamers are able to penetrate tumours 
rapidly and can be cleared quickly from the blood due to their small size (10-
25kDa), making them an effective tool for molecular medicine, biomarker 
discovery and cancer biology. However, due to the abundance of targets on cell 
membranes, it is often impossible to know the precise target of an aptamer prior to 
its´ selection and often aptamers are selected against purified cell surface markers 
[47, 52]. Moreover in every cell preparation dead cells are also present [53], which 
cannot be removed by traditional methods like washing or centrifugation and thus 
may contribute to an inefficient selection process [54]. The use of FACS 
(fluorescence-activated cell sorting) in the selection step facilitates selection of 
aptamers with the  simultaneous removal of selection-hampering dead cells [55].  
 The diversity of targets that have been already used in SELEX indicates that 
aptamers can be selected for virtually any target. However, there are some general 
prerequisites for a potential target to successfully select aptamers of high affinity. 
Selected target molecules should be present in sufficient amount and be of high 
purity. The purity of protein is usually checked by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Mass Spectrometry, which 
measures the mass to charge ratio of charged particles, and is generally used to 
determine the elemental composition of a protein sample.  
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 Target immobilization is one of the efficient partitioning methods used for 
separation of target bound and non-bound nucleic acids in SELEX, and can be 
accomplished by a number of different approaches including physical, covalent, and 
bioaffinity immobilization [56]. A commonly used method is affinity 
chromatography with immobilization of the target on a sepharose or agarose 
column [31, 35, 57-58]. The use of magnetic beads methodology revolutionized 
separation methodologies in the 1980s and different types of magnetic beads have 
used in SELEX, selecting aptamers with high specificity and affinity [59-61].   
 
 
1.1.5 Preparation of single-stranded DNA 
 
 The preparation of single-stranded DNA is one of the critical steps during  
DNA based SELEX process. One of the most widely used methods is magnetic 
separation with streptavidin-coated beads and biotinylated forward or reverse 
primers [62-64]. In this technique, immobilization of biotinylated dsDNA on the 
surface of streptavidin coated beads, followed by denaturation of the dsDNA by 
alkaline treatment or high temperature is used. An alternative method used for the 
generation of ssDNA exploits a urea-polyacrylamide gel, where PCR is performed 
with a specific long primer to produce strands of different lengths, followed by 
strand separation with denaturing gel electrophoresis [37, 61, 65-67]. Another 
possibility is to perform asymmetric PCR, which is used to amplify one strand of 
the original DNA more than the other by using an unequal molar ratio of forward 
and reverse primers. After asymmetric PCR, the PCR products are separated by gel 
electrophoresis and the ssDNA extracted and purified, representing a lengthy 
procedure, which is also known to suffer in terms of efficiency [68-69]. Another 
option for the preparation of single stranded DNA is the use of enzymes such as 
T7 Gene 6 exonuclease [70-71] and Lambda exonuclease via modified primers [72-
UNIVERSITAT ROVIRA I VIRGILI 
SELECTION OF APTAMERS AGAINST PROSTATE SPECIFIC ANTIGEN FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 
Markéta Svobodová 
DL: T. 888-2012 
 
Introduction and Objective 
8 
75]. T7 Gene 6 exonuclease hydrolyzes one strand of DNA non-processively in the 
5´ to 3´ direction, while the second strand is protected against the hydrolytic 
activity of the enzyme with several phosphorothioates at its 5´end, whilst the 
lambda exonuclease selectively digests the phosphorylated strand of double 
stranded DNA and has greatly reduced activity on single stranded DNA and non-
phosphorylated DNA.  
 
 
1.1.6 Alternative SELEX strategies 
 
 There are a variety of techniques available for the isolation of aptamers and 
the choice of technique is largely dependent on the target molecule and the 
application and there is no definitive pattern to predict which method is preferred, 
but it is clear that more efficient methods of partitioning target bound nucleic acids 
are being reported, leading to higher affinity aptamers. 
 
 
1.1.6.1 Photo SELEX 
 
 In photochemical SELEX (Photo-SELEX), modified oligonucleotides are 
capable of photocross-linking the target molecule. The method is based on the 
incorporation of a modified nucleotide that can be activated by absorption of light, 
in place of a native base in RNA/DNA libraries. This method is based on the 
strength of covalent bonding rather than affinity, therefore the specificity of the 
aptamer can be higher, but the false positives obtained with this method is also 
higher, requiring the cross-linking conditions to be optimized to ensure the 
screening validity. An example of the type of modified oligonucleotide used is that 
of 5-bromo-2´-deoxyuridine (5-Br-dUTP) or 5-iodouracil (5-IU) used as a 
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substituent for TTP [76].  The modified oligonucleotide absorbs UV light in the 
310 nm range, where nucleic acids and proteins absorb very weakly, resulting in an 
excited singlet that specifically cross-links with the target's aromatic or sulphur-
containing amino acids, when in close proximity [77-79]. This technique was first 
used in 1995 by Jensen [80], who obtained RNA aptamers for human 
immunodeficiency virus type 1 Rev protein using 5-IU. Later, with a random 61-
mer oligonucleotide library, in which 5-Br-dUTP replaced thymidine, aptamers 
against the recombinant human basic fibroblast growth factor 155 (bFGF155) were 
selected [81]. The kinetic analysis of photoaptamer-protein photocrosslinking 
reactions was studied by Koch and a mathematical model for this was presented 
[82]. The model is based on the hypothesis that specific binding of aptamer and 
target followed by laser excitation can lead to either an aptamer/target complex 
formed with covalent bonds or irreversible photo damage to the aptamer. This 
model was used to characterize the photocross-linking between three 
photoaptamers and their targets and the results obtained from cross-linking data 
were confirmed by other independent measurements [83]. PhotoSELEX results in 
high affinity and highly specific aptamers by improving the separation method; 
however, a major limitation is that low molecular mass molecules that do not have 




1.1.6.2 Toggle SELEX  
 
 Toggle-SELEX allows isolation of aptamers with a wide range of specificities 
by selecting against related targets in alternating cycles [84]. Alternation of the 
target between homologous proteins of different species ensures that aptamers will 
bind to both proteins, most likely to domains conserved between the two proteins 
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[85]. Aptamers that bind both human and porcine thrombin were selected with this 
method [86]. The same method with another name „target switching“ was used in 
order to obtain aptamers called „oligobodies“ against ERK2 [87] and protein 
phosphatase 2A [88].     
 
 
1.1.6.3 Capillary electrophoresis based SELEX 
 
  Methods for aptamer selection that exploit capillary electrophoresis report a 
considerable improvement in the separation of bound and unbound nucleic acids, 
only requiring a few cycles for the isolation of very high affinity aptamers. Capillary 
electrophoresis SELEX (CE-SELEX) involves the selection of binding 
oligonucleotides based on a mobility shift due to complex formation.  Sequences 
bound to the target move through the capillary electrophoresis at a velocity 
different from those not bound to the target, allowing separation of complex 
bound sequences from the rest of the library. The main advantages of CE-SELEX 
are the ability to perform the selection in free solution, reduction of non-specific 
binders, and increased capability of separation. Using CE-SELEX, high affinity 
aptamers against IgE and neuropeptide Y were selected in just a few selection 
rounds [89-91]. Two aptamers with the same sequence were selected against 
cytotoxin ricin using  both affinity chromatography SELEX and CE-SELEX, but 
with markedly shortened selection time in the case of the latter [92]. The 
determination of kinetic and thermodynamic constants can be achieved using an 
efficient selection process based on equilibrium capillary electrophoresis of 
equilibrium mixtures (ECEEM). Using this method an aptamer binding MutS 
protein was selected with a Kd of 15 nM in just three rounds of selection [93]. 
Capillary electrophoresis has also been used in a format called non-equilibrium 
capillary electrophoresis of equilibrium mixtures (NECEEM). NECEEM also 
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enables the "selection" of aptamers with nanomolar Kd values in a few rounds of 
selection [94-96], and has the same advantages as ECEEM for the selection of 
aptamers with pre-defined kinetic parameters [8]. 
 
 
1.1.6.4 Non – SELEX 
 
  Non – SELEX is another method that has been used for aptamer screening. 
This method is based on a process that involves repetitive steps of partitioning with 
no amplification step. A high affinity aptamer for h-ras was obtained using Non-
SELEX with NECEEM as a separation step [97]. The advantage of this method is 
its potential applicability to non-amplifiable libraries, such as those of DNA tagged 




 The MonoLex selection protocol demonstrated that a one-cycle approach 
can isolate ligands with high affinity [98]. The aptamers are isolated in one single 
cycle by exponential amplification after the separation of bound oligonucleotides by 
affinity chromatography. To obtain aptamers with high affinity, desorption of 
oligonucleotides from individual column segments derived from a physical 
disintegration of the affinity column is performed. During the selection process the 
target bound oligonucleotides are sorted along the column with respect to their 
affinity, while low binders are eluted from the column during thorough washing. 
Due to the use of affinity sorting, aptamers amplified from a part of a single 
column show a similar affinity but differ in the binding domain of the target 
molecule. These pools are very similar to those of polyclonal antiserum.  
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1.1.7 Advantages of Aptamers 
 
 
Aptamers are  identified through an in vitro process of selection that 
does not depend on animals, and thus toxins as well as molecules that do not 
elicit a good immune response, can be used to generate high-affinity aptamers. 
Selection conditions and kinetic parameters can be manipulated and as a result 
the properties of aptamers can be changed on demand. Aptamers are produced 
by chemical synthesis with high accuracy and reproducibility and of high purity 
with little or no batch-to batch- variations expected. Reporter molecules such as 
a fluorescein, biotin, etc. can be attached to aptamers at precise locations 
without loss of binding affinities. Aptamers can undergo denaturation, but the 
process is reversible, and aptamers can be regenerated easily within minutes, 
and can also be easily transported at ambient temperature and are inherently 
stable for long-term storage [99]. Aptamers are highly selective in nature and 
designed to have high affinity for a particular target molecule or specific 
isoform of a target protein and can even distinguish between different 
conformational states of the same protein [100-101]. One of the not-yet-
understood features of non-natural aptamers is their apparent lack of 
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Antibodies contribute to a wide range of applications based on molecular 
recognition, and are widely used in a range of different clinical diagnostic assays and 
techniques. However, there are limitations associated with antibodies. The 
production of antibodies exploits the use of animals via induction of an immune 
response, and thus there can be difficulties in obtaining antibodies against targets 
that are similar in structure to endogenous proteins, or, alternatively, against 
compounds that are toxic for the animal host. The generation of polyclonal 
antibodies tends to vary from batch to batch and while monoclonal antibodies 
overcome this problem, they are expensive and laborious to produce. Additionally, 
antibodies can be sensitive to non-physiological conditions and harsh storage 
environments, and, furthermore, antibody affinity can be affected upon conjugation 
to reporter molecules and the kinetics of antibody-antigen interaction cannot be 
changed on demand  [99].   
The application of aptamers as biocomponents in biosensors offers a 
multitude of advantages over their antibody counterparts. Due to their nucleic acid 
nature, aptamers can take advantage of a plethora of surface chemistries, assay 
formats, technology platforms (e.g. microarrays) and linkage chemistries that have 
been developed for genosensors, highlighting their enhanced flexibility, as they can 
effectively perform as both antibodies and nucleic acids. A considerable number of 
comprehensive reviews regarding the application of aptamers in diagnostics are 
available [58, 99, 105-107].  
The first use of aptamers in an enzyme-linked immunosorbent assay 
(ELISA)-like assay, referred to as ELONA (enzyme-linked oligonucleotide assay), 
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or more correctly RLAA (reporter-linked aptamer assay) was reported by Drolet 
[108]. This work highlighted the possibility of aptamers to compete with antibodies 
in bioanalysis, paving the way for a new approach for detection. In simple formats, 
aptamers have been exploited in RLAA in much the same way as antibodies in 
ELISA [109]. Different RLAA sandwich formats were studied [50, 110], elucidating 
the critical parameters for optimal aptamer performance and highlighting that the 
conditions for each aptamer assay must be individually optimized and, unlike 
ELISA, that no universal optimal operating parameters exist. The applicability of 
aptamers in displacement assay highlighted the flexibility to different assay formats 
of aptamers, and has been exploited in a aplethora of formats since the first report 
[111].  
The concept of integrating the sensitivity of nuleic acid amplification with 
the selectivity of aptamers (apta-PCR) has been described, where different 
sandwich formats and amplification methods have been reported producing an 
impressive signal enhancement with considerably lower detection limits [112-115].   
An assay format that exhibits the unique properties possessed by aptamers 
is that of the molecular aptamer beacon, where a plethora of formats in 
immobilized and solution forms using optical and electrochemical detection have 
been reported [116-120], extrapolating from the original concept reported by Tyagi 
and Kramer for the detection of DNA [121]. The beauty of the molecular aptamer 
beacon is that the only required end-user intervention is sample addition, with a 
quantitative response being available in a matter of seconds to minutes. Many of 
the reported molecular aptamer beacons exploit the conformational changes the 
aptamers undergo upon interacting with their target [122-126], whilst others have 
been engineerd into beacon structures [117, 127-129].  
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The concept of using aptamers as therapeutic agents is more than 20 years 
old, based on the specific interaction with the target molecule which can modulate 
its function in a competitive (and antagonistic) way if associated aptatopes are 
involved in the binding [48-49, 130-134]. Aptamers can directly influence metabolic 
processes, they can act by mimicking the target sequence of proteins [135], and 
have been identified as powerful antagonists of protein interactions related to 
several diseases [136], offering the possibility for pharmaceutical applications. For 
example aptamers selected against anti-reverse transcriptase of HIV-1 protein have 
been shown to form a pseudoknot structure that tightly interacts with the 
polymerase active site [137]. However, these aptamers not only did inhibit viral 
replication, but can also be co-packaged into virions, thereby crippling progeny 
virions [138-139]. 
A rapid blood clearance due to their small size (10 – 30 kD) in comparison 
to antibodies (150 kD) can be overcome by pegylation (polyethylene glycol), by 
embedding aptamers in liposomes [130, 140-141], or by 3´biotinylation [142].  
The stability in serum of a 2´aminopyrimidine modified anti-bFGF 
aptamer was increased at least 1000-fold relative to un-substituted RNAs [10], while 
a 2´aminopyrimidine with 2´O-methylpurine modified anti-VEGF aptamer could 
survive for up to 17 hours in urine [143]. After significant efforts, stabilized 
aptamers have been developed for use as intravenous or subcutaneous injectables, 
with blood half lives in the 6-12 hours range [144-145]. New oligonucleotide 
stabilization chemistries continue to be developed, so the possibility of injectable 
aptamer formulations with longer (days or even week time scale) blood half-lives 
are feasible. Moreover, there is evidence of using an unmodified DNA aptamers in 
serum for up to 6 days, more than enough for in vivo and in vitro applications [98]. 
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RNA and DNA aptamers intended for clinical applications are usually 
modified in order to optimize their pharmacodynamic and pharmacokinetic profiles 
and to promote their safety [146]. Studies of the possible toxic effects of aptamers 
in clinical applications were negative in all cases, and based on no-adverse-effect 
levels it has been concluded that the expected pharmacologically applicable doses in 
animals and humans are safe [135]. Moreover, there are no evidence for aptamers 
being immunogenic or activating complement or anticoagulation, showing the 
possibility of repeated administration of doses to the same individual [135-136]. By 
addition of a second, complementary oligonucleotide, the function of the aptamer 
drug can be deactivated. This aptamer antidote principle was first demonstrated for 
the coagulation factor IX [13, 147]. Recently, universal sequence independent 
antidotes were developed for extracellular oligonucleotide-based drugs in animals 
and humans [148].  
Recent developments in aptamer-based therapeutics have been rewarded in 
the form of the first aptamer-based drug approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of age-related macular degeneration 
(AMD), called Pegaptanib (brand name Macugen). In addition to the RNA-aptamer 
Macugen, a DNA-aptamer directed against the platelet-derived growth factor-B has 
been proposed for exudative AMD treatment [149]. A guanosine-rich 
oligonucleotide aptamer (AS-1411) selected against nucleolin is the first 
oligodeoxynucleotide aptamer to reach phase I and II clinical trials for the potential 
treatment of cancers [150]. Among aptamers currently in clinical trials, some are 
directed against blood clotting factors. For example, a DNA-aptamer called 
ARC1779 is directed against the A1 domain of von Willebrand factor (vWF) and is 
able to inhibit its binding to the glycoprotein Ib receptors on platelets, resulting in 
an antithrombotic effect [151]. Another aptamer that prevents blood clotting is 
Nu172, a 26-mer DNA aptamer, directed against thrombin with no chemical 
modifications in its molecular structure. Two spiegelmers, NOX-A12 and NOX-
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E36, for the treatment of hematologic tumors and complications of type 2 diabetes 
are also in clinical trials [152].   
 
 
1.1.9 Prostate Cancer 
 
Prostate Cancer is one the most common male cancers in Western 
Countries, mostly in Europe and North America. It has been estimated to be the 
second leading cause of male cancer death in United States (Figure 1.3) and the 
third in the European Union in years 2008-2011, after lung and colorectal 
carcinomas [153-155]. The incidence of prostate cancer increases with age and 
about 80% cases are in men over 65. The early diagnosis of prostate cancer is of 
major importance, as when prostate cancer is detected early it can be easily treated, 
resulting in a 5-year relative survival rate of 100%. On the other hand, when 
prostate cancer is diagnosed at advanced stages, the 5-year relative survival rate 
drops to 30% [153].  
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Figure 1.2. Ten leading cancer types for estimated new cancer cases and deaths, by 
Sex, United States 2011. *Estimates are rounded to the nearest 10 and exclude basal and squamous 




1.1.9.1 Tumor markers 
 
The identification of tumor markers is a powerful tool in cancer 
diagnostics and therapeutics. Tumor markers are substances that can be found in 
blood, urine or body tissues when cancer is present. They can be products of the 
cancer cells themselves or of the body in response to cancer or other conditions.  
Most tumor markers are proteins, antigens, or hormones. Cancer marker tests are 
not used alone in diagnosis because most markers can be found in elevated levels in 
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people who have benign conditions, and because no tumor marker is specific to a 
particular cancer. Also not every tumor will cause an elevation in the cancer marker 
test, especially in the early stages of tumor and certain tumor markers are more 
accurate than others in their sensitivity to detection of cancer. The more sensitive 
they are, the earlier it is possible to diagnose. In any case, markers can help 
determine if a cancer is likely, they can help diagnose the source of widespread 
cancer in a patient when the origin of the cancer is unknown, and they also help to 
determine the prognosis of certain cancers and effectiveness of cancer treatment. A 
list of the commonly used tumor markers for certain types of cancer is presented 
below (Table 1.1). 
 
 
Table 1.1. List of the commonly used tumor markers for certain types of cancer. 
 
  CANCER MARKER TYPE OF CANCER NORMAL VALUES 
  Alpha-fetoprotein (AFP) liver cancer  ≤ 0 - 6.4 U/ml in men and 
non-pregnant women 
  Beta-2-microglobulin (B2M) multiple myeloma,  
chronic lymphocytic leukemia 
≤ 2.5 µg/ml 
  Bladder tumor antigen  (BTA) bladder cancer ≤ 14 U/ml 
  CA 15-3/MUC1 breast cancer ≤ 25 - 31 U/ml  
  CA 27-29 breast cancer ≤ 3 - 40 U/ml 
  CA 125 epithelial ovarian cancer ≤ 33 -35 U/ml 
  CA 72-4 ovarian and pancreatic cancer, 
cancer of digestive tract 
≤ 4 U/ml 
  CA 19-9 panreactic and colorectal cancer, 
digestive tract cancer 
 ≤ 33 -37 U/ml 
  Calcitonin medullary thyroid carcinoma < 0.155 ng/ml for men 
< 0.105 ng/ml for women 
   Carcinoembryonic antigen (CEA) colorectal, lung and breast cancer  ≤ 5 ng/ml in smokers 
 ≤ 3 ng/ml in non-smokers 
  Chromogranin A (CgA) neuroendocrine tumor   ≤ 76 ng/ml for men 
 ≤ 51 ng/ml for women 
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  Estrogen receptors/ 
  Progesterone receptors 
breast cancer ER, PR negative 
  Human epidermal growth 
  factor HER2, 3 
breast cancer The test is to determine if the  
tissue over expresses HER 2. 
  Nueron-specific  
  enolase (NSE) 
neuroendocrine tumors  ≤ 13 ng/ml 
  NMP 22 bladder cancer ≤ 10 U/ml 
  Postate Specific Antigen (PSA) prostate cancer ≤ 4 ng/ml 
  Prostatic acid phosphatase (PAP) prostate cancer ≤ 0,5 - 1,9 U/ml 
  Prostate-specific membrane 
   antigen (PSMA) 
prostate cancer ≤ 273 ng/ml in men ˂50 
≤ 359 ng/ml in men ˃50 
Normal levels differ between people and between laboratories. Most labs list their own „ reference ranges“of 
cancer markers.  The values listed on the chart are the normals established at The University of Iowa 
Hospitals and Clinics, and on the web page of American Cancer Society.  
 
 
1.1.9.2 Tumor markers in prostate cancer 
 
There are several tissue prostate cancer markers such as for example 
Glutathione S-transferase П (GSTP1) and α-methylacyl coenzyme A racemase 
(AMARC) [156]. Prostate Specific Membrane Antigen (PSMA) is another target for 
the diagnosis and treatment of cancer prostate, and is unregulated in the vasculature 
of most solid tumors, and can be a potential target for the generation of novel anti-
angiogenesis agents [157]. 
The earlist reported serum marker for prostate cancer was human prostatic 
acid phosphatase (PAP) [158]. Recently, early prostate cancer antigen -2 (EPCA-2) 
detection in serum has shown some promising results as it was able to differentiate 
between men with and without prostate cancer with 92% specificity (measures the 
proportion of negatives which are correctly identified) and 94% sensitivity 
(measures the proportion of actual positives which are correctly identified) [159].  
Prostate-specific antigen serum level is currently considered the best tumor 
marker available in clinical medicine. Protate Specific Antigen (PSA), a serine 
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protease, is a glycoprotein produced by prostate epithelium [160]. PSA is secreted 
as propeptide, which is inactive, with removal of the first seven aminoacids yielding 




Figure 1.3. Structure of PSA forms. The leader sequence on preproPSA is cleaved to generate 
proPSA (inactive form). Cleavage of the propeptide by human Kallikrein 2 generates the active mature 
PSA. Truncated inactive form of proPSA can also be generated by cleavage within the propeptide, including 
(-2) proPSA and (-5) proPSA. Active PSA in the lumen of prostate ducts can be further cleaved at the 
indicated positions to generate inactive PSA. Active PSA that enters the bloodstream is rapidly bound to 




Seventy percent of PSA in the seminal fluid is enzymatically active, and the 
rest is in an inactive form. On the other hand the predominant molecular PSA form 
present in blood is an inactive 80-90 kDa complex of PSA with alfa-1-
antichymotrypsin (ACT), alfa-2-macroglobulin, and alfa-1-antitrypsin. These 
fractions are called complexed PSA (cPSA). Free active PSA (fPSA) represents a 
small but variable proportion of the total PSA serum concentration, containing a 
mixture of different inactive PSA forms: nicked PSA (mature forms with different 
broken peptide bonds) and pro PSA forms with the N-terminal propeptide 
truncated at different positions (-2), and (-5) and (-7) pro PSAs [162].  
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PSA is found in the blood of healthy patients at very low concentrations. 
However, prostate cancer patients show a characteristic loss of the basal cell layer 
of prostate glands which allows PSA contained in the prostatic glands access to the 
peripheral circulation and thus to be found in blood in higher quantities. The cut-
off value of PSA concentration of around 4 ng/ml indicates a risk and recurrence 
of prostate disease; however PSA is not fully specific for prostate cancer as other 
prostatic pathologies such as benign prostate hyperplasia (BPH) and prostatitis can 
show serum PSA elevations. Men, who have 4 to 10 ng/ml of serum PSA are often 
subjected to repeated screening and sometimes to biopsy tests. [163]. The variation 
of PSA measurement has been considered due to the different forms of PSA [164], 
and the PSA index (ratio free to total PSA) has been approved by the FDA (Food 
and Drug Administration) to differentiate between prostate cancer and BPH 
patients in the 4 -10 ng/ml range.  In spite of its limitations, PSA is considered a 
useful marker of prostate pathologies, including prostate cancer, because PSA 
serum levels provide an early warning of the development and presence of prostate 
cancer.  
The main function of PSA is the liquefaction of the seminal fluid by the 
degradation of semenogelin I, semenogelin II and fibronectin. PSA also cleaves a 
variety of proteins including insulin-like growth factor binding protein-3 (IGFBP-3), 
and IGFBP-4, releasing active insulin-like growth factor 1 (IGF-1) that can enhance 
tumor growth factor [165-166]. Moreover, PSA also cleaves laminin [167] and 
activates latent TGF-beta [168], which is involved in tumor progression and 
metastasis. The discovery of the involvement of PSA in several events leading to 
the development of malignant tumors has made it a target for prevention and 
intervention [169], and has also prompted some interest in the use of serine 
protease inhibitors and their modulators as useful agents for blocking the 
progression of some preinvasive to invasive carcinomas [170].  However not all 
serine protease inhibitors are candidates for PSA modulation, but it has been 
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reported that PSA can be also inhibited by Zn2+ [171] or boronic acid compounds 
[169].   
Apart from the ability of PSA to cleave several substrates, PSA may also 
have other functions relevant to tumor growth [172-174]. A high expression of 
PSA in prostate cancer tissue has been associated with low vasculature density and 
angiogenic potential [175-176]. High PSA concentrations in the tumor environment 
may contribute to the slow growth of prostate cancer, since PSA has been shown 
to exert antiogenic activity [177-178]. Thus, is possible that PSA plays a dual role in 
cancer progression, first favoring tumorigenesis by activation or release of growth 
factors and degradation of extracellular matrix components, while at later stages 
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1.2 Objectives  
 
 
Currently, PSA is considered the most sensitive marker available for 
prostate cancer detection and for monitoring its progression. To date 
monoclonal/polyclonal antibodies have been used to detect PSA due to their high 
specificity and sensitivity. However, the production of antibodies is time-
consuming and expensive. Moreover the production of antibodies requires a 
substantial number of animals, and the animals are subjected to a number of 
invasive procedures such as antigen injection and blood collection. On the other 
hand, aptamers with specificity and affinity equal to those of antibodies could be an 
alternative way for the detection of PSA. To date there are several reports detailing 
DNA/RNA aptamers selected against cancer markers with affinity in the low 
nanomolar to picomolar range. Both DNA and RNA aptamers can be used in 
diagnostic applications, but DNA aptamers have several advantages over RNA in 
this regard. The selection process for DNA aptamers is simpler and faster and in 
addition DNA aptamers can be easily modified and are less expensive than 
modified RNA aptamers, making them more suitable for diagnostic applications. 
Therefore, a PSA detection method using DNA aptamers (molecular aptamer 
beacon, AptaPCR) would be a comfortable and low cost procedure, and could be 
used to screen for a risk and recurrence of prostate cancer.  
In addition to its importance as a tumor marker, PSA has biological activity 
with regard to cancer growth and proliferation. Therefore the inhibition or 
activation of its biological activity can be used in prostate cancer therapy. 
Innovative targeted therapeutic strategies aim at developing new molecules with 
high affinity and specificity with suitable pharmacokinetic properties for in vivo 
applications. In this perspective aptamers are able to bind with high affinity to a 
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specific protein by folding into complex tertiary structures with the possibility to 
modulate the function of the target. To date, nine RNA and DNA aptamers have 
entered the clinical development pipeline for treating a number of diseases in 
different pathologic states[180].   
This PhD work focused on the selection of both DNA/RNA aptamers 
against Prostate Specific Antigen and their use in diagnostic and therapeutic 
applications. The objectives of this work can be divided in several points; (i) 
selection and amplification of a random library, its optimization and use in SELEX 
process, (ii) characterization of PSA and evaluation of different immobilization 
strategies, (iii) comparison of different methods used for preparation of single 
stranded DNA and their application in SELEX process, and finally (iv) selection of 
DNA and RNA aptamers against PSA and study of their potential use in diagnostic 
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The diversity of targets that have been used in SELEX indicates that 
aptamers can be selected for virtually any target. Peptides, proteins, carbohydrates, 
inorganic or small organic molecules, as well as complex targets like target mixtures 
or whole cells and organisms have been used as targets in  aptamer selection. 
However, there are some general prerequisites for a potential target to successfully 
select aptamers of high affinity. Selected target molecules should be present in 
sufficient amount and of high purity. This helps to minimize the enrichment of un-
specifically binding nucleic acids and to increase the specificity of the selection. 
Some target characteristics such as positively charged groups (primary amino 
groups), the presence of hydrogen donors and acceptors, or planarity (aromatic 
compounds) can facilitate aptamer selection[1]. On the other hand aptamer 
selection can be more difficult for targets with hydrophobic character and 
negatively charged molecules (containing phosphate groups) [2-3]. Specific target 
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features have an important role not only in the binding step during selection but 
also in the immobilization of the target molecule on a particular matrix surface. 
Target immobilization is one of the efficient partitioning methods used for 
separation of target bound and non-bound nucleic acids in SELEX, and the target 
should be immobilized onto the surface with a high density and nonspecific 




2.1.1 Characteristics of PSA 
 
PSA also known as kallikrein-3 (KLK3), seminin, semenogelase, γ-
seminoprotein or P-30 antigen is a glycoprotein encoded by the KLK3 gene located 
on the nineteenth chromosome (19q13) in humans. PSA is a chymotrypsin like 
serine protease produced by the epithelial cells of the prostate. It consists of  237 
amino acids with molecular weight ranging from 30 to 36 kDa [5]. The molecule is 
8% carbohydrate comprised of three O- and one N-linked oligosaccharide chains 
[6]. There is considerable microheterogeneity in PSA glycosylation, resulting in 
isoelectric points ranging from 6.8 to 8.0 [7]. Moreover, differences in sugar 
composition between normal PSA and PSA from tumoral origin have been 
observed [8-10]. As mentioned before, PSA can be found in different molecular 
forms including intact PSA, precursor PSA (pro PSA), and nicked PSA. 
Enzymatically highly active intact PSA is a serine protease cleaved at the NH2 -
terminal end of inactive pro PSA by trypsin or hK2 [11-12]. Different pro-PSA 
forms (zymogen forms) with 1-7 amino acids in the precursor part have been 
identified and characterized [11-14]. Nicked PSA is an inactive form resulting from 
a nick in the PSA sequence, probably at the lysine at position 145 and/or 182 [15].  
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Figure 2.1 Crystal structure of human prostate specific antigen (green/gold cartoon) covalently attached 
to an substrate acyl intermediate (multicolor sticks, carbon: white, nitrogen: blue, oxygen: red) and an glucosamine-




2.1.2 Immobilization of target on the surface of magnetic beads  
 
An immobilization process can be defined as the attachment of molecules 
to a surface which leads to a decrease or loss of mobility. In some cases, 
immobilization may lead to partial or complete loss of protein activity, due to 
random orientation and structural deformation. In order to retain biological 
activity, proteins can be attached onto surfaces without affecting conformation and 
function. The choice of a suitable immobilization strategy is usually determined by 
the chemical and physicochemical properties of both the surface and protein. 
Immobilization techniques are mainly based on the following three mechanisms: 
physical, covalent, and bioaffinity immobilization and frequently magnetic beads 
with coatings suitable for these types of immobilization are used [17-20]. 
 
 
2.1.3 Physical Immobilization 
 
When physical immobilization is used, proteins can be absorbed on 
surfaces via intermolecular forces, such as ionic, hydrophobic and polar 
interactions, with the type of intermolecular forces taking part in the interaction 
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being dependent on the particular protein and surface involved. The magnetic 
beads are generally non porous, although the potential of porous magnetic beads as 
"microreservoirs" for enzyme entrapment has also been studied [21]. The 
disadvantages of the adsorption mechanism includes random orientation and weak 
attachment of the protein, as proteins immobilized in this way can be removed by 
some buffers or detergents used in the SELEX process. 
 
 
2.1.4 Covalent Immobilization 
 
Proteins can be covalently bound to an immobilization support through 
functional groups of exposed amino acids. Covalent bonds are generally formed 
between functional groups exposed on the side-chains of proteins with suitable 
modified surfaces, resulting in irreversible binding. The functional groups on the 
support are produced by chemical treatment, and several pretreated magnetic beads 
are commercially available (Table 2.1).   
 
Table 2.1 The most common commercially available modified magnetic beads with 
corresponding aminoacids containing functional groups.  
 
Type of magnetic beads Aminoacids         Side groups 
Carboxylic acid Lys - NH2 
Amine 














Magnetic beads modified with carboxylic acids (Figure 2.2 a) are the most 
commonly utilized in SELEX as lysine is typically present on protein exteriors. The 
other large fraction of surface groups present on proteins are aspartic and glutamic 
acid, which can be immobilized on amine modified magnetic beads (Figure 2.2 b). 
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Carboimidine chemistry is the most commonly used method for coupling with 
amine groups, forming stable amide bonds. 
 
         A) 
 




Figure 2.2 Covalent coupling with carbodiimide method using carboxyl and amine modified 
beads. In carboxyl modified beads (a) activation of carboxyl groups on the surface of the beads by EDC is followed by 
formation of reactive O-acylisourea complex. Covalent binding is performed via amine groups of target. In the case of 
amine modified beads (b) activation of carboxyl groups is done on the surface of target. After activiation with EDC and 
formation of  O-acylisourea complex, covalent binding is performed in the presence of amine modified beads.  
 
 
Thiol chemistry is based on linking to the cysteine to amino acid which 
contains a thiol group, and generally forms internal disulfide bonds, that contribute 
to the stability of the protein. The coupling reaction between bromacetyl activated 
beads and proteins containing sulfhydryl groups is very fast and the coupling 
product offers extremely stable thioether bonds between the modified bead and 
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protein (Figure 2.3). Nevertheless this type of bead is not very common in SELEX 
process since cysteines are not as abundant or accessible as the above mentioned 
amino acids.   
 




Epoxide chemistry is another widely used system, due to its stability at 
neutral pH values, wet conditions, and reactivity with several functional groups to 
form strong bonds with minimal chemical modification of the protein. The epoxide 
chemistry can be used to link to ligands containing amino, thiol and hydroxyl 
functional groups (Figure 2.4).  
 
 




There is a wide range of special types of covalent bindings available. 
Different terminal reactive groups allow the convenient and efficient covalent 
binding of various biomolecules. Magnetic beads can be modified with cyanuric, 
hydroxyl, polyglutaraldehyde, chitosan, thiol, and many other reactive groups, 
including hydrazide modified beads, which link with ligands containing aldehyde 
and ketone groups forming stable hydrazone bonds (Figure 2.5).  
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   Figure 2.5 Site–directed immobilization through carbohydrates with hydrazide modified 
beads. Oxidation of carbohydrate residues is followed by fformation of aldehyde groups which react with 
hydrazide modified beads.   
 
 
2.1.5 Bioaffinity immobilization 
 
Biochemical affinity immobilization offers an oriented attachment of 
proteins, and the most common system takes advantage of the avidin-biotin 
interaction (Figure 2.6). This approach is based on one of the strongest non-
covalent bonds (Kd = 1015 M-1) ever known and the interaction is very specific and 
permits uniformly oriented protein immobilization. An alternative bioaffinity 
system is used with recombinant proteins, which are produced by genetic 
engineering and can be expressed with affinity tags [19] that are placed at defined 
positions, in order to achieve optimal accessibility of the protein. Histidine is the 
most popular tag due to the advantages of small size, compatibility with organic 
solvents, low immunogenicity, and effective purification under native and 
denaturing conditions. 
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The choice of a suitable immobilization strategy is determined by the 
physicochemical properties of the target. The extrapolation of immobilization 
strategies is difficult and mostly unsuccessful due to the wide subset of 
characteristics and functional properties of proteins. Therefore, the question of 
which strategy is best should be studied for each specific target. This chapter can be 
divided in three parts. The first part is dedicated to methods used for the 
characterization and quality control of PSA, the second part deals with different 
types of immobilization processes, including covalent, and bio-affinity 
immobilization techniques, and finally the last part of this section details the 
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2.3.1 Reagents  
 
Prostate Specific Antigen (>96% pure) purified from seminal fluids was 
purchased from SCIPAC (Kent, UK), and fluorogenic PSA substrate from 
Calbiochem/Bionova Scientifica (Madrid, Spain). Monoclonal antibody Anti-PSA 
10 was obtained from Fujirebio (Barcelona, Spain). All reagents used for 
polyacrylamide gel were supplied from Biorad (Madrid, Spain). Simag carboxyl, 
amine and hydrazide activated beads were purchased from Chemicell (Berlin, 
Germany), and M 270 epoxy and My One T1 streptavidin coated beads from 
Invitrogen (Madrid, Spain). EZ-Linker sulfo-NHS-biotin, EZ-Link Amine PEGn-
Biotin, and Slide-A-Lyzer Dialysis cassettes were from Fisher scientific (Madrid, 
Spain). Polyvinylchloride (PVC) microtiter plate, TMB substrate, EDC/NHS, and 
enzyme linked secondary antibody (AP 9044) were purchased from Sigma (Madrid, 
Spain).  Amicon spin columns, 10 K device were from Milipore Iberica S.A.U 
(Madrid, Spain).   
 
 
2.3.2 Quality control of protein 
 
The protein concentration was determined by measuring the OD280, using 
the extinction coefficient for PSA (1.84 mL/mg/cm). The quality of the protein 
was checked by 15% (w/v) polyacrylamide gel. The gel consisted of two sections: a 
resolving gel (12.5 ml 30% (w/v) acrylamide (37:5:1 acrylamide: bisacrylamide); 6.3 ml 
1.5 M Tris HCl pH 8.8, 5.7 ml di-distilled water (dd-water), 250 µl 10% (w/v) SDS, 
250 µl 10% (w/v) APS, 15 µl TEMED) and stacking gel (1.3 ml 30% (w/v) 
acrylamide (37:5:1 acrylamide:bisacrylamide), 1.9 ml 1M Tris HCl  pH 6.8, 80 µl 
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10% (w/v) SDS, 80 µl 10% (w/v) APS, 10 µl TEMED). The resolving gel was 
poured first, overlaid with butanol (to form a straight, level interface) and allowed 
to polymerise. After removal of the butanol (and rising with dd-water) the stacking 
gel was poured and allowed to polymerise. Samples were mixed with an equal 
volume of SDS/loading buffer (50 mM Tris HCl pH 6.8, 100 mM DTT, 2% (w/v) 
SDS, 0.1% (w/v) bromphenol blue, 10% (v/v) glycerol) heated to 95°C for 3 
minutes before loading. The gels were run in SDS/running buffer (25 mM Tris, 250 
mM glycine pH 8.3, 0.1% (w/v) SDS) at 120 V for 90 minutes.  The gel was stained 
for approximately 1 hour in Coomasie Blue, and then placed in destaining solution 
for approximately 12 hours. Sample of PSA for mass spectrometry were prepared 
in 5 mM ammonium acetate.  The composition of different SELEX binding buffers 
is detailed in Table 5.1. 
 
 
2.3.3 Immobilization of protein on the surface of magnetic beads  
 
2.3.3.1 Amine chemistry using carboxylic acid modified magnetic beads 
 
Ten milligrams (200 µl, 50 mg/ml) of carboxylated magnetic beads (CMBs) 
were washed twice with 500 µl of 100 mM MES, pH 5, for ten minutes with good 
mixing to remove preservatives. Washed CMBs were activated with 150 µl of 80 
mg/ml of EDC and NHS in cold 100 mM MES, pH 5 and incubated for 20 
minutes at room temperature under shaking conditions. Following incubation, the 
EDC/NHS solution was removed and activated CMBs were washed twice with 500 
μl of 100 mM MES pH 5 to ensure elimination of free EDC/NHS. After activation 
with EDC/NHS 150 µg of PSA in 100 mM MES, pH 5 (total volume 300 µl)  was 
added to activated beads and incubated overnight at room temperature with slow 
tilt rotation. Following incubation, the mixture of CMBs with PSA was placed in 
contact with a magnet for 4 minutes and any unbound target was removed. PSA 
coated beads were washed three times with 500 µl of PBS buffer and un-reacted 
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carboxylic groups on the CMB surface were blocked with 300 μl of 50 mM 
ethanolamine in PBS, pH 8 for 1 hour under shaking conditions. After blocking, 




2.3.3.2 Carboxyl chemistry using amine modified magnetic beads 
 
Ten milligrams (200 µl, 50 mg/ml) of amine modified magnetic beads 
(AMBs) were washed twice with 500 µl of 100 mM MES, pH 6, for ten minutes 
with good mixing to remove preservatives. Washed AMBs were resuspended in 150 
µl of 80 mg/ml of EDC and NHS in cold 100 mM MES, pH 6 and mixed at room 
temperature. PSA (150 µg) was added to the solution and mixed on a shaker. After 
incubation, the mixture of AMBs with PSA was placed in contact with a magnet for 
4 minutes and any unbound target was removed. Target coated beads were washed 




2.3.3.3 Epoxide chemistry 
 
Ten milligrams (200 µl, 50 mg/ml) of epoxy activated magnetic beads 
(EMBs) were resuspended by vortexing for 1-2 minutes and transferred to a new 
tube.  After washing, 150 µg of PSA in 0.1 M phosphate buffer and ammonium 
sulfate was added to the solution. The final concentration of ammonium sulfate 
was 1 M. The target was incubated with EMBs for 24 hours at 37°C with slow tilt 
rotation. After incubation, the coated beads were washed four times with 500 µl of 
PBS and rinsed in 200 µl of SELEX binding buffer.  
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Glycons in the PSA target were oxidized by dissolving 0.5 mg of PSA in 
100 µl 0.1 M sodium phosphate buffer, pH 7. This solution was added to an 
opaque vial containing 0.5 mg oxidation reagent (NaIO4) and swirled gently to 
dissolve the oxidizing agent, and then incubated in the dark at room temperature 
for 30 minutes. Unreacted oxidation reagents were removed and buffer was 
changed by using spin columns. Ten milligrams (200 µl, 50 mg/ml) of hydrazide 
activated magnetic beads (HMBs) were washed with phosphate buffer using the 
magnetic separator. After the washing step HMBs were resuspended in 200 µl of 
coupling buffer containing 150 µg of PSA, and the mixture was incubated for 12 
hours at room temperature. After incubation, the PSA coated beads were washed 
and rinsed in 200 µl in SELEX binding buffer.  
 
 
2.3.3.5 Immobilization of biotinylated target on streptavidin coated magnetic 
beads 
 
Biotinylation of PSA using EZ-Linker sulfo-NHS-biotin 
 
One milligram of EZ-Linker sulfo-NHS-biotin was dissolved in 1 ml of 
RNAse free water reaching 1 mg/ml concentration. 50 µl of prepared solution was 
added to 200 µl of 1 mg/ml of PSA and incubated together on ice for 15 minutes. 
After incubation, 100 µl of 1M Tris HCl, pH 7.2 was added to inactivate the 
reaction. The non-reacted biotin was removed by dialysis with 2 mM Tris HCl, pH 
7.2 overnight at 4°C.  
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Biotinylation of PSA using EZ-Link Amine PEGn-Biotin 
 
Alternatively, one milligram of EZ-Link Amine PEGn-Biotin was 
dissolved in 50 µl of RNAse free water reaching 50 mM solution in 0.1 M MES pH 
4.7 buffer. Immediately before use, 100 mM solution of EDC in MES buffer was 
prepared and 2 µl of this solution was added to the 50 mM biotin solution. Finally 
200 ul of 1 mg/ml of PSA in MES buffer was added to the solution and incubated 
together for 2 hours at room temperature with mixing. Non-reacted biotinylation 
reagents and EDC by-products were removed by desalting using spin columns.  
 
Coupling of biotinylated PSA to streptavidin beads 
 
Two milligrams (200 µl, 10 mg/ml) of streptavidin beads were rinsed in 1 
ml  of 20 mM Tris HCl pH7, 200 mM NaCl to remove preservatives. The prepared 
beads were then suspended in 200 µl of 20 mM Tris HCl pH7, 1mM EDTA, 1M 
NaCl containing 150 µg of biotinylated PSA, and the beads were incubated for 30 
minutes at RT, on an orbital shaker (200 r.p.m.) to prevent the beads settling out. 
Following incubation, the PSA-functionalised streptavidin coated beads were 
separated and rinsed in 200 µl SELEX binding buffer.  
 
 
2.3.4 Characterization of target coupled beads 
 
2.3.4.1 Competitive ELISA bead assay 
 
Competitive ELISA bead assay was performed using a PVC microtiter 
plate. The plate was coated with 50 µl of 5 µg/ml of PSA in carbonate buffer and 
blocked with 200 µl PBS tween. PSA of different concentrations (0 – 60 µg/ml) 
and PSA coupled magnetic beads were incubated off-plate with anti PSA 10 
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antibody (9.6 µg/ml) and enzyme–linked secondary antibody (1/10 000 dilution). 
The appropriate concentration of antibody and enzyme linked secondary antibody 
was determined using a checkerboard titration. After this off-plate incubation step, 
the mixture of PSA, PSA beads and antibodies were added to the plate and 
incubated together. For each step, plates were incubated for 1 hour at 37°C on an 
orbital shaker (150 r.p.m.) before being washed three times with PBS-tween buffer.  
Finally 50 µl of TMB substrate was added to each well and incubated for 15 
minutes at room temperature. Following addition of 50 µl of 0.1 M sulfuric acid, 
plates were analyzed using a Spectra max 340 PC plate readers (BioNova cientifica, 
Barcelona, Spain) at 450 nm.   
 
 
2.3.4.2 Peptide Mass Fingerprinting 
 
Digestion of PSA immobilized on the surface of beads 
 
Ten microliters of PSA-functionalised magnetic beads were washed twice 
with 50 μl ammonium bicarbonate 25 mM (pH 8) for 2 minutes incubation 
followed by removal of supernatant using magnetic separation.  After washing, the 
beads were resuspended in 10 μl of 20 mM DTT in 50 mM ammonium bicarbonate 
and incubated for 1 hour at 56ºC. The supernatant was removed and 10 µL of 50 
mM iodoacetamide in 50 mM ammonium bicarbonate was added to the beads and 
incubated for another 20 minutes at RT, protected from light. Following reduction 
and alkylation, the PSA on the bead surface was digested by adding trypsin (14 
ng/µl) in 25 mM ammonium bicarbonate, in a protein/trypsin ratio (w/w) of 1/50, 
for 16 hours at 37ºC. To allow complete peptide elution, the resulting digestion was 
sonicated for 10 min at 4º C and the supernatant containing peptides was collected 
and stored for further analysis. 
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MALDI-TOF Mass Spectrometry 
 
One microliter of extracted peptides was spotted onto a MALDI plate and 
let to dry, followed by addition of 1 μl of the matrix (3 mg/ml α-cyano- 4- 
hydroxycinnamic acid matrix in 50% acetonitrile, 0.1% trifluoroacetic acid). 
Peptides were selected in the mass range of 750–3500 Da, and acquired in a 
positive reflector mode. All mass spectra were externally calibrated with the 
Sequazyme peptide mass standards kit and internally with trypsin autolysis peaks. 
The spectra obtained were processed using Data Explorer Software and MASCOT 




2.3.4.3 PSA stability assay  
 
PSA coupled beads were stored at 4°C for 4 weeks and the amount of PSA 
was studied using the ELISA bead assay (2.3.4.1).  
 
 
2.3.4.4 Measurement of PSA activity  
 
PSA activity was compared using 25 µg/ml of free PSA and PSA 
immobilized on the surface of the beads. PSA substrate (C44H60N12O13F3·2HOAc ) 
was diluted to a final concentration of 400 μmol/L. The hydrolysis of the substrate 
by PSA was measured with a spectrofluorimeter (Cary Eclipse, Varian), using an 
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2.4 Results and Discussion 
 
 
2.4.1 Physicochemical characterization of PSA 
 
Two different lots of PSA sample were studied in order to allow 
comparison of lot-to-lot variations. The purity and homogeneity of PSA obtained 
from seminal fluids was analyzed on sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE, Figure 2.7). The bands of major intensity migrated to 
the position of about 25 kDa under reduced conditions and 31-33 kDa under non-
reduced conditions. It should be noted that SDS-PAGE tends to overestimate the 
molecular weight of glycoproteins. On reducing SDS-PAGE gel electrophoresis, 
fragments of lower intensity with different molecular weights were observed, which 
could be due to the nicked form of PSA or different forms of pro-PSA. The 
majority of the nicked PSA remains intact in vivo because of the presence of 
multiple disulfide bonds. Therefore under non-denaturing conditions, the nicked 
PSA co-migrates with the intact PSA, while on reducing SDS-PAGE, the PSA 
fractions separate, and molecules of lower molecular weight are revealed [22]. 
Fragments of different molecular weights observed on native PAGE can also 
indicate that PSA samples are composed of multiple forms of pro PSA varying in 
sugar moieties, which would affect the isoelectric point and resulting in 
heterogeneous pattern on the gel [23]. 
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Figure 2.7 SDS-PAGE gel with two different 
lots of PSA sample obtained from seminal 
fluid. A) under non denaturating conditions B) under 
reduced conditions, 1, 4 PSA sample with with lot 
number, 2, 5 PSA sample with another lot number.  
 
Mass spectrometry (MS) ionizes chemical compounds to generate charged 
molecules or molecule fragments and measures their mass-to-charge ratio [24]. The 
presence of different forms of PSA in our sample was also confirmed by MS 
(Figure 2.8). The predominant PSA molecular species (B bubble) with Mr 28 433 is 
very close to the calculated molecular mass of the intact PSA molecule (Mr 28 431) 
that contains a sequence of PSA (Mr 26 079.5) with a carbohydrate residue (Mr 
2351.8). It must be noted that the original stock of PSA was dissolved in a 
potassium phosphate buffer, which can explain the formation of the potassium 
adduct at Mr 28 474 (C bubble). The other peaks in the spectrum observed at Mr 28 
286 and 28 324 were assigned to the major glycoform of PSA minus fucose (Mr 
146.1) and its potassium adduct (Mr 39.1), respectively as described in Belenger 
1995 [25]. The two different lots of PSA sample used for the analysis showed 
almost identical spectra, indicative of a high consistency in the proportion of PSA 
isoforms in seminal fluids.  
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Figure 2.8 Spectrum of molecular weight for the PSA protein as obtained by 
TOF MS ES+ and reconstructed mathematically from m/z to molecular scale.  
 
 
2.4.2 Immobilization of PSA on the surface of the beads 
 
Taking into account specific features of PSA such as the composition of 
exposed amino acids, hydrophobicity, size of molecule, and the presence of 
carbohydrate chains, several immobilization strategies were evaluated. PSA contains 
primary amines in the side chain of 12 lysine (Lys) residues and the N-terminus of 
each polypeptide that are available for linkage. There are also 23 aminoacids 
containing carboxyl groups (Asp, Glu) and the carboxyl groups on C-terminus. 
Taking into consideration these factors carboxyl, amine, and epoxy modified 
magnetic beads were selected for the binding of ligands containing amine and 
carboxyl functional groups. PSA also contains 10 cysteine residues whose sulphur-
containing side chains participate in stabilizing tertiary and quaternary structure 
through the formation of disulfide bonds. These disulfide bonds can be reduced to 
expose free sulfhydryls, but this can significantly interfere with required protein 
function or structure, therefore thiol chemistry was excluded from these studies.  
The presence of carbohydrate chains in the PSA structure provided another type of 
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site-directed immobilization using hydrazide modified beads. The bioaffinity biotin-
avidin system was also evaluated.  
 
 
2.4.3 Characterization of PSA-coupled beads  
 
The degree of magnetic particle surface coated with PSA was studied using 
different techniques. Enzyme-Linked ImmunoSorbent Assay (ELISA), is a 
biochemical technique used to detect the presence of a target analyte in a sample, 
and we developed a competitive ELISA to quantify the amount of PSA 
immobilized on the beads. (Figure 2.9). Peptide mass fingerprinting was another 
method used to confirm the presence of PSA on the surface of the beads. In this 
method, protein immobilized on the beads is digested and the masses of released 





Figure 2.9 Scheme of competitive ELISA - bead assay. Target coupled and naked beads are preincubated 
with detecting antibody and enzyme-linked secondary antibody. This mixture is then added to target coated well and 
incubated together. The plate is washed, and unbound antibodies removed. The more target in the preincubation solution, 
the less antibody will be able to bind to the target in the well, hence “competition”. Finally substrate is added, and 
remaining enzymes elicit a signal. Naked beads are used in order to substract the background, which can be caused due 
to the presence of magnetic beads.  
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2.4.3.1 Peptide Mass Fingerprinting 
 
The attachment of PSA was firstly studied using peptide mass 
fingerprinting (p.m.f.). The resulting mass spectrometric data was processed using 
Data Explorer Software (Figure 2.10) and the Swiss Prot.2008.06.10 database 
(Table 2.2). Clear spectra were obtained indicating immobilization of pro-PSA for 
all the beads studied (the example given in Figure 2.10 is for carboxyl magnetic 
beads). This technique provided qualitative confirmation of the immobilization of 
the PSA target, but does not give quantitative information as to which of the beads 
provides the best surface for a high loading of PSA. However, in the case of targets 
for which no antibody exists and thus no ELISA can be developed to quantify the 





Figure 2.10 Mass spectrometric data obtained from Data Explorer Program. In bubbles there 
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Table 2.2 Peptide mass fingerprinting of protein immobilized on the beads obtained 
from Swiss Prot database. 
 
 
Hit Number Protein name MOWSE Protein MW pI Accession Species 
1 Prostate Specific 
Antigen precursor 




2.4.3.2 Quantification of PSA coupled beads 
 
An ELISA bead assay, based on competition between PSA immobilized on 
the plate and PSA coupled to the surface of beads was used for the quantification 
of immobilized PSA. A calibration curve was constructed in the range of 0 to 60 
µg/ml and a sigmoidal relationship was obtained (R2 = 0.999), with a detection limit 
of 0.023 µg/ml (Figure 2.11). The calibration curve was used to quantify samples of 
PSA coupled beads prepared by different methodologies. Ten milligrams (200 µl, 
50 mg/ml) of amine, carboxyl, epoxy and hydrazide functionalized beads and two 
milligrams (200 µl, 10 mg/ml) of streptavidin beads were used for these studies.  
The different bead concentrations were chosen due to the theoretical different 
binding capacities of the selected beads according to the manufacturer’s 
instructions.   
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Figure 2.11 Standard curve for competitive 
ELISA bead assay and the best fit values. 
 
   
The amount of PSA bound on the surface of amine, carboxyl, and epoxide 
functionalized beads is depicted in Figure 2.12. Similar amounts of PSA was 
observed using carboxyl (204 ± 12 µg/ml, n=5) and epoxy modified beads (218 ± 
25 µg/ml, n=5), whilst a lower amount was found in the case of amine 
functionalized magnetic beads (107 ± 16, n=5). With respect to control (naked) 
beads, a high background was observed in the case of amine modified beads (31 ± 
12 µg/ml, n=5), while in the other cases, a low (epoxide beads 7 ± 3 µg/ml, n=5) 
or no background (carboxyl beads) was observed. This background is probably due 
to the presence of magnetic beads in the assay, which could be eliminated using 
more washing steps.  
FIT VALUES 
LOD 0,023 µg/ml 
EC50 1,468 µg/ml 
R2 0,999 
Replicates 3 
UNIVERSITAT ROVIRA I VIRGILI 
SELECTION OF APTAMERS AGAINST PROSTATE SPECIFIC ANTIGEN FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 
Markéta Svobodová 
DL: T. 888-2012 
 































 PSA coupled beads
 Naked beads
 
Figure 2.12 The degree of PSA on the surface of PSA coupled and 




In the case of the hydrazide modified magnetic beads, no consistent results 
were obtained (data not shown), which can be attributed to large losses of target 
during the oxidation process and a very low amount of PSA immobilized on the 
surface of the beads.  
 
For the biotin-avidin system, two different linkers were used for 
biotinylation of PSA. Sulfo-NHS-Biotin enabled simple and efficient biotin labeling 
of any primary amine on the PSA, while Amine-PEG-Biotin linked to carboxyl 
groups on the PSA. The biotinylation of the protein was confirmed by Mass 
Spectra (Figure 2.13), where we could see additions of biotin xn (Mr 452.75) to the 
un-derivatized PSA (Mr 28 433).  
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Figure 2.13 Spectrum of molecular weight for the biotinylated PSA with Sulfo-NHS-Biotin 
as obtained by TOF MS ES+ and reconstructed mathematically from m/z to molecular 
scale. In the spectrum additions of 1 (A), 2 (B), 3 (C), and 4 (D) biotins can be observed.   
 
 
The amount of biotinylated PSA immobilized on the surface of 
streptavidin coated beads was estimated by measuring the OD280 of pre and post-
bead binding solutions (Table 2.3).µ 
 
 
Table 2.3 The amount of PSA immobilized on the surface of streptavidin coated 




PSA bound to 
the beads (µg/ml) 
Total PSA for one 
mg of beads (in µg) 
Total PSA for one mg of 






107 ± 12 
79 ± 11 
 
11 ± 1 
8 ± 1 
 
356 ± 41 
263 ± 37 
 
 
These results are in good correlation with those obtained from ELISA 
bead assay (Figure 2.14), where the amount of immobilized PSA was 98 ± 10 
µg/ml (n=5) in the case of Sulfo-NHS-Biotin, and 67 ± 12 µg/ml (n=5) in the case 
of Amine-PEG-Biotin. The slightly higher values obtained with absorbance 
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measurements may be due to non-specific absorption of biotinylated PSA to the 
tube. A higher amount of immobilized PSA was observed when Sulfo-NHS-Biotin 
was used for biotinylation of PSA. This is in agreement with the high levels 
obtained with the carboxyl coated beads and it appears that linking through the 
amine groups on PSA achieves a higher loading even though a lower number of 
lysine residues are available as compared to carboxyls.  





































Figure 2.14 The degree of PSA on the surface of streptavidin 
coated beads determined by ELISA bead competitive assay, 
(n=5). 
 
It is not only the amount of immobilized PSA but also the amount of 
magnetic beads in solution that is important during SELEX. A higher amount of 
beads represents more surface, which can result in higher nonspecific binding of 
oligonucleotides. For this reason we calculated the amount of immobilized PSA per 
milligram of modified beads (Figure 2.15), obtaining 134 ± 8 pmol (n=5) on 
carboxyl, 145 ± 16 pmol (n=5) on epoxide, and 71 ± 10 pmol, (n=5) on amine 
modified beads. In the case of the streptavidin beads, as expected due to the 
different binding capacity, higher values were observed per milligram of beads, with 
values differing according to the linkers used for biotinylation with 223 ± 39 pmol 
(n=5) for the Amine-PEG-Biotin linker and 326 ± 33 pmol (n=5) for the Sulfo-
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NHS-Biotin linker showing the highest values of PSA immobilized on the surface 
of the beads, the latter thus having the highest loading of PSA/mg beads.   







































Figure 2.15 The amount of PSA (in pmol) calculated for 
one mg of beads (n=5). S-APB - streptavidin beads with Amine-
PEG-Biotin linkedr, S-SNB  - streptavidin beads with Sulfo NHS 
linker. 
       
 
 
2.4.3.3 Stability of immobilized PSA  
 
The stability of PSA coupled beads was also evaluated. PSA coupled beads 
prepared as described previously were stored at 4° C for 4 weeks. After this period 
of time, the amount of remaining PSA was studied using the ELISA bead assay. 
The amount of PSA after 4 weeks storage was 117 ± 15 pmol (n=5) on carboxyl, 
64 ± 10 pmol (n=5) on amine, and 83 ±13 pmol (n=5) on epoxy modified beads, 
whilst for the streptavidin beads, the amount of PSA was 325 ± 33 pmol (n=5) 
when Sulfo-NHS-Biotin linker was used, while 223 ± 39 pmol (n=5) was found in 
case of Amine-PEG-Biotin linker. In most of cases, ≥ 80 % of the amount of PSA 
was obtained, indicating that the PSA coupled beads are relatively resistant to 
storage conditions. Only PSA immobilized on the epoxy beads showed a severe 
reduction of PSA to 57% (Figure 2.16).  
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Figure 2.16 The amount of PSA converted into %. 100 % 
represent the amount of PSA obtained for each methodology in first 
ELISA beads Assay (week 0). S-APB - streptavidin beads with Amine-





2.4.3.4 Activity of immobilized PSA 
 
The influence of the different types of immobilization process on the activity 
of PSA bound to the beads was evaluated by using fluorogenic PSA substrate. To 
this end, the activity of PSA was monitored before, immediately after, and 4 weeks 
after the immobilization process (Figure 2.17). Results indicate, that none of the 
various types of immobilization process used in this work interfere with the 
structural and functional integrity of PSA.  
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 bound PSA (0 week)
 bound PSA (4 weeks)
 
Figure 2.17 PSA activity before and after the 
immobilization process. PSA protease activity was measured by 
means of the cleavage of a fluorogenic peptide substrate before (free PSA), 
immediately after (bound PSA 0), and 4 weeks (bound PSA 4) after the 
immobilization process. The values obtained prior to the immobilization 
were normalized to 100%. S-APB - streptavidin beads with Amine-
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The characterization of PSA samples obtained from seminal fluids was 
performed using different techniques. The purity and homogeneity of the samples 
were analyzed on SDS-PAGE. Fragments of different molecular weights observed 
on the gel indicated that the PSA samples are composed of different forms of PSA 
resulting in heterogeneous pattern on the gel. This heterogeneity of PSA samples 
was also confirmed by Mass spectrometry. Two different lots of PSA samples used 
in these studies showed identical MS spectra and a very similar pattern on SDS-
PAGE gel electrophoresis, indicating a high consistency in the proportion of PSA 
isoforms in seminal fluids in the sample tested. Different immobilization strategies 
were investigated in order to determine the best strategy for PSA immobilization. 
Two promising strategies have been obtained from these studies: (i) the amine 
coupling using carboxyl modified beads and (ii) the use of bioaffinity technique 
with the biotin – streptavidin system. The use of carboxyl modified beads 
represents a covalent type of immobilization. This type of target binding can 
sometimes lead to the changes in protein structure or enzymatic activity, 
nevertheless in the case of PSA no changes in enzymatic activity were observed. In 
addition generally low non-specific binding of oligonucleotides is observed with 
this type of bead. On the other hand, the use of streptavidin coated beads seemed 
to be the best choice in terms of the amount of immobilized PSA. In comparison 
to other methods a lower amount of streptavidin beads needs to be used for the 
same amount of immobilized PSA. However the presence of streptavidin can be 
problematic during SELEX, as it can present an additional target for aptamer 
selection. Hitherto, several aptamers against streptavidin have been selected which 
is favoured as streptavidin appears to be an ideal target for aptamer selection [20, 
26-27]. However, this can be solved using a negative selection step prior to the 
positive selection in order to remove oligonucleotides that bind to streptavidin.  
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The starting point of a SELEX process is a chemically synthesized random 
library. This library consists of a multitude of single stranded DNA (ssDNA) 
fragments (~1015 molecules) comprising a central random region flanked by two 
fixed sequences, which function as primer binding sites in the PCR amplification 
(Figure 3.1). For the selection of RNA aptamers, this library needs to be transcribed 
into a RNA library. In the case of a DNA based SELEX process, this library can be 
used directly in the first round of selection. Amplification of the oligonucleotide 
random library at the beginning and throughout the SELEX is of considerable 
importance, as the correct choice of library and efficient PCR amplification of the 
random library contribute to the success of aptamer selection.  
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Figure 3.1 Scheme of oligonucleotide library. Random region is flanked by two fixed regions 
which serve for annealing of primers during PCR amplification.  
 
 
3.1.1 Design of primers and oligonucleotide library 
 
      The design of the oligonucleotide library such as the size of the 
randomized region and primer-binding sequences flanking the randomized region 
plays an important role for the amplification of DNA.  The size of the random 
region varies from 20 to 80 nucleotides. Although any length of randomized 
region may be used to provide 4n theoretical random sequences, the 
maximum number of molecules that can be manipulated in standard 
molecular biology laboratories is in the order of 1015, and errors of synthesis 
and workup have been estimated to reduce this diversity to 1013 - 1014 [1]. 
This number corresponds to the total number of different sequence variants 
for oligonucleotides of 25 nucleotides in length (425≈1015). Libraries with the 
random region longer than 25 nt are thus under represented and contain the 
same number of different variants as shorter libraries [2]. An aptamer for the 
human thrombin was selected by Bock [3] from a DNA library of 96-mer 
oligonucleotides containing a random sequence with 50 nucleotides. The 
aptamer was truncated to the minimal size required for binding of the 
thrombin target and a consensus sequence with 15 nucleotides was obtained, 
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suggesting that libraries with short randomized regions are sufficient for 
aptamer selection. On the other hand longer randomized regions of libraries 
can lead to greater structural complexity and provide more opportunities for 
the selection of aptamers [4].  It has been demonstrated with selection of 
aptamers to isoleucine that both short (16nt) and the long (90nt) 
randomized regions complicate aptamer selection [5]. In practice, therefore, 
randomized regions of 30-60 nucleotides are most common. The primer 
binding regions should be long enough (20 - 23 nt) to ensure stable and specific 
hybridization of primers at the required temperature. These regions should not 
contain regions of internal complementary sequences so as to avoid hairpin 
structures. In addition, regions of sequence overlap with another primer should be 
avoided to circumvent primer-dimer formation [6]. A non-observance of these 
points may lead to the generation of longer or smaller size PCR products. 
 
 
3.1.2 PCR amplification of a random library  
 
An efficient SELEX procedure has to be accompanied by efficient PCR 
amplification to obtain one defined length of double stranded DNA (dsDNA). The 
specificity of PCR amplification is subject to variation depending on a fine balance 
of target concentration, primer specificity and amplification conditions [7]. Within 
the cocktail of components the concentration of magnesium, primer concentration 
and DNA polymerase activity may all influence the efficiency of the PCR reaction 
[8]. In addition, temperature, time, and number of PCR cycles must be optimized 
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3.1.3 PCR optimization of a random library during SELEX process 
 
In PCR for the selection of aptamers, the random DNA or RNA is used as 
the PCR template, and the heterogeneity of template sequences with different GC 
contents can cause non-uniform amplification during the PCR due to the stable 
stem-loop secondary formation of GC-regions. These structures promote 
polymerase jumping during PCR amplification,  which yields PCR products of 
smaller sizes missing the stem-loop region of the template [9]. This non-uniform 
amplification then biases the composition of DNA sequences in the amplified 
library and consequently will affect the selected sequences. In addition, this will 
cause a loss of sequences that form stable secondary structures, which are usually 
found in ss-DNA or RNA aptamers. For this reason, it is critical to retain those 
sequences that form stable secondary structures during the iterative cycles of 




3.1.3.1 Additives in PCR amplification 
 
One of the common methods to improve yield and specificity of PCR 
amplification is the addition of certain organic additives, such as DMSO, betaine, 
polyethylene glycol, glycerol, formamide, 7-deaza-dGTP, or dITP to the reaction 
mixture [11-18]. Specifically, the effect of DMSO in the PCR amplification of some 
GC-rich sequences is the most widely studied [12-14]. There are also reports 
demonstrating that the addition of betaine also improves the amplification of GC-
rich sequences [15-17]. Both additives can also act simultaneously and improve 
PCR amplification by increasing the ratio of full-length products to shortened 
products [10]. The presence of single-strand binding protein (SSB) in a PCR 
mixture,  which is commonly used to prevent premature annealing,  can also 
improve PCR efficiency [19]. The use of these additives for amplification of a 
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random library during SELEX process, will provide a greater chance to isolate 
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The main objectives of this chapter were the analysis and optimisation of 
PCR amplification of three selected random libraries. The optimisation of PCR 
conditions was performed particularly for SELEX. More specifically, this 
encompassed 1) selection of 3 different random libraries and their specific primers,  
2) analysis and optimisation of PCR amplification of the initial pool of random 
libraries, 3) optimisation of PCR amplification of random libraries during the 
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3.3.1 Oligonucleotide libraries 
 
Three different libraries were used in this work.  All libraries contain a 
random region of the sequence flanked by fixed primer hybridization regions. 
Library I (5'-AGC TGA CAC AGC AGG TTG GTG - N(49) - CA CGA GTC 
GAG CAA TCT CGA AAT-3') was amplified using a forward primer F_1 ( 5´-
AGC TGA CAC AGC AGG TTG GTG-3´), and reverse primer R_1 ( 5´-ATT 
TCG AGA TTG CTC GAC TCG TG-3´). Library II (5´-GCC TGT TGT GAG 
CCT CCT AAC – N(49) – CA TGC TTA TTC TTG TCT CCC-3´) was amplified 
using a forward primer F_2 (5´- GCC  TGT TGT GAG CCT CCT AAC-3´), and 
reverse primer R_2  (5´-GG GAG ACA AGA ATA AGC ATG-3´). Library III 
(5´-AGC TCC AGA AGA TAA ATT ACA GG – N(53) – CAA CTA GGA TAC 
TAT GAC CCC-3´) was amplified by forward primer F_3 (5´- AGC TCC AGA 
AGA TAA ATT ACA GG-3´),  F_3 primer containing T7 promotor sequence 
F_3_T7 (5´- CCC AAG CTT AAT ACG ACT CAC TAT AGG GAG CTC CAG 
AAG ATA AAT TAC AGG-3´), and reverse primer R_3 (5´-GGG GTC ATA 
GTA TCC TAG TTG-3´). The first two random libraries and their primers were 
synthesized, purified, lyophilized and purchased from BIOMERS (Ulm, Germany). 
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3.3.2 Amplification of a random libraries  
 
 
3.3.2.1 Library I 
 
The amplification of library I was performed in 100 µl reactions with 200 
nM of primers (R_1, F_1), 3 mM of  MgCl2, 0.2 mM of dNTP, 1x Taq buffer (200 
mM Tris pH 8.4, 500 mM KCl), and 2.5 units of Taq polymerase. Four PCR 
reactions containing different concentrations of initial template (100 pM, 200 pM, 
300 pM, 400 pM,) with one PCR reaction without DNA template as the negative 
control were heated at 95°C for 2 minutes, followed by 15 rounds of PCR, with a 
denaturing step at 95°C for 30 seconds, annealing step at 60°C for 30 seconds, and 
an elongation step at 72°C for 30 seconds. A final extension step was performed at 
72°C for 5 minutes. PCR amplification was carried out in a DNA Engine Dyad® 
Peltier Thermal cycler. All PCR reagents were obtained from Invitrogen (Barcelona, 
Spain). Double stranded PCR products were checked by electrophoresis. For each 
sample, 10 µl was run on the gel with 4 µl of loading buffer (Invitrogen, Madrid, 
Spain) on a 4% w/v agarose gel stained with GelRed nucleic acid stain (Biotium, 
Hayward, USA) and visualized with a UV lamp (Biorad, Madrid, Spain). Certified 
Low Range Ultra Agarose was supplied by Biorad (Madrid, Spain). Fragment sizes 
were determined by comparison with a 10 bp molecular weight standard 
(Invitrogen, Madrid, Spain) and analyzed using Image-J software. 
 
 
3.3.2.2 Library II 
 
The amplification of library II was performed in 100 µl of PCR reactions 
with 1.1 µM forward primer (F_2), 0.9 µM reverse primer (R_2), 3.5 mM MgCl2, 
0.2 mM dNTP, 0.5 µg/µl BSA, 1x Taq PCR buffer, 2.5 units of Taq polymerase, 1 
µl of template and water to final volume.  Five PCR reactions containing different 
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concentrations of initial template (100 pM, 200 pM, 300 pM, 400 pM) or water in 
place of DNA in the case of the negative control were heated at 95°C for 2 
minutes, followed by settings: 1 min 95°C, 1 min 54°C, 1.5 min 72°C for 15 times. 
The final extension was performed at 72°C for 5 minutes. The gel electrophoresis 
and analysis of amplified product was carried out as described above (section 
3.3.2.1).   
 
 
3.3.2.3 Library III 
 
The initial pool Library III was generated by amplification using 50 µl of 
PCR reactions. Six PCR reactions containing different concentrations of starting 
library (0.4 µM, 40 nM, 4 nM, 0.2 nM, 20 pM) were used.  Each reaction contained 
0.2 mM dNTPs, 0.5 µM of both primers (R_3, F_3_T7) 1 x KAPA 2G Buffer 
(containing 1,5 mM MgCl2), 1 x KAPA enhancer, 2 Units of 2G robust enzyme, 1 
µl of template, and nuclease free  water to 50 µl of final volume. This was heated for 
2 minutes at 95°C, followed by 10 cycles of 30 seconds at 95°C, 60°C, and 72°C. 
After PCR, amplified product was checked on agarose gel as described above 
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3.4 Results and Discussion 
 
 
3.4.1 Selection of random libraries 
 
There are a lot of commercially available oligonucleotide libraries which 
have been successfully used to select aptamers with high affinities for their targets. 
These random libraries are reliable and the affinity characteristics of the selected 
oligonucleotides are generally very good. Three different libraries were used in this 
work. Library I  was previously used by Bock in 1992 for the selection of the 
thrombin binding aptamer [3]. Library II was previously used for the selection of 
different biotinylated targets bound to the streptavidin beads [20]. The last library 
(III) was used in the selection of 2´F modified RNA aptamers in the group of Prof. 
Peter Stockley (University of Leeds, England). All these three libraries contained 
49-50 randomized regions, which give the libraries a greater structural complexity. 
This is particularly important for challenging targets. Therefore, a longer random 
sequence pool may provide better opportunities for the indentification of aptamers 
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3.4.2 PCR analysis and optimisation  
 
 
3.4.2.1 Library I 
 
Library I was primarily amplified using standard PCR conditions. In the 
case of primers > 20 nt it is recommended to use an annealing temperature about 
3°C higher than the lowest Tm of the pair of primers used in the PCR reaction [21-
22], therefore the annealing temperature of  about 60°C (Ta) was selected for the 
first amplifications of Library I. The template concentration was used in the range 
100 – 400 pM. In the preliminary assessment (Figure 3.2.), a PCR product of 
desired size was amplified, but also significant non-specific amplification (by-
product) was observed. It was deemed that this could be overcome with further 
optimisation of the PCR reaction.  
                      
 
 
Figure 3.2 Preliminary PCR amplification of library I with different concentration of 
template (1: 100 pM, 2: 200 pM, 3: 300pM, 4: 400 pM, 5: Non Template Control (NTC)), MW 
– 10 bp molecular weight marker. 
 
 
Optimisation of MgCl2 concentration using two different DNA polymerases 
 
The most suitable polymerase for SELEX process was evaluated by using 
Taq polymerase, and Tfi polymerase. These polymerases were selected as they are 
readily available and are cost effective in comparison to more specialised 
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polymerases on the market. The MgCl2 concentration was optimised for each 
enzyme by amplifying 300 pM of synthetic library in PCR cocktails containing one 
of the two polymerases and using between 3 and 7 mM of MgCl2 (Figure 3.3). In 
the case of Taq polymerase the MgCl2 concentration associated with a higher yield 
of desired DNA band was 5 mM and above. However, with increasing 
concentrations of MgCl2 non-specific products were also observed. Tfi polymerase 
showed the optimum concentration of MgCl2 to be 5 mM. At higher 
concentrations of MgCl2 the amount of specific product decreased, which can be 
due to the inhibition of DNA polymerases by high concentrations of MgCl2. 
Taking into consideration the amount of amplified specific band and the amount of 
non-specific product, Tfi polymerase with 5 mM of MgCl2 was selected for the 




Figure 3.3 Optimisation of concentration of MgCl2 for DNA polymerases. 
Amplification was carried out with each polymerase (A – Taq polymerase, B – Tfi polymerase) and 
optimised with MgCl2 concentration ranging from 3 to 7 mM (1: 3mM, 2: 4mM, 3: 5mM, 4: 6mM, 5: 
7mM). Negative controls were run for each sample, on the gel the NTC is shown (6) for Tfi polymerase 
with 5 mM concentration of MgCl2. 
 
 
Optimisation of annealing temperature, dNTP´s, primer and polymeras concentrations, and 
number of PCR cycles.  
 
Having selected the DNA polymerase, MgCl2 and template concentration, 
the remaining components of the PCR reaction were optimised with the aim of 
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improving PCR specificity.  The primer, dNTPs and polymerase concentrations, 
along with the amplification temperature and number of PCR cycles were 
optimised in a series of multi-factorial experiments. The specificity and the amount 
of yield of PCR product was not improved by changing the primer, dNTPs or 
polymerase concentrations. On the other hand, a considerable improvement in the 
specificity of the PCR amplification was observed by decreasing the annealing 
temperature from 60° C to 58° C (Figure 3.4).  
 
 
Figure 3.4 Effect of annealing temperature on the specificity of PCR product.  
The optimisation was carried out ranging from 58° C to 60° C (1: 58° C, 2: 58.5° C, 3: 59° C, 4: 
59.5° C, 5: 60° C). MW – 10 bp molecular weight marker, 6 – NTC. 
 
This was further improved by decreasing the number of PCR cycles, 




Figure 3.5 Different template concentration using 15 (A), 10 (B), 5 (C) numbers of 
PCR cycles. MW – 10 bp molecular weight marker.  Different template concentration (1: 100 pM, 2: 
200 pM, 3: 300 pM,  4: 400 pM).  
 
UNIVERSITAT ROVIRA I VIRGILI 
SELECTION OF APTAMERS AGAINST PROSTATE SPECIFIC ANTIGEN FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 
Markéta Svobodová 
DL: T. 888-2012 
 
Selection and amplification of a random library, its optimization and use in SELEX process 
80 
 
We have also found that when more than 15-20 PCR cycles was used, non-
specific amplification occurred. As PCR amplification in this work involves libraries 
of random DNA sequences, it is in essence different from PCR amplification of 
homogenous DNA templates. Product formation for a homogenous DNA 
template progresses until primers are depleted, however for a random DNA library, 
synthesis stops even when PCR primers are still in abundance. The products then 
promptly transmute into by-products. Moreover, over-amplification may also cause 
a complete loss of products.  The optimal conditions elucidated for the 
amplification of library I was 200 nM primers, 200 µM dNTP, 2.5 units of Tfi 
polymerase, 5 mM MgCl2 with an annealing temperature of 58°C and the number 
of PCR cycles not exceeding more than 15 cycles. This optimized protocol was 
subsequently adopted for SELEX. 
 
        
3.4.2.2 Library II 
 
The amplification of library II was achieved using a previously described 
protocol [20]. No PCR product of desired size was present in any sample, while 
very significant amounts of non-specific “by products” were observed (Figure 3.6). 
Non-specific amplification was also found in the non-template control indicating a 




Figure 3.6 Preliminary PCR amplification of library II with different concentrations 
of template (1: 100 pM, 2: 200 pM, 3: 300 pM, 4: 400 pM, 5: NTC), MW – 10 bp molecular 
weight marker. 
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A series of multi-factorial experiments were carried out using different 
PCR conditions such as amount of template, primer, dNTPs, DNA polymerase, 
and MgCl2 concentrations with changes in the number of PCR cycles, time and 
temperature. Following optimisation, a new protocol containing 200 nM primers, 
200 µM dNTP, 2.5 units of Tfi polymerase, 5 mM MgCl2, 0.5 µg/µl BSA with a 
reduced cycle length (30 sec 95°C, 30 sec 54°C, 45 sec 72°C) resulted in a 
considerable improvement in the specificity of PCR product (Figure 3.7).  
 
 
Figure 3.7 Different number of PCR cycles using two different template 
concentrations (A – 300 pM, B – 100 pM) using new optimised protocol. MW – 10 bp molecular 
weight marker.  Different number of PCR cycles (1: 5, 2: 10, 3: 15, 4: 20, 5: 25), NTC (6).  
 
 
3.4.2.3 Library III 
 
Library III was used for the preparation of a RNA library, and thus a 
specific forward primer containing T7 promotor sequence (F_3_T7) was used for 
PCR analysis. The amplification of this library was performed using serial dilutions 
of starting library, and the optimum concentration of the initial pool was found to 
be 4 nM (Figure 3.8) where a discrete and specific band was observed without any 
non-specific products.  
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Figure 3.8 Preliminary PCR amplification of library III with different concentrations 
of template (1: 0.4 uM, 2: 40 nM, 3: 4 nM, 4: 0.2 nM, 5: 20 pM, 6: NTC), MW – 10 bp 
molecular weight marker. 
 
 
3.4.3 Amplification of random libraries during SELEX process 
 
During several selection processes problems with the amplification of the 
random library were observed. The most evident was that an initial nucleic acid 
population that appeared as a discrete band on a separating agarose gel after three 
or four rounds of the SELEX process smeared into a multi-sized population 




Figure 3.9 PCR product from different rounds of SELEX. MW - 10 bp molecular weight 




The most likely explanation is that there is mispriming of the 3´ends of 
DNA in the random regions of other molecules in the population. This smeared 
band affected subsequent generation of ssDNA, resulting in a lower yield. To solve 
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this problem, different methods such as emulsion PCR [23], or addition of different 
reagents which are potentially effective for amplification of random libraries (see 
section 2.1.3.1) were used. The addition of single stranded binding protein (SSB), 
and optimization of PCR conditions after each round of SELEX with shorter 
annealing times, higher concentrations of template and a low number of PCR cycles 
were found to prevent such smearing (Figure 3.10).  
 
                                            
Figure 3.10 Double stranded DNA product of enriched library using optimized PCR 
conditions. Enriched library was amplified using optimized conditions with 0,1 µg/ml  SSB (1), x 0,5 
µg/ml SSB (2), or without SSB , 4 - 10 bp molecular weight marker. 
 
In another case of selection, after several rounds of SELEX, PCR products 
of smaller sizes appeared. This problem seemed to be related to the selection of 
sequences with high GC contents as mentioned above. Periodic gel band 
purification and addition of different concentrations of certain organic additives, 
such as DMSO, betaine, polyethylene glycol, glycerol and formamide, to the 
reaction mixture were used to resolve this problem. Figure 3.10 depicts one of the 
selection processes with this specific problem, where a smaller band appears in the 
second selection round, and with increasing intensity in further selection rounds. 
For this reason, the purification of the 100 bp band was performed after the 4th and 
6th round of SELEX. Nevertheless, this band repeatedly appeared during the 
selection process. The best conditions to decrease the amount of these undesired 
products were obtained by performing PCR amplification with 3% DMSO and 500 
mM Betaine. 
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Figure 3.11 PCR product from different rounds of SELEX.  MW – 10 bp molecular weight 
marker, 1-9 different SELEX rounds. Lower band is evident from third round.  After 4th and 6th round 
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3.5 Conclusions  
 
The selection of three different libraries with their specific features was 
performed, and the analysis of amplified products and the optimization of PCR 
conditions for all libraries were carried out to ensure a high purity of the amplified 
libraries. At the end of PCR optimisation new protocols specific for each library 
were determined for use in SELEX (Chapters 5, 6). The composition of random 
libraries changes during the SELEX process and optimisation of enriched libraries 
is often required. We have found that the addition of SSB protein with optimized 
PCR conditions prevented smearing of the band into a multi-sized population. 
When products of smaller sizes appeared during SELEX process, PCR 
amplification performed with 3% of DMSO and 500 mM of Betaine helped to 
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Single stranded DNA (ssDNA) generation is a crucial step in several 
molecular biology applications, such as sequencing or DNA chip and microarray 
technology.  Molecules of ssDNA also play a key role in the selection of ssDNA 
aptamers through SELEX. The generation of the ssDNA is a critical step as the 
purity and the amount of ssDNA can have a significant impact on the successful 
evolution throughout the SELEX process.   
Various methods have been reported for the generation of ssDNA, and 
one of the most widely used methods is magnetic separation using streptavidin 
coated beads [1-2]. In this technique, a biotinylated primer is used during 
amplification, resulting in a biotinylated double-stranded (ds) DNA duplex, which 
is then captured by the strepatavidin coated magnetic beads, and subjected to 
chemical/thermal denaturation, where the non-biotinylated DNA strand is released 
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into a supernatant and eluted.  An alternative method used for the generation of 
ssDNA exploits a urea-polyacrylamide gel [3-5] where PCR is performed with a 
specific long primer to produce strands of different lengths, which are separated 
using denaturing gel electrophoresis and the separated strands are identified by UV 
shadowing or fluorescence and the desired strand is excised from the gel.  In 
another approach termed asymmetric PCR, one strand of the template DNA is 
amplified more than the other by using an unequal molar ratio of forward and 
reverse primers, and when the primer present at a markedly lower concentration 
becomes exhausted, single stranded DNA is thus produced in each PCR cycle [6-7]. 
Alternatively, exonucleases such as the T7 Gene 6 exonuclease [8-9] and Lambda 
exonuclease [10-12] can be used to produce ssDNA, via modification of the 
primers used in amplification. The T7 Gene 6 exonuclease hydrolyses one strand of 
DNA non-processively in the 5' to 3' direction, while the second strand is protected 
against the hydrolytic activity of the enzyme with several phosphotorothioates at its 
5'end. In the case of the lambda exonuclease, phosphorylated strands of DNA are 
selectively digested by the enzyme, which has greatly reduced activity on ssDNA 
and non-phosphorylated DNA.  Finally, using denaturing high performance liquid 
chromatography, a biotinylated primer is used for amplification and, following 
denaturation, the strands are separated based on differences in retention time [13].     
Generation of ssDNA is not only important in SELEX, but also for other 
applications such as Pyrosequencing [14-15], solid phase DNA sequencing [16] 
DNA single strand conformation polymorphism (SSCP) analysis [17], nuclease S1 
mapping [18], probe preparation and labelling [19], subtractive hybridization [20], as 
well as for DNA chips and microarrays [21-22].  
Specifically related to SELEX, several studies comparing different methods 
for the generation of ssDNA have been reported [17, 22]. Recently, detailed review 
about DNA aptamers achieved by different type of ssDNA generation methods 
was described [23], showing that aptamers with similar characteristics have been 
selected by different methods, and suggesting that success of DNA SELEX is not 
principally influenced by the type of methods employed in generating ssDNA. The 
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most critical points are the quality of ssDNA and the amount of obtained ssDNA. 
Final ssDNA should be free from impurities such as remaining dsDNA, proteins 
and enzymes which can be present together with ssDNA depending on the 
technique used for ssDNA generation. And no less important is the amount of 
ssDNA which should be controlled in each selection round for successful selection 
of highly affine aptamers. All generally used methods required many parallel 
reactions in order to prepare sufficient amount of ssDNA which can be used for 
one selection round.  
Moreover, generation of ssDNA is very time-consuming in methods such 
as enzyme digestion and magnetic separation due to the several purification steps, 
including purification of PCR product in order to use buffers specific for each 
technique and purification of ssDNA at the end of process which is absolutely 
necessary to remove any possible impurities which remain in the solution. In this 
work we compare the yield obtained from purified and unpurified PCR product 
showing the possibility of ssDNA generation directly from PCR product without 
the need of extra purification step.  
In addition, we present a new technique which combines the high efficient 
asymmetric PCR with enzyme digestion resulting in minimum remaining impurities 
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The main objective of this part was to compare techniques generally used 
for the generation of ssDNA, including the previously reported methods of 
asymmetric PCR, lambda exonuclease digestion and magnetic separation, as well as 
new combined method mentioned above. The efficiency of each system for the 
generation of ssDNA was quantitatively evaluated using an enzyme linked 
oligonucleotide assay (ELONA) which specifically quantifies ss DNA and the 
quality of ssDNA was assessed using agarose gel electrophoresis. Finally, all studied 
methods were compared in terms of time and cost needed for preparation of 50 
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A single stranded DNA library containing a 49-mer sequence flanked by 
fixed primer hybridization regions (SL-lib_ 5'-AGC TGA CAC AGC AGG TTG 
GTG - N(49) - CA CGA GTC GAG CAA TCT CGA AAT-3') was used.  This 
library was amplified using a forward primer (F_ 5´-AGC TGA CAC AGC AGG 
TTG GTG-3´), and reverse primer (R _ 5´-ATT TCG AGA TTG CTC GAC TCG 
TG-3´). Modifications of the reverse primers with biotin (R_bio), phosphate 
(R_pho), and modifications of the forward primer with phosphorothioate (F_pto) 
were used depending on the method of ssDNA generation. Horseradish peroxidase 
labelled probe (HRP probe_ 5´-CAC CAA CCT GCT GTG TCA GCT-3´) was 
used in ELONA studies.  The random library, all primers, and HRP labelled probe 
were HPLC-purified, lyophilised and purchased from BIOMERS (Ulm, Germany). 
Taq polymerase and dNTP Set were supplied from Invitrogen (Madrid, Spain). 
Certified Low Range Ultra Agarose was purchased from Biorad (Madrid,Spain), and 
T7 Gene 6 Exonuclease with Lambda Exonuclease from Affymetrix, Wycombe 
Lane, United Kingdom. 
 
4.3.2 Amplification of the random library 
 
Amplification of the random library was performed with 300 pM of initial 
template. All PCR reactions were performed in a total volume of 100 µl with 200 
nM of primers, 5 mM of MgCl2, 200 µM of dNTP, 1x Taq buffer (200 mM Tris pH 
8.4, 500 mM KCl) and 2.5 units of Taq polymerase.  The PCR reactions were 
heated at 95°C for 2 minutes in order to completely denature the template, 
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followed by 10 rounds of PCR, with 30 seconds of denaturation at 95°C, 30 
seconds of annealing at 58°C, and 30 seconds of elongation at 72°C. A final 
extension step was performed at 72°C for 5 minutes. Double stranded PCR 
products were checked using electrophoresis. For each sample, 10 µl was run with 4 
µl of loading buffer (Invitrogen, Madrid, Spain) on a 4% w/v agarose gel stained 
with GelRed nucleic acid stain (Biotium, Hayward, USA) and imaged with UV lamp 
(λ 254 nm).   When purified dsDNA was used, 100 µl of PCR product was purified 
using Quick Gel Extraction and PCR Purification Combo Kit (Invitrogen, Madrid, 
Spain) according to the manufacturer’s instructions.  Purified dsDNA was diluted 
in 100 µl of 10 mM Tris-HCl, pH 8.5 and checked using electrophoresis. For the 
semi-quantitative determination of the concentration of the purified and unpurified 
PCR products, 10 µl of each sample were compared with 10 µl of dsDNA 
standards of known concentration (50 nM, 60 nM, 70 nM, 80 nM, 90 nM) using 
agarose gel electrophoresis. All standards were prepared Electrophoretic analysis of 
the band intensities was performed using Image J program.  
 
 
4.3.3 Generation of ssDNA 
 
4.3.3.1 Magnetic separation with streptavidin coated beads 
 
The random library was amplified using R_Bio modified reverse primer 
and unmodified forward primer. A half miligram of streptavidin beads (Chemicell, 
Berlin, Germany)  was washed twice with 200 µl of 1x B & W buffer (150 mM 
NaCl, 15 mM trisodium citrate, pH 7.0) and re-suspended in 100 µl of 2 x B&W. 
For each reaction, 100 µl of biotinylated PCR product was incubated for 20 
minutes with pre-washed magnetic beads on a Dynal Sample Mixer (Invitrogen, 
Barcelona, Spain).  After incubation, the beads were washed with 1x B&W buffer, 
and subsequently an alkaline denaturation with 50 µl of 150 mM NaOH for 3 
minutes was performed. The eluted non-biotinylated ssDNA was purified using the 
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QIAEX II Gel Extraction kit, which desalts and concentrates DNA (Qiagen Iberia, 
Madrid, Spain) and was diluted in 100 µl of 10 mM Tris-HCl, pH 8.5. 
 
4.3.3.2 Enzyme digestion  
 
The random library was amplified using R_pho or F_pto modified primer 
with the corresponding un-modified primer. For each reaction, 100 µl of PCR 
product modified with F_pto primer was incubated with 40 U (40U/µl) of T7 
Gene 6 Exonuclease in a total reaction volume of 101 µl at 37°C. Similarly, 100 µl 
of PCR product modified with R_pho was incubated with 10 U (10U/µl) of 
Lambda Exonuclease. Digestion times of 10, 30, 45 and 60 minutes were evaluated 
for both enzymes. All reactions were stopped by 10 minutes incubation at 80°C. 
Samples were purified and diluted in 100 µl of 10 mM Tris-Cl, pH 8.5.  
 
 
4.3.3.3 Asymmetric PCR with combination of enzyme digestion  
 
The random library was first amplified as described above using primers 
depending on the method used for elimination of remaining dsDNA.  For Lambda 
digestion modified reverse primer (R_pho) was required, whilst for T 7 Gene 6 
exonuclease and for extraction of ssDNA from agarose gel, modified F_pto was 
used. Asymmetric PCR (A-PCR) was then performed using an optimised protocol 
as described previously [24]. All A-PCR reactions were performed in a total volume 
of 120 µl, with 100 µl of master mix (5 mM of MgCl2, 200 µM of dNTP, 1x Taq 
buffer (200 mM Tris pH 8.4, 500 mM KCl), and 2.5 U of Taq polymerase) with 0.4 
µM of a single primer (R_pho or F_pto) and direct addition of 20 µl of the 
amplified random library (ds-PCR). The thermocycling protocol established for 
amplification of the random library was modified by increasing the extension time 
from 30 seconds to 2 minutes. The optimum number of A-PCR cycles was 12 for 
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both single primers. Following A-PCR amplification, the product was divided into 
two aliquots.   One aliquot was purified and diluted in 100 µl of 10 mM Tris-HCl, 
pH 8.5, whilst the other aliquot was treated with the appropriate exonuclease 
enzyme as described above. When extraction of ssDNA from agarose gel was used, 
fifty microliters of A-PCR product was run through the gel. The ssDNA band was 
subsequently excised from the gel, and purified using the QUAEX II Gel 
Extraction kit for purification of DNA fragments from gels and solutions 
according to the manufacturer's instructions (Qiagen Iberia, Madrid, Spain) and 
diluted in 100 µl of 10 mM Tris-HCl, pH 8.5. 
 
 
4.3.4 Qualitative evaluation of ssDNA by electrophoretic analysis 
 
For all the studied methods for ssDNA generation, 10 µl of the ssDNA 
generated were run on an agarose gel with 4 µl of loading buffer and 2 µl of 150 
mM NaOH.  
 
 
4.3.5 Quantitative evaluation of the ssDNA by ELONA  
 
ELONA experiments were carried out on streptavidin-coated plates 
(Sigma, Barcelona, Spain). Biotinylated reverse primer (20 nM in 50 mM PBS, pH 
7.4) was added to each well of the SA plates and incubated for 1 hour at 37°C. The 
plates were then washed with the Hydroflex automatic plate washer (Tecan, 
Barcelona, Spain) three times with 200 µl of PBS. A dilution series of different 
concentrations (0.1 to 100 nM) of synthetic ssDNA of the same length as the 
random library (93 bases) were applied to the immobilized R-bio primer and 
incubated for 1 hour at 37°C. Following thorough washing, 1 nM of HRP probe 
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was added to the plate for one hour incubation at 37°C. The presence of the HRP 
enzyme label was detected using TMB substrate (Sigma, Madrid, Spain), and 
monitoring of colour development was carried out at 650 nm and stopped after 20 
minutes with 0.1 M H2SO4, and measured at 450 nm using a Spectra max 340 PC 
plate reader (BioNova cientifica, Barcelona, Spain). The ssDNA generated using the 
different techniques were diluted using different dilution factors, and quantified by 
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4.4 Results and Discussion 
 
 
4.4.1 Concentration determination of the starting dsDNA 
 
Single stranded DNA generation is the most time-consuming step of the 
DNA-SELEX process, normally requiring purification of dsDNA from the PCR 
product. Not only is the purification a time-intensive and expensive process, but it 
also results in loss of the dsDNA product which can varied from 10 to 40% 
depending on the purification methods used. To this end, the different methods 
studied were carried out on purified and unpurified/purified dsDNA.  In order to 
calculate the efficiency of the generation of the ssDNA, it is necessary to know the 
starting concentration of dsDNA.  However, in the case of the unpurified dsDNA, 
it is not possible to use UV-Vis spectrometry to measure the DNA concentration at 
= 260 nm, as the primers, smaller/larger side-products of the PCR as well as the 
Taq polymerase would interfere and contribute to the absorbance reading.  
Therefore, the concentration of the dsDNA was determined via electrophoretic gel 
analysis using the Image J software to measure the intensity of bands of dsDNA 
standards of known concentration, which were used to construct a calibration curve 
(R2 = 0.9934), which was used to quantify the purified and unpurified dsDNA.  For 
the unpurified dsDNA, concentrations of 71 ± 4 nM (n=3), 72 ± 3 nM (n=3), 70 ± 
3 nM (n=3), were obtained for each of the pto, pho and bio modified PCR 
products, respectively, whilst for the purified concentrations of 50 ± 3 nM (n=3), 
49 ± 3 nM (n=3) and 52 ± 3 nM (n=3) were obtained for the pto, pho and bio 
modified PCR products. The concentration of both type of PCR products was 
confirmed by 2100 Bioanalyzer (Agilent) using  DNA 1000 chip and excellent 
correlation was obtained, highlighting the reliability of the electrophoretic gel 
analysis methods.  It is interesting to note that in this case 30 % of dsDNA was lost 
during the purification process. 
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4.4.2 Qualitative and quantitative analysis of ssDNA 
 
In order to check the quality of ssDNA, samples obtained from different 
methodologies were analyzed by electrophoretic analysis. Standards of ssDNA of 
known concentration were run in agarose gel together with other samples in order 
to roughly quantify the yield of ssDNA using Image J software. The accurate 
quantification of ssDNA was carried out using ELONA (Figure 4.1). Biotinylated 
probe (R-bio) was immobilized on a streptavidin coated plate, followed by addition 
of ssDNA, which hybridises to the immobilised probe. After incubation, 




Figure 4.1 Scheme of the Enzyme Linked OligoNucleotide Assay (ELONA). Biotinylated probe 
(R_bio) is immobilized on a streptavidin coated plate, followed by addition of ssDNA which binds to the biotinylated 
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4.4.3 Enzyme digestion and magnetic beads based methods 
 
The quality of the single stranded DNA obtained from purified and 
unpurified PCR products was checked by agarose gel electrophoresis. As can be 
seen in Figure 4.2 a, there is a clear and well-defined band that corresponds to 
ssDNA. For the enzyme digestion methods, some remaining dsDNA was observed 
and, as expected, when unpurified dsDNA was used, there were bands 
corresponding to the primers, whilst only the ssDNA band was observed for the 
magnetic bead method.  Electrophoretic analysis of the DNA bands in the agarose 
gel showed similar yields of ssDNA obtained from both purified and unpurified 
PCR products indicating the possibility of generation of ssDNA directly from 
unpurified PCR product, which was confirmed by the quantification of ssDNA 
using ELONA. The theoretical maximum yield of ssDNA was derived from the 
initial dsDNA concentration (i.e. ~ 70 nM for unpurified PCR product, and ~ 50 
nM for purified PCR product). The percentage recovery yields of ssDNA obtained 
using the different methods for both purified and unpurified PCR products is 
depicted in Figure 4.2 b. A calibration curve was constructed in the range 0.1 to 100 
nM and a sigmoidal relationship was obtained (R2= 0.9976), with a detection limit 
of 0.19 nM. The yield of ssDNA obtained by T 7 enzyme digestion was 58 ± 10 % 
(n=5) for purified PCR product, 63 ± 9 % (n=5) for unpurified product. For the 
magnetic beads based method the yield of ssDNA was 58 ± 8 % (n=5) for purified 
PCR product and approximately 5 % less for unpurified PCR product, 52 ± 8 % 
(n=5), and in the case of Lambda exonuclease digestion the yield of ssDNA 
differed 15 % dependent on the purity of the dsDNA (69 ± 7 % (n=5) for purified 
PCR product, and 52 ± 7 % (n=5) for unpurified PCR product). The total amount 
of ssDNA obtained from unpurified PCR products is higher in all cases taking into 
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                                (a)         
 
      
 
         (b)                       (c) 
 
   
 
Figure 4.2 Analysis of ssDNA obtained from purified and unpurified PCR product 
by magnetic beads (MB), T7 gene 6 exonuclease (T7), and Lambda exonuclease (L) 
(a) 4% w/v agarose gel analysis; A –purified PCR product; B –  unpurified PCR product; (1, 4) -  
ssDNA from MB;  (2, 5) – ssDNA from T7; (3, 6) – ssDNA from L; C - ssDNA standards  (7: 10 
nM, 8: 20 nM, 9: 30 nM, 10: 50 nM, 11: 70 nM). (b) Recovery of ssDNA in % obtained from MB, 
T7, and L by ELONA. (c) The final concentration of ssDNA (in nM) obtained from purified 
/unpurified PCR products.   
 
 
As we mentioned previously the magnetic beads based method is one of 
the most widely used in SELEX. However, previous studies have demonstrated the 
possible dissociation of streptavidin due to high temperature or alkaline treatment 
[25-26] and the presence of this streptavidin during the incubation step of SELEX 
can cause selection of an aptamer against this additional target, which is favoured as 














 Purified PCR product































 Purified PCR product
 Un-purified PCR product
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major problem for SELEX where the target is not immobilised and is in its' 
preferred native state (e.g. use of nitrocellulose membrane for partitioning of bound 
and unbound DNA). The presence of streptavidin can be eliminated by 
phenol/chloroform extraction and subsequent ethanol precipitation, which is 
however, associated with a loss of approximately 30% of DNA.  This loss of DNA 
could be overcome by the use of specific purification kits, which minimise the loss 
of DNA, but are relatively expensive. Alternatively, aptamer selection against 
dissociated streptavidin can also be avoided by employing an appropriate counter 
selection step, but this is time-intensive, and increases the complexity of the 
SELEX. Furthermore, and affecting all types of SELEX independently of whether 
the target is immobilised, any biotinylated capture DNA linked to the dissociated 
streptavidin can re-anneal to the complementary strands of the random pool, and 
thus cause loss of tertiary structure, which is important for target binding [10]. 
In the case of the exonuclease digestion, Lambda exonuclease has a 
reduced activity on ssDNA but after a certain period of time it can start to digest 
un-phosphorylated ssDNA.  A study was thus carried out to optimise the time for 
maximal ssDNA generation and minimal ssDNA digestion.  As can be seen in 
Figure 4.3, a decreasing intensity of the dsDNA band was observed as digestion 
time increased, reaching a plateau at 45 minutes. However, still after 1 hour there 
was a visible weak band which corresponds to dsDNA. Nevertheless, this band is 
not necessarily composed from complete dsDNA product, as sometimes ssDNA 
alone or bound to the primer leads to the similar migration behaviour as the 
dsDNA [10]. The optimal time of incubation for the efficient generation of ssDNA 
was thus estimated to be 45 minutes for both enzymes, as the longer digestion time 
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             (a) 
 
             (b)  
                             
Figure 4.3 Evaluation of the effect of time on dsDNA digestion. (a) 4% Agarose gel 
analysis.  Samples for T7 (A) and Lambda (B) enzyme with starting ds-PCR product (1), after 10 min 
(2),  30 min (3), 45 min (4), and 60 minutes of digestion (5). (b) Graphic analysis of remaining dsDNA 
during different time of digestion using electrophoretic analysis with Image J program.  
                   
 
4.4.4 Asymmetric PCR with combination of enzyme digestión 
 
An asymmetric PCR generates one of the strands by linear amplification. In 
comparison to others method, A-PCR produces new molecules of ssDNA, 
resulting in a final yield of ssDNA that can be much higher than initial 
concentration of dsDNA template. The diversity of ssDNA, which is also 
important for the SELEX process, depends on the concentration of initial dsDNA 
template. However, the error prone nature of the polymerases used in PCR leads to 
the introduction of mutations that effectively result in a greater diversity [29]. 







 T 7 Gene 6 Exonuclease
 Lambda Exonuclease
%
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Products from Asymmetric PCR (A-PCR) contain both ssDNA and dsDNA, 
which can interfere in the binding step during the selection process, and to 
eliminate this dsDNA a time-consuming purification step, extracting from 
polyacrylamide or agarose gel has been reported [7, 30-31]. However this 
purification step based on the extraction of band from agarose or polyacrylamide  
gel results in a poor yield of ssDNA (29 ± 10 %, n=5 ) that can affect the selection 
process due to the large loss of aptamer candidates, and thus diversity, which is 
particularly important in the first cycles of SELEX where the amplification step and 
preparation of ssDNA is critical. We thus explored the possibility of combining A-
PCR with the exonuclease digestion to improve the yield of ssDNA. As can be seen 
in Figure 4.4 a, using agarose gel electrophoresis the band of dsDNA is not visible 
indicating that most of the remaining dsDNA had been converted into ssDNA.  
The ssDNA samples generated were then quantified using ELONA (Figure 4.4 b). 
For asymmetric PCR, the theoretical maximum yield of ssDNA (366 nM) was 
calculated by single primer concentration and dsDNA template used in A-PCR 
reaction. The yield of ssDNA obtained by A-PCR was 72 ± 5 % with modified 
forward primer (F-pto) and 67 ± 5 % with modified reverse primer (R-pho), 
demonstrating a marked improvement in the yield of ssDNA, but is still 
contaminated with dsDNA.   However, after enzyme digestion of A-PCR product 
the yield increased to 84 ± 6 % with T7 enzyme and 75 ± 6 % due to elimination 
of the remaining dsDNA.  
 
                         (a)                                                                                                                                                                     
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                         (b) 
 
Figure 4.4 Analysis of ssDNA obtained from Asymmetric PCR (A-PCR), A-PCR and 
enzyme digestion (combo A-PCR), and extraction of ssDNA band from agarose gel (EX-ssDNA). (a) 
4% w/v agarose gel analysis; A –  A-PCR with modified primers (1 – F_pto for T7 enzyme digestion, 2 
– R_pho for lambda digestion); B –  Single stranded DNA obtained from A-PCR with combination of T 
7 enzyme (4), or  lambda digestion (5), and 2 x diluted sample of extraction of ssDNA band (3); C – 
standards of ssDNA (6: 50 nM, 7: 100 nM, 8: 200 nM, 9: 400 nM) (b)   The recovery of ssDNA 
obtained from A-PCR, combo A-PCR (T7 or L), and EX-ssDNA  by ELONA. 
 
 
Other factors that should be considered in selecting the preferred method 
for SELEX are the time required for generation of ssDNA and the cost. Table 1 
summarizes the percentage recovery yield with the final amount of ssDNA 
obtained for each of the approaches studied, as well as the time required for each 
technique and finally an estimation of the costs associated with the preparation of 
50 pmol of ssDNA. Asymmetric PCR followed by enzyme digestions produces the 
highest amount of ssDNA with low cost in comparison to other methodologies 
reported in this study. The highest cost is associated with the generation of ssDNA 
from purified PCR products, which is 10-15 times more expensive than asymmetric 
PCR followed by enzyme digestion. Asymmetric PCR and both enzyme digestions 
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Table 4.1 Comparison of all methodologies in terms of ssDNA recovery, the amount 
of ssDNA obtained, time needed for its preparation and estimated costs calculated 
for 50 pmol of ssDNA (n=5).   
 
















57.3 ± 7.7 
 
 





T7 Gene 6 Exonuclease* 58.2 ± 9.8 
 
29,1 ±4,9  1.5-2 
 
52 
Lambda Exonuclease* 68.7 ± 6.9 
 
34,6 ± 3,5  1.5-2 45 
Magnetic beads 51.9 ± 8.2 
 
36,3 ± 5,7  1-2 30 
T 7 Gene 6 Exonuclease 62.6 ± 8.7 
 
43,5 ± 6  1-1.25 15 
Lambda Exonuclease 52.3 ±7.2 
 
36,6 ± 5  1-1.25 14 
A-PCR with F_pto primer 72.4 ± 5.3 
 
265 ± 19  0.75-1 2 
A-PCR with R_pho primer 66.7 ± 4.8 
 
244 ± 19,5  0.75-1 2 
A-PCR with T7 enzyme 83.9 ± 6.2 
 
307 ± 22  1.5-2 4 
A-PCR with Lambda  74.9 ± 6.5 
 
274 ± 23,8  1.5-2 3 
A-PCR (extraction of ssDNA) 29.1 ± 10.6 
 
106 ± 39   2-2.5 14 
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The preparation of high-quality ssDNA is of paramount importance to 
ensure the success of SELEX and numerous other molecular biology procedures. 
In this work we have performed comparison studies of different methods that can 
be used for the generation of ssDNA for consequent use in SELEX. The quality of 
ssDNA compared using electrophoretic analysis showed a clear and well-defined 
band, which corresponds to ssDNA, for all the studied methods. The quantity of 
ssDNA was determined using ELONA, which permitted quantification of the 
different yields of ssDNA, showing high efficiency and good reproducibility for all 
studied methods confirming that all the reported methods can be used for the 
generation of ssDNA, once their disadvantages are clearly taken into consideration 
and the SELEX adapted accordingly. We have demonstrated that the purification 
of PCR product is not necessary as the yield of ssDNA obtained directly from PCR 
product is comparable to that obtained from purified PCR product, thus decreasing 
the time required for ssDNA preparation. In comparison to others methods, 
asymmetric PCR followed by enzyme digestion was clearly demonstrated to have 
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 Chapter 5 
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The selection of an aptamer depends greatly on the properties of the 
target, its´ availability and purity. Moreover, there is no a well established and 
generic methodology for aptamer selection and in many cases, the success of 
SELEX depends on the experimental conditions used during the selection 
process [1]. Futhermore, the pI value and hydrophobicity of the target molecule 
can influence the capacity of negatively charged oligonucleotides to bind to the 
target, and conditions for the final use of the aptamer also should be taken into 
consideration [2]. To date, a large number of aptamers have been selected 
against various targets, with several examples of both RNA and DNA aptamers 
being selected against the same target, showing similar affinities and specificities 
[3]. Compared with RNA aptamers, DNA aptamers have certain advantages, 
such as a simpler and faster selection process, greater stability than unmodified 
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RNA aptamers, ease of labelling, as well as being less expensive than RNA or 
modified RNA. Consequently, DNA aptamers have become more widespread 
during recent years and seem to be more suitable as a molecular recognition 
element in biosensors.  
 
 
5.1.1 DNA based SELEX process 
 
A typical DNA based SELEX round involves five basic steps, namely, (i) 
incubation of single stranded DNA (ssDNA) oligonucleotides with the target of 
interest; (ii) partitioning of target bound oligonucleotides from the rest of the 
library; (iii) elution of bound ssDNA from ssDNA/target complex; (iv) 
amplification of eluted oligonucleotides, and (iv) preparation of ssDNA 
oligonucleotides for use as template in the next SELEX round (Figure 5.1). This 
selection and amplification process is repeated (usually 8 to 15 rounds) and the 




Figure 5.1. Schematic of DNA based SELEX. 
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5.1.1.1 Incubation of oligonucleotide pool with target molecule 
 
 
The binding properties of aptamers depend on the folding of nucleic acid 
sequences and the docking with its target, which is very sensitive to 
environmental conditions. Changes in the environment can affect the 
conformation and hence binding properties of aptamers. Buffer composition 
also plays an important role, as well as the net negative charge on all nucleic 
acids which make their conformation and interaction with other molecules 
extremely sensitive to salt concentrations [4]. The best buffer to use in selection 
experiments is therefore one as close as possible to the conditions in which the 
aptamer will be applied and used.  
Another important parameter is the length incubation of the library with 
the target, which should allow an efficient interaction between the different 
species. Incubation for too short a period of time can result in the selection of 
an aptamer with rapid association rates but not necessarily high affinity. A good 
rule of thumb is that competition between species with nanomolar dissociation 
constants (KD) requires minutes, and picomolar requires hours [5]. In order to 
avoid incubation periods of several hours, one can simply increase the 
competition between species by adjusting the pool:target ratio. A low ratio will 
allow species with low binding affinities to remain in the pool whereas high 
ratios will favor competition between aptamers and therefore generate a 
population with a higher binding affinity. In most cases a pool:target ratio 
between 10:1 and 100:1 is optimal [5-6].  
 
 
5.1.1.2 Partitioning methodology  
 
 After binding, partitioning of the oligonucleotide-target complex from 
oligonucleotides not bound to the target can be achieved by various techniques. 
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A commonly used method is affinity chromatography with immobilization of 
the target on a sepharose or agarose column [7-10]. The use of magnetic beads 
is also widely used for the separation of target and nucleic acids [11-13], as this 
method only requires small amounts of target and is simple to handle. Whilst 
the immobilization of the target on a specific matrix allows an effective 
separation, protein immobilization can destroy key features of some aptatopes 
and reduce the mobility of the protein; to overcome this, an alternative is to use 
ultrafiltration without target immobilization [14-17]. Alternative partitioning 
strategies have been reported, based on the use of flow cytometry [18-20], and 
surface plasmon resonance (SPR), which provide binding efficiency information 
and on-line evaluation during the selection process [21]. Atomic force 
microscopy (AFM) can dynamically detect the adhesion or affinity force 
between a sample surface and a cantilever, a feature that is useful for the 
selection of high affinity aptamers, but is inherently expensive [22]. 
Electrophoretic separation [23-26] or centrifugation [27-28] are further 
examples of tools for partitioning.  
 
 
5.1.1.3 Elution of ssDNA from the ssDNA/target complex 
 
 Following removal of the unbound part of the library, bound 
oligonucleotides are generally eluted from the ssDNA/target complex. Methods 
used for elution include denaturing methods such as heat treatment [29] or 
addition of denaturing substances like urea, SDS, EDTA or NaOH [14]. Other 
approaches used are affinity elution [30] or photoelution by application of a 
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5.1.1.4 PCR Amplification 
 
For the first round of DNA selection, a chemically synthesized ssDNA 
library can be used directly without PCR amplification. Some researchers 
perform amplification of the starting random DNA library before SELEX in 
order to eliminate damaged DNA synthesis products, which cannot be amplified 
by PCR [32]. This preliminary step can lead to the loss some of the target-binding 
sequences after the first selection round due to the different efficiency of DNA 
polymerase to amplify chemically synthesized DNA [3]. Whilst large-scale PCR is 
a time and material consuming process, this initial PCR step provides several 
copies of the original library which can bind to the target and thus increases the 
probability of selection of the desired sequence. 
  The high degree of diversity of the initial oligonucleotide library results 
in a very small percentage of the library bound to the target at the end of the 
first selection step, which consequently requires to be amplified. Single stranded 
DNA aptamers are amplified by straightforward PCR, and it is possible to 
attach modifications via special primers during the amplification step, which can 
be used to monitor a specific oligonucleotide enrichment during the selection 
process or for the preparation of single stranded DNA [3].  
 
 
5.1.1.5 Preparation of single stranded DNA 
 
The generation of ssDNA and their application in DNA based SELEX 
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5.1.2 Regulation of aptamer specificity 
 
  The aptamer specificity to a target can be regulated during selection. 
Thus, to obtain an aptamer with high specificity, it is necessary to select only 
sequences that bind the specific target but do not interact with the matrix, or 
other molecules structurally similar. On the other hand, if it is necessary to 
obtain an aptamer to recognize several related molecules, then sequences are 
selected with the ability to broadly bind several targets [33].  
 
 
5.1.2.1 Negative SELEX  
 
 To exclude oligonucleotides absorbed by the support matrix material (e.g. 
affinity chromatography column, magnetic beads, nitrocellulose filters etc.), 
negative SELEX step is performed with the aim of selecting aptamers that bind 
only to the specific target. During negative selection, oligonucleotides are 
incubated with the matrix in order to eliminate the absorbed sequences. The 
unbound part is subsequently incubated with targets to select the desired 
aptamers. It has been demonstrated that the use of negative selection during 
SELEX process reduces the possibility of evolving non-specific binders [34].  
 
 
5.1.2.2 Counter SELEX 
 
  The purpose of counter selection is to produce highly selective aptamers. 
The aptamer´s selectivity is improved by excluding oligonucleotide molecules 
with affinity to molecules similar in structure to the target [15, 35]. An example 
of the importance of incorporating a counter SELEX step is shown in case of 
the the RNA aptamer selected against theophylline, where caffeine was used as 
the counter target and resulted in a discrimination factor of 10,000 of the 
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aptamer for theophylline over caffeine, despite the fact that their structures only 
differ by a methyl group [35]. Another excellent example is the highly selective 
aptamer for ADP, which was selected incorporating a counter selection step 
against ATP [36].  
 
 
5.1.3 Monitoring of evolution during SELEX 
 
 Another  key aspect for the success of SELEX is the efficient monitoring 
of the evolution of the selection process, which allows control and adjustment 
of the selection stringency to achieve the desired properties of the selected 
aptamers. The most commonly used technique for monitoring the evolution 
uses radioactively labelled nucleic acids [37-39], which is a very sensitive method 
that enables detection of nucleic acids at low concentrations. However, the use 
of radioactivity is not possible in every laboratory and strict safety precautions 
have to be taken. Fluorescence, with fluorescent labels inserted via PCR, allows 
rapid and non-radioactive monitoring of the selection progress [29]. This 
method is rather costly and might also interfere with the binding properties of 
the nucleic acid [40]. The fluorescent dye-linked aptamer assay (OliGreen) is an 
alternative approach used for the monitoring of evolution [41]. The fluorescent 
dye OliGreen is specific for single-stranded DNA and enables the quantification 
of nucleic acid concentrations around 100 pg/ml with a standard 
spectrofluorimeter. Denaturing high-performance liquid chromatography [42], a 
technique based on the fact that the diversity of a nucleic acid library is 
dramatically reduced during the selection process has also been reported. Other 
methods used for the monitoring of aptamer selection include capillary 
electrophoresis, affinity chromatography, Reporter Linked Aptamer Assay 
(RLAA) and SPR [21, 43-45].  
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5.1.4 Cloning and Sequencing 
 
  When the affinity saturation of an enriched library is achieved, the final 
oligonucleotide pool is cloned into a bacterial vector and individual colonies are 
sequenced. Typically 50 - 100 clones are sequenced and analyzed by sequence 
analysis. Sequence alignments are used to identify aptamers with homologous 
sequences and a comparative analysis of the aligned sequences is performed to 
determine the consensus motif. Indeed, these conserved regions are crucial for 
the specific target binding of the aptamers.  
 
 
5.1.5 Determination of secondary structure  
 
 Analysis of the conserved regions is used for the prediction of the 
secondary structure of aptamer candidates using specialized programs such as 
M-fold [46]. This program calculates the possible configuration of single 
stranded nucleic acids considering stems, loops and bulges by energy 
minimization methods. The determined consensus motifs are often located in 
stem-loop structures, pseudoknot formations, or G-quadruplexes. Knowing the 
secondary structure of aptamers, truncation studies of selected aptamers can be 
performed to increase their specificity and affinity, as well as to reduce the 
length and inherently the cost of the aptamer. 
 
 
5.1.6 Binding studies 
 
 Binding experiments are used to study the specificity and affinity of 
selected aptamers, and the correct estimation of these parameters is essential for 
the successful application of the selected aptamers. In this context, the 
determination of the dissociation constant (Kd) is fundamental in order to 
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estimate the affinity of an aptamer for its corresponding target (i.e. a small KD 
value designates high affinity for the target). Techniques generally used for 
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The main objective of this chapter was the selection of a DNA aptamer 
against PSA. As there is no standard SELEX protocol suitable for all targets, the 
conditions of an in vitro selection need to be optimized for PSA taking into 
consideration the potential applications of the desired aptamer. The 
subobjectives of this chapter can be divided in; (i) selection of DNA aptamers 
against PSA using two different partitioning methods for the separation of the 
oligonucleotide/PSA complex from the rest of the library, (ii) monitoring of the 
evolution of the aptamer selection using different techniques, (iii) cloning and 
sequencing of the enriched oligonucleotide pool, (iv) prediction of secondary 
structures of aptamer candidates and (v) characterization of selected aptamer 
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A filter holder 13 mm in diameter was purchased from GE Osmotics 
Labstore (Spain). Nitrocellulose filter with pore size 0,45 mm, Bovine serum 
albumin (BSA), Tris Buffered Saline (TBS), Phosphate Buffered Saline (PBS), 
and NUNC Maxisorp plates were obtained from Sigma (Spain). Binding buffer 
A consists of TBS at pH 7.9 with 1,5 mM of MgCl2; Binding buffer B consists of 
PBS at pH 7.4  with 3 mM of MgCl2, and Binding buffer C has the same 
composition as buffer B with addition of 1 mg/ml of BSA, washing buffers (A, 
B, C) have the same composition as binding buffers with addition of Tween. 
TOPO TA Cloning® kit was obtained from Invitrogen (Spain), QIAprep Spin 
Miniprep kit from Qiagen (Spain), and GenomeLab DTCS Quick Start Kit from 
Beckman Coulter (Spain).  
 
 
5.3.2 In vitro selection process using nitrocellulose filter 
 
Before the incubation step of the random library with target, a negative 
selection was performed in order to eliminate potential binders to the 
nitrocellulose filter. The binding buffer (500 µl) containing 500 pmol of the 
starting library was heated to 95°C for 5 min and then gradually cooled to 25° C 
over a period of 30 min. This solution was incubated with a pre-wetted 
nitrocellulose filter for 1 hour at 25°C. After incubation, the binding buffer 
containing a random library was centrifuged at maximum speed through the 
nitrocellulose filter, collecting the elute. The unbound random library was then 
incubated with 50 pmol of target for 1 hour at 25°C with slight tilt rotation. 
Followed incubation, the solution was centrifuged as previously described and 
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filter containing bound oligonucleotides was thoroughly washed several times 
with 500 µl of washing buffer. Bound oligonucleotides were eluted from the 
filter by denaturation at 95° C for 5 minutes, precipitated and resuspended in 
100 µl of MilliQ water. A sample of eluted DNA was amplified using pilot PCR 
where different numbers of rounds of PCR were used in order to elucidate the 
optimal number of rounds for amplification of the remaining DNA. Ten 
microliters of DNA were amplified in 100 µl of Master Mix using protocols 
previously optimized for each library (see section 3.3.2). The resulting dsDNA 
was used for the preparation of ssDNA which was then used for the next 
SELEX round. For the generation of ssDNA T7 gene 6 enzyme digestion and 
magnetic separation with streptavidin beads were used. Both methods were used 
as described in Chapter 4 (see section 4.3.3).  
 
 
5.3.3 In vitro selection process using magnetic separation with 
functionalized beads 
 
In the initial round of selection, the random library was incubated with 
50 pmol of PSA immobilized on the surface of the beads using a 10-fold molar 
excess of ssDNA in selection buffer. Half nanomole of library was diluted into 
100 µl of binding buffer in a PCR tube, heated to 95°C for 5 min and 
immediately cooled at 4° C. PSA coupled beads were then added to this mixture 
and incubated under shaking conditions for 1 hour at 25° C. Following 
incubation, the beads were washed several times with 500 µl of washing buffer. 
DNA bound to the beads was eluted twice with 50 µl MilliQ water by 
denaturation at 95° C for 5 minutes, and the eluted DNA was subsequently 
amplified by PCR as described above. After the first round, a negative selection 
step was introduced prior to the positive selection step, in order to remove non-
specific binders. Selected DNA was incubated with control (naked) beads in 
binding buffer for 1 hour at 25° C and unbound DNA was used for the positive 
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selection step. Different approaches used for the preparation of ssDNA such as 
T7 enzyme 6 gene exonuclease, magnetic separation with streptavidin beads or a 
combination of asymmetric PCR with T7 Gene 6 enzyme  digestion were used 
in these selection processes. All methods were used as described in Chapter 4 
(section 4.3.3).  
 
 
5.3.4 Monitoring of SELEX evolution 
 
 
5.3.4.1 PCR studies 
 
After the amplification step at the end of each selection round, nucleic 
acids that had bound to the matrix (pre-selection step) and nucleic acids that 
bound specifically to PSA were amplified using pilot PCR. In pilot PCR a small 
aliquot of the SELEX pool was amplified in ranges from 4 to 16 PCR cycles in 
order to elucidate the optimal number of PCR cycles. Following PCR, the 
amplified products were checked on agarose gel and analyzed as described 
previously (Chapter 3, section 3.3.2).  
 
 
5.3.4.2 Direct Reporter-Linked Aptamer Assay (Direct -RLAA) 
 
Ten µg/ml (330 nM) of PSA was immobilized on plates in 50 mM 
carbonate buffer, pH 9.6 for 1 hour at 25° C, followed by a blocking step with 
PBStween (10 mM pH 7.4, 0.05% v/v Tween 20) for 1 hour. The wells were 
then washed three times with 200 µl of PBS-Tween. After the protein 
immobilization step, normalized aliquots of the biotinylated ssDNA obtained 
from different SELEX cycles were diluted in binding buffer, heated to 95°C and 
gradually cooled to 25° C. A 50 µl aliquot of different ssDNA samples were 
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incubated with proteins on the plate for 1 hour at 25°C, shaking gently. The 
plates were then washed 5 times with 200 µl of PBS-tween for 5 minutes each 
on a plate vortex, followed by the addition of streptavidin-HRP  (0.02 µg/ml) in 
50 µl of PBS. The wells were again washed as described above, and 50 µl of 
TMB substrate were then added to each well. After 20 minutes the reaction was 
stopped with 1 M H2SO4 and measured at 450 nm using a Spectramax 340PC384 
plate reader.  
 
 
                                  Figure  5.2. Scheme of Direct RLAA assay. 
 
 
5.3.5 Cloning and Sequencing 
 
The enriched library was cloned into the plasmid pCR2.1 using the 
TOPO TA Cloning® kit according to the manufacturer’s instructions. Colonies 
were subsequently selected and grown overnight in a culture of 5 ml LB 
medium under vigorous shaking conditions. Plasmid clones were purified with a 
QIAprep Spin Miniprep kit. Purified plasmid DNA were sequenced by the 
GenomeLab DTCS Quick Start Kit according to the manufacturer's 
instructions, and analyzed in a CEQ8000 Beckman Coulter instrument. The 
sequences derived from SELEX were analyzed using the GeneBee service 
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(http://www.genebee.msu.su/), SDSS Biology Workbench 
(http://workbench.sdsc.edu/), and CLC Main workbench version 6. 
 
 
5.3.6 Secondary structure prediction 
 
The secondary structure model of the sequences obtained was predicted 
using M-fold program by fixing parameters such as temperature (25ºC) and 
concentration of Na+ (0.138 M). The concentration of magnesium differed with 




5.3.7 Binding studies 
 
 
5.3.7.1 Direct RLAA assays 
 
Direct RLAA assay was used for screening of binding capacities of all 
aptamer candidates. This assay was used as previously described (see section 
3.3.4.2), with aptamer candidates at concentrations of 1 µM each.  
 
 
5.3.7.2 Competitive RLAA assay 
 
PSA (10 µg/ml) was immobilized on microtiter plate in 50 mM 
carbonate buffer, pH 9.6 for 1 hour at 37°C, followed by 1 hour blocking with 
PBS-Tween. The plates were then manually washed three times with PBS-
Tween. In individual eppendorf tubes, serial dilutions of PSA ranging from 0-33 
µM (0-1 mg/ml) were incubated with the selected biotinylated aptamer 
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candidate I1 (200 nM) in binding buffer for 30 minutes at 25°C. The plates were 
washed three times, followed by addition of streptavidin–HRP (0.02 µg/ml) and 
incubation for 30 minutes. The wells were again washed as described above, and 
TMB substrate was added to each well. The reaction was stopped after 20 
minutes with 1 M H2SO4 and the colour measured at 450 nm using a 
Spectramax 340PC384 plate reader.  
 
 
5.3.7.3 SPR experiments  
 
Surface plasmon resonance (SPR) was performed with a BIAcore 3000 
(Biacore Inc.). Proteins of interest (PSA, and control proteins such as 
streptavidin, and BSA) were immobilized on separate channels of a CM 5 sensor 
chip activated with EDC/NHS (30 µl of a 1:1 mixture of EDC (400 mM) and 
NHS (100 mM)) followed by injection of 200 µg/ml (6,7 µM) protein at a flow 
rate of 5 µl/min. After immobilization of the proteins, unreacted NHS esters 
were deactivated via injection of an excess of ethanolamine hydrochloride (1M). 
Unbound proteins were then washed from the surface with 75 mM NaOH. The 
aptamer candidates were diluted in binding buffer to a final concentration of 1 
µM and injected during 6 min at a flow rate of 5 µl/min followed by a 3 min of 
stabilization time and 10 min of dissociation time. The binding of DNA was 
analyzed through the corresponding changes in the refractive index of the 
optical signal, and expressed as resonance units (RU). All reagents and buffers 
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5.4 Results and Discussion 
 
 
5.4.1 In vitro selection process 
 
Variations of SELEX protocols were performed for the selection of a 
DNA aptamer against PSA. Protocols differed in the method used for 
partitioning bound nucleic acids and the generation of ssDNA, as well as in the 
type of library and binding buffer used in the selection process.  
Two types of partitioning including ultrafiltration and magnetic beads 
methodology were used. For ultrafiltration, nitrocellulose filters with 0,45 µm 
pore size were selected. Unbound ssDNA (~28 kDa) and free PSA (~30 kDa) 
passed through the filter, whilst the complex (~60 kDa) remained on the filter. 
The problem with use of nitrocellulose filters is the high level of non-specific 
binding of ssDNA to the filters. The negative-selection step before each round 
of selection decreased the non-specific binding but did not eliminate it 
completely. The immobilization of PSA on the surface of magnetic beads 
allowed an effective separation with minimum losses of target bound sequences. 
Different immobilization protocols have been studied previously (Chapter 2), 
and two strategies were found to be optimal for PSA immobilization and their 
use in SELEX. These strategies include covalent immobilization by amine-
coupling with carboxyl modified beads and bioaffinity immobilization with 
streptavidin beads and biotinylated PSA.  
Single-stranded DNA preparation is the most time consuming step in the 
standard SELEX procedure. The comparison of different methods used for 
ssDNA generation was studied previously (see Chapter 4). According to the 
results obtained from these experiments, several methods were selected and 
used for the selection of DNA aptamers, including magnetic separation with 
streptavidin beads, enzyme digestion with T7 gene 6 exonuclease, and 
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asymmetric PCR with a combination of enzyme digestion with T7 gene 6 
exonuclease. The preparation of ssDNA was directly performed from PCR-
product as it was observed that the yield of ssDNA obtained from unpurified 
PCR product was comparable to that obtained from purified PCR product, 
overcoming a loss of dsDNA during the purification step, and thus decreasing 
the time required for SELEX.  
Two binding buffers - Tris-buffered Saline (TBS) and Phosphate-
buffered saline (PBS) were used (Table 5.1). These buffers were chosen for 
SELEX experiments, due to their osmolarity and similar ion concentrations to 
that found in human serum. PBS contains sodium chloride, sodium phosphate, 
potassium chloride and potassium phosphate, and the phosphate ions help to 
maintain a constant pH (7.4). TBS also maintains the pH in a relatively narrow 
range (7-9.2) and has a slightly alkaline buffering capacity which is influenced by 
the temperature of the solution. Tween 20 was added to both buffers (TBS-
Tween, PBS-Tween) for use as a washing buffer in the selection process and as 
a blocking buffer in binding assays. Divalent cations are generally required for 
high-affinity aptamers [47] and therefore its presence in the binding buffer is 
desirable. One of the sources of divalent cations is magnesium chloride and as 
the binding ability of aptamers has to be functional in physiological conditions, 
concentrations between 1-3 mM were chosen as optimal for binding buffer 
solutions. Bovine Serum Albumin (BSA) was another component of these 
binding buffers, as the presence of BSA helps to prevent nonspecific protein 
adhesion to surfaces. 
 
Table 5.1. Different buffers used in DNA based SELEX process.  
 
BB  WB 
A TBS + 1,5 mM MgCl2 A TBS-Tween + 1,5 mM MgCl2 
B PBS + 3 mM MgCl2 B PBS-Tween + 3 mM MgCl2 
C PBS + 3 mM MgCl2 + BSA C PBS-Tween + 3 mM MgCl2 + BSA 
         BB – binding buffer, WB – washing buffer.  
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Two different libraries (I, II) were used for the selection of DNA aptamers 
against PSA. Both libraries had been previously optimized to ensure a high 
purity of the amplified product (see Chapter 3). In some cases (SELEX A, B, C, 
D, H) large-scale PCR amplification of the random library was carried out 
before initiating the selection process in order to eliminate damaged DNA 
synthesis products, which cannot be amplified by PCR. However, as mentioned 
in the introduction of this chapter, it is possible to lose some of the target 
binding sequences from the original library. This library was checked using 
denaturing polyacrylamide gel, showing the intact length of the majority of the 
oligonucleotides. Thus, in other cases (SELEX E, F, G, I, J), 500 pmol library 
(about 3 x 1012 different sequences) was used directly in the first round of the 
selection process. For the following rounds of selection, 100 pmol of ssDNA 
were employed when magnetic beads and enzyme digestion were used for the 
generation of ssDNA, while 250 pmol of ssDNA were used in the case of 
asymmetric PCR combined with enzyme digestion due to the higher efficiency 
for the ssDNA production.   
Taking into account the concentration of the random library in every 
selection cycle, the amount of protein was reduced from the intitial 50 pmol to 
10 pmol (rounds 4-6), and subsequently 5 pmol (from 7 round onwards ) in the 
case of magnetic beads and enzyme digestion ssDNA generation methods and 
25 pmol (rounds 4-6) and 10 pmol (from 7 round onwards) in the case of 
asymmetric PCR with a combination of enzyme digestion in order to maintain 
the optimum library:target ratio between 10:1 to 100:1.  
All protocols used are summarized in Table 5.2 according to the type of 
partitioning, method for generation of ssDNA, the random library and buffer 
used in each selection process. In Table 5.2, it is also indicated when large-scale 
PCR amplification was used and which of the selection processes led to the 
cloning and sequencing of enriched libraries. 
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Table 5.2. Variations of SELEX protocols. 
 
SELEX Partitioning ssDNA Library B&WB L-S PCR C/S 
A F MS I A X  
B F T7 I A X X 
C CMB MS I B X X 
D CMB T7 I B X  
E CMB T7 I B   
     F CMB A-T7 I B  X 
G StMB MS II C   
H StMB T7 II C X X 
I StMB T7 II C  X 
J StMB A-T7 II C  X 
F – nitrocellulose filter, CMB – carboxyl modified magnetic beads, StMB – Streptavidin 
modified magnetic beads, MS – magnetic separation, T7 – T7 Gene 6 Exonuclease, A-
T7 – Asymmetric PCR with T7 enzyme digestion, Library I, II, B&WB – binding and 




5.4.2 Monitoring of in vitro selection 
 
The first and simplest manner to monitor the evolution of a selection 
process is to check the amount of ssDNA at the end of each selection round. 
Hence, the amount of ssDNA bound to the target as well as the amount of 
ssDNA bound to the matrix (nitrocellulose filter or naked magnetic beads) was 
measured throughout whole selection process. The amount of ssDNA was 
represented by the number of PCR cycles needed for optimal PCR 
amplification. A higher amount of bound ssDNA required less PCR cycles and 
vice versa. An increasing amount of ssDNA bound in positive selection was 
observed in SELEX B, C, F, I and J  indicating that the ssDNA pool was 
evolving to be more selective towards the PSA target,  whilst in SELEX A, D, 
E, G, H no evolution was observed (Figure 5.3). Usually, when nitrocellulose 
filters are used, a high amount of ssDNA binds to the matrix (Figure 5.3, 
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SELEX A, B), probably due to the large matrix surface. In the case of magnetic 
beads nonspecific ssDNA binding was less pronounced, and a slight decrease in 
the amount of ssDNA bound to the matrix was obtained during the selection 
process with magnetic beads. In the majority of cases a decreasing amount of 
ssDNA (around 2-3 PCR cycles) was observed in the second round of SELEX. 
This jump in PCR cycles was due to the use of a lower concentration of ssDNA 
after the first round of SELEX, as well as the introduction of negative selection 
(in the case of magnetic beads). Other smaller shifts can be observed in the 4th 
and 7th selection round when smaller concentrations of target were introduced 
to the selection process.   
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Figure 5.3. Monitoring of evolution with PCR studies. 
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To monitor evolution, RLAA was also carried out. As shown in Figure 
5.4, with an increasing the number of SELEX rounds in SELEX B, C, F, J and 
I, the binding affinity for PSA increased, again indicating evolution. In SELEX 
A, D, E, G, and H no evolution was observed.  
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Figure 5.4. RLAA type assay. All data was corrected for nonspecific binding by 
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5.4.3 Cloning and Sequencing       
 
According to results from PCR and RLAA monitoring studies, SELEX 
B, C, F, I, and J were selected to be cloned and sequenced. At the end of the 
cloning process, plasmids were extracted from individual clones and amplified 
to ensure the insertion of the aptamer sequence. Plasmids containing the desired 
aptamer sequence were selected and used for sequencing. Sixteen sequences 
were obtained for SELEX B, 19 for SELEX C, 16 for SELEX F, 20 for SELEX 
I, and 20 for SELEX J. The aptamer sequence can be inserted in the plasmid 
vector in either orientation, thus the complementary sequence can be 
determined if it is needed by using a sequence manipulation software (CLC 
Main Workbench), to ensure that all the data will be analyzed in the correct 
orientation. The modified sequence data were searched to locate the inserted 
sequences using (SDSS Biology Workbench). Altogether, 91 individual 
sequences were characterized and revealed 75 different variants; from which 11 
sequences were represented twice and 5 sequences three times (Table 5.3). Some 
of the sequences had a slightly shorter or longer length than expected. This 
often happens due to errors in replicating sequences in the random region of the 
aptamer pool. In some cases (aptamer candidates B12-14) the random region 
was considerably longer than 50 nt (around 60-70 nt). This can be explained due 
to the fact that non-proof reading DNA polymerases, such as Tfi polymerase, 
often ¨slip¨ when amplifying multiple short-sequence repeats, leading to 
elongation of the amplified region [6].  
 
Table 5.3 Sequence frequency of selected aptamers. 
 
SELEX Aptamers Number of 
clones 
Length (nt) Frequency 
(%) 
SELEX B  B01-B02 2 93 13% 
B03-B11 1 92-95 6% 
B12-B14 1 105-115 6% 
SELEX C C01 - C03 2 93-94 11% 
UNIVERSITAT ROVIRA I VIRGILI 
SELECTION OF APTAMERS AGAINST PROSTATE SPECIFIC ANTIGEN FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 
Markéta Svobodová 
DL: T. 888-2012 
 
  Selection of DNA aptamer against PSA 
136 
 
C04 - C16 1 91-95 5% 
SELEX F F01-F02 3 93 19% 
F03-F05 2 91-93 13% 
F06-F09 1 92-94 6% 
SELEX I  I01-I02 2 90 10% 
I03-I18 1 89-91 5% 
SELEX J  J01-J03 3 90-91 15% 
J04 2 90 10% 
J05-J13 1 89-91 5% 
 
 
Once the random regions had been identified, alignments were 
attempted using the GeneBee program. This program identifies local sequence 
motifs by searching for a conserved motif present in more than one sequence, 
and an alignment of aptamer candidates revealed several distinct regions of 
conservation (Figure 5.5). Furthermore, alignments of all sequences together 
trying to identify families of aptamers with conserved motif were carried out. 
However, no obvious pattern was observed, apart from the fact that the 
majority of aptamer candidates appear to be very rich in A residues.  
 
 
(i) SELEX B 
 
                ....++++.++..+ .  ...... 
B01         (2) ggatCGGACCGGcactctatttaa 
B02         (2) cgatCGGACCGGcacatgatgtat 
B09         (1) ----CGGAGCGAAAtatcgaaaga 
B10         (1) –tgaCGGACCGGAAgtaaaataga 
 
                   +      ++ +++++++ +++     +   +                
B07         (1) cacgtagtatAGAAAAATAGTTAAaacaccacaa 
B10         (1) acggaccggaAGTAAAATAGATAActgtgcttga 
           
                            +++++++         
B05         (1) cgccgcgcaaCCGTAAAGCCA---------- 
B06         (1) ggcgagaggttaGTAAAGCCAagggaggcgg 
B14         (1) tctgtgtaatCCGTAAAGCtttgcaaaa--- 
 
(ii) SELEX C 
 
                   ....... ...+ ..+....  ..+ .+ .+.+  ...  .. ....  . ....   
C03         (2) -----------ACAAAAGAATAGC-A-AAAAGAACC--ATCCGAGTCTAAggacacgtaa 
C06         (1) ---gttgAATGACAACGAAAACAA-GGACAACAAAC--CGAATAACATAGAcagcca--- 
C13         (1) ----------ccatACGAAAAAAAcTGATTATCAAC--ATATTAAAACAAAaccctatcg 
C14         (1) taagtaaatgaACTAAAGACTCGT-A-AGTAAAAACgtATCCGGGGCTAA---------- 
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C16         (1) ---caaaAATGACTATAAAATAAC-AGAAAAGGACC--AGAAAAAgccttcgca------ 
 
                      .   .++....+.+.. +..... ...+ + ..  + .+.+..+......  
C08         (1) gatccggcgtcAATAGAACTCATACATAAGAGAAGAAG--GAATATAAGCCa----- 
C13         (1) ccatacgaaaAAAACTGATTATCAA-------CATATTAAAACAAAACCCTATCGC- 
C16         (1) ---------cAAAAATGACTATAAAATAACAGAAAAGGACCAGAAAAAGCCTTCGCa 
 
                .  ....   ++.. +++... .... .....  ..+. .   +..... .  .  ...  
C08         (1) atccggcgtcAATAGAACTCAT-----ACATAAGAGAAGA---AGgaatataagcca--- 
C10         (1) -------gaaAAAGTAACA-AA-----TAGCACGGAAACG---AGCATgaagtcgtaaat 
C12         (1) -------------ACAACAGTCTATCCACATTTACAAtactatAGCCTTCactcagaaag 
C13         (1) ---ccatacgAAAAAAACTGATTATCAACATATTAAAACA---Aaaccctatcgc----- 
C16         (1) aaatgactatAAAATAACAGAA-----AAGGACCAGAAAA---AGCCTTCgca------- 
 
 
(iii) SELEX F 
 
                  .     . .+++      +....+..+ + ++..+ +.++.+..+.+      .    
F04         (2) --ggagcaacaGGC------ACAGGCGGACAGGA-GC-ACCGCTAAATAgcttccggtc 
F05         (2) cggcgtatagGGGC------AGAACCGGAGAAGAATC-AACGGTATAGA---------- 
F08         (1) ------ggtaGGGCagatcaAGCGCCAAAAACGAATCtAACGGTGTAGAcagaagg--- 
 
                       +  ++ +++++++++        +  
F02         (3) ---atatggtAACACAGCAGACgacaagccat 
F07         (1) cttgctggacAAGACAGCAGACagacgtgaaa 
 
                        + ++++ +++++++       +   
F03         (2) aggatacccgCTAGGGGGGACCcactccaaag 
F07         (1) --------caCTAGAGGGGACCttgctggaca 
 
(iv) SELEX I 
 
                .    . .  ...++.+++..   ..++ +..+..++. . .  .   
I03         (1) -----------tgACCGATCT---CCGAAGCGAAGGAagcaggtatg 
I10         (1) gctagcagttAACACCGATCT---GTGAGGCAAAAGAgcccgtaaaa 
I11         (1) ggactcggcaAACACTGATtcgcaGTGACGGAATAGAa--------- 
 
                  ..   .  ..++.+++.++.++ +.  ..    .  
I02         (2) aaacgcaggagaAACGATAACAGAAAGa--------- 
I16         (1) --------tgCTAAAGATAACAGAtacgacactacgt 
I17         (1) tcactaggctCTAAAGATTACTGAGAGttcaaacaga 
 
(v) SELEX  J 
 
                    ++++   +   +++++ +++  ++      +++ + +++ +++ +         
J9          (1) cgtgAGTAGACCAA-CCCTTGAAAaTACtgtctgGTGTGGTGCTTCCttt------- 
J12         (1) ---tAGTACCTCCGgCCCTTTAAA-GAC----gtGTGAGATGCCTCCatatctgcgg 
 
                          ++ + ++  +++++ +++  ++++  +        
J2          (3) tccaagcgacAGTCTGATTGGCGTcATTACGGAAcgat------ 
J6          (1) --------ggAGACGGAAGGGCGT-ATTCAGGAAtaaatcatgc 
 
                    ++ ++++  + + ++++ ++++ +  +        
J1          (3) aagcGACGACCCAGCGAGGCATCCAGCTtataccacgg 
J7          (1) ----GAGGACCACGTGGGGCAGCCAGGTatttgtggct 
 
(vi) All aptamer candidates 
 
                   .  . .. . .  .    .+.+  .++.+.+ ..+.....+ 
B08         (1) ----------------------ATAACgcacaTACGCACCATAA 
B11         (1) ---------------------GATAACgcacaTACGCACCATAA 
B13         (1) ---ttagggccattgatgagAGATACTttataTTACGAACGTCA 
UNIVERSITAT ROVIRA I VIRGILI 
SELECTION OF APTAMERS AGAINST PROSTATE SPECIFIC ANTIGEN FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 
Markéta Svobodová 
DL: T. 888-2012 
 
  Selection of DNA aptamer against PSA 
138 
 
C05         (1) tcacacgtcatcctctatctcaATACCGCACAGAtacaagcggc 
C16         (1) --------caaaaatgactataAAATAacagaAAAGGACCAGAA 
F01         (3) ---cggaaccacatataatcAGAAAATtcataTAAGGAGCATAA 
I12         (1) -------------tcacgcccgcagtgGCACAGAgggaaaggaa 
 
                                 .. . .  ...+..+......+.. . ...  .  
C14         (1) -------------taagtaaatgaaCTAAAGACTCGTAAGtaaaaacgtat 
C16         (1) ---------------caaaaatgactatAAAATAACAGAAAaggaccagaa 
I02         (2) tgcgcattaagaactaaacgcaggagaAACGATAACAGAAAga-------- 
I16         (1) -----------------------tgCTAAAGATAACAGAtacgacactacg 
I17         (1) --------------atcactaggCTCTAAAGATTACTGAGAgttcaaacag 
J12         (1) ---------tagtacctccggccCTTTAAAGACGTGTGAGAtgcctccata 
 
                ... ....   ....+.++++... ...  .  .   . 
B07         (1) gattcacgtagtatAGAAAAATAGTTAAaacaccacaa 
B10         (1) --tgacggacCGGAAGTAAAATAGATAActgtgcttga 
C14         (1) actaaagactCGTAAGTAAAAAcgtatccggggctaa- 
I15         (1) acgtcagggttGTAGGTAAAAAgcag------------ 
J13         (1) --------ccgGTATGTAAAATAGGTAAggcattgctg 
 
Figure 5.5. Local super-motifs identified within the random regions of sequenced 
aptamer candidates selected against PSA. Conserved motifs are shown in grey colour. Perfect 
matches are indicated by ¨+¨, strong bias towards one base are indicated by ¨.¨ The frequency of 
individual sequence is written in parentheses. Supermotifs were found in  SELEX B (i),  SELEX C 
(ii),  SELEX F (iii),  SELEX J (iv),  SELEX I (v), and in all aptamer candidates (vi).   
 
 
5.4.4  Secondary structure of aptamer candidates 
 
An alternative method of identifying aptamer families is to compare the 
secondary structures and thus, identify common elements. Theoretical aptamer 
secondary structures were predicted by the Zuker algorithm [48], using the M-
fold program (version 3.2) with conditions set up as those used in the selection 
process. The majority of selected sequences were folded into different structures 
and no common secondary structure elements could be assigned to these 
variants. The similar secondary structures were found comparing sequences J 9 
and J 12 with large central loop and 3 smaller loops on the side of the central 
loop (Figure 5.6), and between sequences F 3, F5 and F8 with big central loop 
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                    J 9 ΔG = -3,4                                J 12  ΔG = -4,3 
 
Figue 5.6. Predicted secondary structure for aptamer candidate J9 and J12,  ΔG 




       
 
     F 3  ΔG =-18,4                    F 5  ΔG = -17,03               F 8  ΔG = -11,61 
 
Figue 5.7 Predicted secondary structure for aptamer candidate F3, F5 and F8,  
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5.4.5 Binding studies 
 
The binding capacities of all unique aptamer candidates for PSA were 
examined in a screening manner by using a RLAA. The 13 different sequences 
displayed some affinities to the PSA compared with the random ssDNA library 
and the background control (Figure 5.8). The rest of the sequences showed 
lower or the same affinities to PSA as the starting random ssDNA library. 
 
    





















Figure 5.8 Binding test of aptamer candidates. The x axis shows the 
names of different sequences, B indicates binding buffer used as background control, L 
indicates starting random ssDNA pool, (n = 3). 
 
To characterize the binding of the selected aptamer candidates to PSA, 
and to determine their ability to discriminate between different targets such as 
BSA or Streptavidin, SPR was used (Figure 5.9). The binding capacities of 
selected aptamer candidates to PSA obtained from SPR were similar to those 
obtained from RLAA. In terms of specificity, higher affinities to BSA were 
observed in SELEX F, where BSA was present in the binding buffer, and 
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similarly in SELEX J, where higher affinities to Streptavidin were observed. It 
should be noted that sequences with similar secondary structures showed similar 
affinities and specificity to BSA (F3, F5, F8) or to Streptavidin (J9, J12). It may 
simply be a coincidence that several aptamer candidates with comparable 
specificities and affinities have similar 2D structures. Moreover, aptamers often 
contain non-canonical base pairing which is not accounted for in 2D structure 
prediction programs such as M-fold [6]. The possible selection of aptamers 
against BSA or Streptavidin is not so surprising, as both proteins seem to be 
ideal targets for aptamer selection [29, 49-51]. The aptamer candidates with the 
highest specificity to PSA and the lowest nonspecific binding to other proteins 
were sequences obtained from SELEX I (I1, I4). 
  















 PSA    Streptavidin    BSA
 
Figure 5.9 SPR experiments showing the specificity and cross-
reactivity of selected aptamer candidates, n = 2. 
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Aptamer truncation was carried out to define the part of the sequence 
that is essential for binding as well as to obtain shorter and better binders for 
possible future applications. Since sample I1 and I4 (Figure 5.10) showed the 
lowest unspecific binding, these aptamer candidates were truncated by removing 
fixed primer regions (Table 5.4).  
 
               
 
               I 1 ∆G = -7,8                                      I 4 ∆G = -9,5 
 
Figure 5.10 Predicted secondary structure for aptamer candidates I1 and I4 ∆G 
indicates the predicted free energy of secondary structure formation given in 
kcal/mol.  
          
Table 5.4 Sequences I1 and I4 and truncated variants with the appropriate length 
and the predicted free energy of secondary structure formation (∆G) 
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I4c TAAGGTATGCACACGATATAGGGCCAGGAAGCGCAAAGAAGCAAGACAG 49 -1,3 
 
 
However, the predicted free energy of secondary formation of 
truncated sequences indicated a lower stability as compared to the full length I1 
and I4, and as expected the ability of short variants to bind to PSA was lower 
(Figure 5.11).  










Figure 5.11 Binding test of all short variants using 
SPR with PSA immobilized on the surface of the 
chip, (n = 2).   
 
 
The KD values of full length aptamer candidates, I1 and I4, were 
estimated by analyzing the binding of a range of concentrations (0.1 µM to 10 
µM) with PSA, using a one to one Langmuir binding model (Figure 5.12). The 
resulting KD were 5.8 x 10-6 M and 6.3 x 10-6 M for aptamer candidate I1 and I4, 
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respectively (Table 5.5). In many other cases, DNA aptamers selected by 
conventional SELEX strategy achieved similar affinities [52-59]. However, since 
the dissociation constant of the antibody used for the detection of PSA, had 
been reported to be 1 x 10-7 to 1 x 10-10 M, the DNA aptamers with affinities in 




Figure 5.12 SPR Sensogram for aptamer candidate I1 using range of 





Table 5.5 Dissociation constants obtained in Biacore with relevant 
statistics of the aptamer candidates obtained. 
 
Aptamer Model KD (µM) χ2* 
I1 Langmuir Binding 5.8  1.145 
I4 Langmuir Binding 6.3  1.265 
*The Chi2 value is a standard statistical measure of the closeness of fit of data to the model used 
for elucidation of the KD, where for good fitting to ideal data, χ2 is of the same order of 
magnitude as the noise in RU, typically <2. 
 
 
Aptamer I1 was subsequently used in competitive RLAA assay for the 
quantitative detection of PSA in order to evaluate the functionality of aptamer 
candidate I1. PSA was immobilised on a microtiter plate competing with PSA 
analyte in solution for binding to the aptamer candidate I1, where similarly to a 
competitive ELISA format, in the presence of higher concentrations of PSA 
analyte, less aptamer bound to the immobilised PSA, resulting in a lower signal. 
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A calibration curve between 32 nM and 33 µM (0,001 – 1mg/ml) of PSA was 
obtained (Figure 5.13), with r2 0.993,  EC50  5.6 µM and LOD of 268 nM 
demonstrating the possible functionality of the aptamer candidate I1. 
Nevertheless, similar response was observed also in case of control 
proteins (BSA, Streptavidin) which were used at the same concentration range 
(Figure 5.14). Results obtained from RLAA assay showed that the low 
specificity which aptamer I1 exhibit does not meet the requirement for its use as 
molecular recognition element. 
 




































Figure 5.13 Detection of PSA by competitive RLAA 
assay using aptamer candidate I1, with relevant 




LOD 268 nM (8,6 µg/ml) 
EC50 5,6 µM (168 µg/ml) 
R2 0,993 
Replicates 3 
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Figure 5.14 RLAA assay with PSA and control proteins 
(streptavidin, BSA), n=3.  
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Variations of protocols used to select DNA aptamers differed in the 
partitioning methodology, generation of ssDNA, starting random library and 
buffer compositions. Several aptamer candidates that exhibited ability to bind to 
PSA were identified, however all aptamer candidates showed high cross-
reactivity with control proteins (BSA, streptavidin). Aptamer I1 and I4, with 
dissociation constant in low µM range, showed the lowest cross-reactivity with 
control proteins. For the evaluation of the functionality of aptamer I1, a 
competitive RLAA with different concentrations of PSA was used achieving the 
limit of detection 268 nM. However, the low specificity of selected aptamer 
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Despite a chemical structure that is similar to DNA, RNA adopts two- and 
three-dimensional conformations that are more complex than its DNA counterpart 
offering the possibility to select an RNA aptamer when DNA SELEX has failed. In 
terms of affinity and specificity, there is no difference between RNA and DNA 
aptamers, but DNA aptamers are inherently more stable. Nevertheless the stability 
problem of RNA can be overcome by specific modifications that greatly increase 
the stability of RNA allowing them comparable, or even improved stability as 
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6.1.1 RNA based SELEX  
 
For the selection for RNA aptamers, the random DNA library has to be 
transformed into a RNA library before starting the first round of the selection 
process. A special forward primer with an extension at the 5´end containing a T7 
promoter sequence and normal reverse primer are necessary to convert the ss-
DNA library into a ds-DNA library by PCR. The ds-DNA is then in vitro 
transcribed by the T7 RNA polymerase resulting in a randomized RNA library, 
which can be used to start RNA SELEX. During the SELEX process, a 
randomized RNA pool is incubated with the target of interest (i), RNA bound to 
the target is separated from the rest of the library (ii) and eluted (iii). Eluted RNA 
has to be reverse transcribed (iv) and amplified with special forward primer as 
described above (v). The new RNA pool is then generated by in vitro transcription 
(vi), remaining DNA is hydrolyzed using DNAse (vii), resulting RNA is purified 
(viii) and can be used for the next round of the selection process (Figure 6.1).  
 
 
Figure 6.1 Schematic of RNA based selection process. 
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6.1.2 Modifications of RNA aptamers 
 
The susceptibility of RNA to enzymatic degradation can be overcome by 
modifying the 2’ position of the ribose ring in the RNA backbone. The most used 
modified nucleotides use 2’-amino and 2’-fluoro or 2-O alkyl groups [1]. However, 
the incorporation of modified nucleotides may render them not to be recognized 
and processed by the T7 RNA polymerase. This can be solved by using  2- amino 
or 2- fluoro modified CTP and UTP, as it has been shown that modified 
pyrimidines can be incorporated by a special type of T7 RNA polymerase [2-4].   
 Alternatively, it is possible to introduce similar chemical modifications at the 
end of SELEX process. Moreover, modifications added at 3´ and 5´ ends of 
oligonucleotides such as amine, phosphate, phosphotiothate, cholesterol, fatty acids 
etc., protect oligonucleotides from exonucleases [5-7]. However, these 
modifications may result in a change of aptamer affinity and specificity.  
 Furthermore, aptamers can be easily modified for desired applications to 
increase the stability or to regulate their in vivo function. Using analogues of natural 
nucleotides that bear photolabile groups, aptamer can be modified and activity of 
the aptamer can be regulated by light irradiation [8-9].  
  Spiegelmers, whose name was coined from German word for mirror, spiegel, 
offer an interesting alternative route to produce nuclease-resistant aptamers. 
Spiegelmers are mirror-images of aptamers, composed of L-ribose or L-
2´deoxyribose, that bind specifically to a target, but are not recognized by 
ribonucleases, the chiral inversion leading to high biological stability and long 
lifetime [10-11]. Spiegelmers are produced using a mirror-image SELEX procedure. 
Since RNA and DNA polymerases are not able to carry out polymerization of L-
nucleotides, selection is performed using original D-oligonucleotides that are 
selected against synthetic enantiomers of a chosen target. It is accepted that 
spiegelmers do not hybridize with nucleic acids of natural configuration and it has 
been shown that spiegelmers show the same high affinity for targets as their 
aptamer analogues [12]. These favourable properties led to the identification of 
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several spiegelmers that bind to various target molecules [12-17]. Moreover, as they 
are chemically and structurally similar to D-oligonucleotides, they induce minimal 
immunogenic response [18], making spiegelmers ideal candidates for in vitro and in 




6.1.3 Automated SELEX 
 
 The in vitro selection process in practice is repetitive, time-consuming and 
not always applicable for high-throughput selections. To overcome these 
limitations the SELEX process has been automated, handling multiple targets 
efficiently since they are processed in parallel [20]. The first robotic work station 
was a modified Beckam Biomek 2000 pipetting robot in which a PCR thermal 
cycler, a magnetic bead separator, reagent trays and a pipette tip station were 
integrated [21]. The automated selection was later further optimized, substituting 
the magnetic separator by more efficient vacuum-filtering [22]. The new protocol 
was applied to the generation of anti-protein aptamers in a matter of days, and the 
automated selection was demonstrated through the selection of an anti-lysosyme 
aptamer that functions as an efficient inhibitor of cell lysis. This automated 
selection was successful in developing aptamers towards proteins such as CYT-18, 
MEK1 and Rho with dissociation constants in the pico- to nanomolar range [23], 
against proteins that had been transcribed and translated directly on the robotic 
workstation [24], and against the mirror image configuration (Spiegelmer) of 
substance P [20]. The prototype of a microfluidic, microline-based assembly that 
uses Labview-controlled actuable valves and a PCR machine has also been reported 
for the selection and synthesis of an anti-lysozyme aptamer [25]. 
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6.1.4 Next Generation Sequencing  
 
Next generation sequencing (NexGen sequencing) technologies provide 
possibilities for global investigation of multiple genomes and transcriptomes in very 
short time frames and with much lower cost than Sanger-based sequencing 
methods.  These technologies have already been used in different technologies 
including; polymorphism discovery [26], non-coding RNA discovery [27-30], large-
scale chromatin immunoprecipitation [31], gene-expression profiling [32], mutation 
mapping and whole transcriptome analysis. Reports that demonstrate the usefulness 
of next generation sequencing in the SELEX process are also reported [33-34]. 
Currently three commercially available next-generation sequencing platforms exist 
at the forefront of the sequencing industry, the original Roche 454 platform and the 
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6.2 Objectives  
 
The main objective of this chapter was to perform 2´F modified RNA 
aptamer against Prostate Specific Antigen within the laboratory of Prof. Peter 
Stockley in the University of Leeds, UK. The chapter can be divided in four parts. 
The first part is dedicated to in vitro selection process performed on a Biomek 2000 
laboratory automation workstation. The second part deals with sequencing and 
characterization of selected aptamer candidates, and the third part details binding 
studies of the aptamer candidates and finally the last part outlines the potential use 
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2´F modified CTP and UTP were supplied from TRI-LINK 
BioTechnologies (USA). TEMED, APS, spermidine were purchased from Sigma-
Aldrich (Spain). QIAgen PCR up kit was obtained from Qiagen (Spain). RNA 
3´end Biotinylation Kit, and Sulfo LC Biotin linker from Thermofisher (Spain). 
PSA substrate was supplied from Bionova (Spain), and RNA Clean from IZASA 
(Spain). Binding and Washing buffer (B&W) is composed of PBS buffer 
containning 3 mM MgCl2.  
 
 
6.3.2 In Vitro Selection  
  
6.3.2.1        Generation of starting RNA pool 
 
A synthetic ssDNA library (Library III) was used for generating dsDNA 
pool using reverse primers (R_3), and forward primer containing T7 promotor 
sequence (F_3_T7) as described previously (Chapter 3.3.2.3). The efficiency of 
PCR was assessed on a 10 % (w/v) DNA polyacrylamide gel. The gel was 
composed from 35 ml of 10 % (w/v) acrylamide (29:1 acrylamide: biscarylamide) in 
1 X TBE buffer with 500 µl 10 % (w/v) APS, and 50 µl TEMED. The samples 
were thoroughly mixed with 6 x loading buffer and loaded into separate wells. A 10 
bp DNA ladder was used as a size marker. The gel was run in 1 x TBE at 300 V for 
45 minutes. The gel was stained with ethidium bromide 1 µg/ml in 1 x TBE buffer 
for 5 minutes and then viewed and photographed under UV light. In vitro 
transcription reactions were carried out using the starting ds-DNA pool as a 
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template. Each reaction was set up by mixing 5 µl of 10 x transcription buffer (400 
mM Tris HCl pH7.9, 260 mM MgCl2, 0.1% (v/v) Tritor X-100, 25 mM 
spermidine), 2,5 µl 100 mM 2´F modified NTP mix, 0,05 Units YIP, 2 µl 100 mM 
DTT, 100 Units T7 RNA polymerase, 10 µl template DNA and R- water (to 50 µl 
final volume). The samples were thoroughly mixed and incubated at 37° C for 2 
hours. Transcripts were treated with DNase (5 units DNse, 5 µl of 10 X buffer, and 
45 µl of template) and purified with RNA clean kit according to the manufacturer´s 
instructions. A sample of the clean transcript was analysed on a 10% denaturing 
polyacrylamide gel. In this case, 35 ml of 10 % (w/v) acrylamide (19:1 
acrylamide:bisacrylamide) in 1 x TBE with 7.5 M urea, with 200 µl 10 % (w/v) APS, 
and 20 µl TEMED were used to analyze RNA samples. A prepared gel was run in 1 
x TBE at 15 watts for 30 minutes before loading to allow the gel temperature to 
reach 40° C. Samples were thoroughly mixed with an equal volume of formamide 
loading buffer and heated to 95°C for 3 minutes before loading.  A 10 bp DNA 
ladder was used as a size marker. The gel was then run for 45 minutes, and then 
stained and analyzed as described above.  
 
 
6.3.2.2              Automated in vitro selection 
 
 In vitro selection was performed using a Biomek 2000 workstation, using 
magnetic beads as the partitioning method. PSA was biotinylated using EZ-Linker 
sulfo-NHS-biotin linker and immobilized on the surface of streptavidin coated 
magnetic beads as described before (Chapter 2.3.3.5). Twenty microliters of PSA 
bound streptavidin coated beads (approximately 65 pmol of PSA) were added to 80 
µl of B&W buffer and mixed. Fifty microliters of the starting RNA pool (around 
750 pmol) which had been preincubated with the magnetic beads (bare), in order to 
remove nonspecific binders, was then added and incubated at 37° C for 30 minutes. 
Mixing was repeated every 5 minutes to prevent the beads settling out. Following 
the incubation, the beads were magnetically separated. Buffer and unbound RNA 
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species were removed by slow aspiration from the bottom of the eppendorf. The 
magnetic beads were washed several times in 1 ml of B&W buffer. Finally bound 
RNA species were resuspended in 30 µl nuclease free water, incubated at 95°C for 
15 minutes, and eluted. The eluted RNA was reverse transcribed by adding 10 µl 
RT buffer, 1 µl of 100 µM reverse primer, 2 µl 10 mM dNTP mix, 10 units of  
reverse transcriptase and water to a final volume of 50 µl. This was thoroughly 
mixed and incubated at 52°C for 2 hours. The resulting DNA template was 
amplified and analyzed as described previously (Chapter 3.3.2), and used as the 
template for the subsequent round. PAGE was used to assess the success of the 
RT-PCR at the end of each selection round.  
 
 
6.3.2.3  Pull down assays 
  
In the pull-down assay (Figure 6.2), free biotinylated PSA (30 pmol) was 
incubated with RNA pool (300 pmol) in 100 µl of binding buffer at 37° C for 30 
minutes. Following incubation, the RNA-PSA complex was immobilized on the 
surface of magnetic beads. Following the immobilization, the RNA-PSA bead 
complex was washed several times in 1 ml of B&W buffer and unbound RNA was 
removed.  RNA bound to PSA was eluted, amplified, and analysed by PAGE as 
described above. Negative selection with naked beads was performed prior to the 
incubation of RNA with biotinylated PSA, in order to remove surface binders. 
 
 
Figure 6.2 Schematic of pull down assay. 
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6.3.3 Cloning & Sequencing 
 
Samples for NexGen sequencing were prepared by taking the enriched 
pool obtained at the end of the SELEX process. The enriched pool was PCR 
amplified using short forward primer (which lacks the T7 promoter) and the 
reverse primer. The resulting PCR product was purified using the QIAgen PCR up 
kit, checked on Bioanalyzer and used for sequencing. For standard cloning and 
sequencing processes protocols were used as described previously in Chapter 5 
(section 5.3.5).   
 
 
6.3.4 Binding studies 
 
Surface plasmon resonance (SPR) binding studies were performed with a 
BIAcore 3000 (Biacore Inc.). The protein of interest (PSA, and control proteins 
such as streptavidin, and BSA) were immobilized on separate channels of a CM 5 
sensor chip activated with EDC/NHS (30 µl of a 1:1 mixture of EDC (400 mM) 
and NHS (100 mM) followed by injection of 200 µg/ml (6,7 µM) protein at a flow 
rate of 5 µl/min. After immobilization of the proteins, unreacted NHS esters were 
deactivated via injection of an excess of ethanolamine hydrochloride (1M). 
Unbound proteins were then washed from the surface with 100 mM NaOH. The 
aptamer candidates were diluted to a final concentration of 1 µM in binding buffer 
and injected during 6 minutes at a flow rate of 5 µl/min followed by 3 min 
stabilization time and 10 minutes dissociation time. The binding of DNA was 
analyzed through corresponding changes in the refractive index of optical signals, 
and expressed as resonance units (RU). All reagents and buffers were previously 
filtered and dissolved in MilliQ water.  
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6.3.5 Apta PCR 
 
A range of PSA concentrations (1, 5, 10 µg/ml) diluted in 50 mM 
carbonate buffer, pH 9.6 were incubated on a microtiter plate for 1 hour, followed 
by 1 hour blocking with PBS-Tween. After the washing step, selected aptamer 
candidates (200 nM) were added to each well and incubated for 30 minutes at 25°C 
in the presence of 3 µg/ml of salmon sperm. Finally, after the last washing step, 
MilliQ water was added to heat eluted aptamer.  
 
6.3.6 Competitive Apta PCR 
 
PSA (10 µg/ml) was immobilized on a microtiter plate in 50 mM carbonate 
buffer, pH 9.6 for 1 hour at 37°C, followed by 1 hour blocking with PBS-Tween. 
The plates were then manually washed three times with PBS-Tween. In individual 
eppendorf tubes, serial dilutions of PSA ranging from 2.6 pM – 8.3 µM (80 pg/ml -
250 µg/ml) were incubated with 100 nM of aptamer candidate S2 in binding buffer 
for 30 minutes at 25°C in the presence of 3 µg/ml salmon sperm. Following the 
final washing step performed with binding buffer, MilliQ water was added, and the 
aptamer heat-eluted. Eluted RNA molecules were reverse transcribed and amplified 
using a 1-step protocol with Power Sybr Green RNA-to-Ct (Applied Biosystems, 
Spain) according to the manufacturer’s instructions.  
 
 
6.3.7 Stability studies of selected aptamers 
 
Aptamers at a concentration of 500 nM were incubated in 80% human 
serum at 37°C for periods of up to 48 hours. Following incubation, all samples 
were diluted in PBS buffer and purified with the RNA clean kit according to the 
manufacturer´s instructions. Purified aptamers were run on 4% (w/v) agarose gel 
and analysed with Image J software.  
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6.3.8 PSA activity assays 
 
PSA was incubated with aptamer candidates at equal concentrations (1µM) 
in selection buffer for 2 hours prior to addition of fluorogenic substrate. Substrates 
were diluted to a final concentration of 400 μM. The hydrolysis of the substrate by 
PSA was measured with a spectrofluorimeter (Cary Eclipse, Varian), using an 
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6.4 Results and Discussion 
 
 
6.4.1 In vitro selection process  
 
A DNA library III with a random sequence of 50 nt was used for in vitro 
transcription by amplifying it with a long forward primer bearing T7 promotor and 
reverse primer (Figure 6.3). Modification of RNA library was performed by 
introducing 2´F modified CTP and UTP into the in vitro transcription reaction.  
 
 
Figure 6.3 Diagramatic representation of the 3 oligos used to generate the dsDNA pool of 
library III. The sequence shown in red indicates the T7RNA polymerase binding site. 
 
 
The in vitro selection process was performed utilizing a Biomek 2000 
automated workstation (Beckman Coulter) based upon protocols previously 
described by Cox [24] and optimized by Bunka [35]. This automated system was 
then used with PSA as the target in 10 rounds of in vitro selection with 2´F modified 
RNA library. Selection was carried out using buffer conditions and temperature 
appropriate for PSA activity and taking into account the possible application of 
RNA aptamers. The negative selection was carried out by incubating 2´F modified 
RNA library with underivatized bare streptavidin coated beads in the absence of 
PSA. Samples from the reverse transcriptase - PCR products were taken at the end 
of each round and analyzed by native PAGE to confirm the isolation of products 
for the next round of selection (Figure 6.4).  
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Figure 6.4 PAGE analysis of RT-PCR products from 10 selection rounds performed on 
automated workstation. L – 10bp ladder, 1-11 selection rounds (round 6 was perdformed manually using pull down 
assays), C – non template control. *The intensity of band obtained from first round during automated SELEX is more intense due to 





6.4.2 Pull down assays  
 
The in vitro selection process was separated in two parts, and the automated 
part of the selection was performed using the Biomek Workstation 2000 and the 
pull down assays were performed manually with the aim of increasing selection 
stringency. In the pull down assays, 2´F modified RNA pool was incubated with 
free biotinylated PSA in solution before the capture and immobilization of formed 
complex onto streptavidin coated beads. The advantage of this method is the 
incubation of RNA with PSA free in solution, overcoming problems due to protein 
immobilization, which can destroy key features of some aptatopes as well as reduce 
the mobility of the PSA. The 2´F modified RNA pool obtained at the end of 5th 
round of SELEX was compared with the starting pool of 2´F modified RNA 
(Figure 6.5). 
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Figure 6.5 Fraction of 2´F modified RNA obtained using starting random pool (Round 0) and 
5th round (Round 6) of SELEX in pull down assay. The columns indicate the amount of RNA eluted and 
amplified in the negative selection step in the absence of PSA, after washing steps, and in the selection step with PSA. 
The amount of RNA is represented by the intensity of ds-DNA bands obtained by native PAGE gel.  
 
 
 The analysis of band intensities from the native PAGE gel clearly shows 
the difference between the starting RNA pool and the enriched pool obtained at 
the end of the 6th round of SELEX performed by pull down assay. In the starting 
RNA pool a higher amount of RNA bound to the streptavidin beads and lower 
amount in the selection step with PSA coupled beads is observed, whilst in the 6th 
round, more RNA is bound in the selection step. Similarly, pull down assays were 
performed in the 11th, 12th, and 13th rounds of SELEX.  
 
 
6.4.3 Monitoring of evolution using pull down assays 
 
The amount of RNA obtained in both the pre-selection and selection 
procedures using pull down assays in round 0, 6, 11, 12, and 13 were used to 
monitor the evolution of the SELEX process, and Figure 6.6 shows the increasing 
amount of RNA bound to PSA. Since there was no significant increase in cycle 13, 
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the SELEX was assumed to have reached completion. There was no obvious 
increase of RNA bound in the negative selection step.  
 































Figure 6.6 Fraction of 2´F modified RNA obtained in different rounds of SELEX. The columns 
indicate the amount of RNA eluted and amplified in the pre-selection step in absence of PSA, after washing steps, and 
in selection step with PSA. The amount of RNA is represented by the intensity of ds-DNA bands obtained by native 
PAGE gel.  
 
 
6.4.4 Cloning and Sequencing process 
 
The enriched pool of 2´F modified RNA library obtained from round 13 
was used for NexGen sequencing. Unfortunately, the major fraction of sequences 
obtained from NexGen sequencing was composed from parts of primers, 
indicating some problems in the preparation of the sample or during the 
sequencing process (Figure 6.7).  
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Figure 6.7 The frequency of selected sequences obtained from NexGen sequencing. P1-P11 
present sequences composed from parts of primers with different length, R1-R4 sequences containing random region.  
 
 
Nevertheless, from the analysis of all sequences, 4 different variants 
containing a random region from 37 to 40 nt was found. In Table 6.1 the final 
length of aptamer candidates which differ from the original 94 nt pool RNAs and 
the frequency of individual variants, is summarized.  
 
Table 6.1 Sequences obtained from NexGen sequencing. 
 
Aptamers Number of clones Lenght (nt) 
R1 144 81 
R2 77 81 
R3 41 84 
R4 11 81 
 
Based on the sequence analysis, it was found that aptamer candidate R1 
differed from R4 only in one base (Figure 6.8), while aptamer candidates R2 and R3 
were unique sequences. 
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  R1           (144) CGAGUUUUGAACCGCGUAAUAAAACAUUCCUCAUUUG 
  R4           (11)   CGAGUUCUGAACCGCGUAAUAAAACAUUCCUCAUUUG 
 
Figure 6.8 Sequences of aptamer candidates R1 and R4. The frequency 
of individual sequence is written in parentheses. 
 
 
Due to the problems in NexGen sequencing, the enriched library was cloned 
and sequenced again as described previously in Chapter 5. 48 individual clones were 
obtained, which revealed 22 different sequences (Table 6.2). The lengths of the 
majority of sequences were the same as the original 94 nt pool of RNAs, however 
some of the sequences were shorter, as had been observed with the NexGen 
sequencing.  
 
 Table 6.2 Sequence obtained from Sanger sequencing. 
 
Aptamers Number of clones Length (nt) 
S1 7 84 
S2 6 84 
S3 3 94 
S4-S6 2 93-94 
S7 – S22 1 91-95 
 
 
Eight sequences were represented more than once. Moreover, sequence S1 
which appeared 7 times in second sequencing process was identical to sequence R3 
(Figure 6.9). From the sequence analysis of all aptamer candidates no obvious 
pattern was obtained.   
                
R3     (41)     UCCAGGCGCGUUAGCAAAACCGCGGAUCAAACUUAGUUGA 
 S1     (7)      UCCAGGCGCGUUAGCAAAACCGCGGAUCAAACUUAGUUGA 
 
Figure 6.9 Sequences of aptamer candidates R3 and S1. The frequency of 
individual sequence is written in parentheses. 
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6.4.5 Binding analysis  
 
The binding capacities of all unique aptamer candidates for PSA were 
examined in a screening manner using SPR and BIACORE (Figure 6.10). Ten 
different sequences displayed higher binding abilities to PSA compared to the 
starting library and the background control. Significant binding was observed for 
sequences R1, R2, R3, and S2.  
 














Figure 6.10 SPR experiments showing the specificity and cross-reactivity of 
selected aptamer candidates (1 µM), n = 2. 
 
 
The signal observed in the control channels with immobilized BSA and 
streptavidin was negligible for all selected aptamers, demonstrating the high 
specificity of these aptamer candidates. Aptamer candidate S2 was passed through 
the channels at 10 µM in order to confirm the specificity of aptamer in higher 
concentrations (Figure 6.11) 
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Figure 6.11 SPR Sensogram obtained for aptamer candidate S2 at 10 µM passed through the 
CM 5. Biacore chip surface showing the interaction with the immobilized target (Channel 2: PSA, Channel 3: BSA, 
Channel 3: Streptavidin) All sensograms were corrected for nonspecific binding and refractive index changes by 
subtracting the signals of an equivalent aptamer injection across the underivatized flow cell (Channel 1).  
 
 
The secondary structure of the selected aptamer candidates R1, R2, R3 and 
S2 (Table 6.3) was predicted using the online program M-fold for RNA folding 
(Figure 6.12). According to the proposed secondary structures, all four variants 
could be folded into similar loop-stem structures. The predicted free energy of 
secondary structure formation of aptamer candidates R2, R3 and S2 indicated a 
higher stability of these sequences as compared to the DNA aptamers reported in 
Chapter 5.  
 
Table 6.3 Sequences R1, R2, R3, and S2 with the appropriate length and the predicted free 
energy of secondary structure formation (∆G). 
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                  R1 ∆G = -7,5                   R2 ∆G = -14,9 
       
         R3 ∆G = -15,7          S2 ∆G = -15,2 
 
Figure 6.12 Predicted secondary structure for aptamer candidates R1, R2, R3, and S2, ∆G 
indicates the predicted free energy of secondary structure formation given in kcal/mol.  
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The dissociation constant (KD) of aptamer candidate R3 and S2 was 
estimated by analyzing the binding of a range of concentrations (50 nM to 1 µM) 
with PSA, using a one to one Langmuir binding model (Figure 6.13). The resulting 
KD were 8,7 x 10-7 M, and 6,3 x 10-7 M for aptamer candidates R3 and S2, 
respectively, and a good fit to the model was obtained (Table 6.4). 
 
 
Figure 6.13 SPR sensogram for aptamer candidate S2 using range of concentrations (50 
nM - 1 µM).    
 
 
Table 6.4 Dissociation constants obtained in Biacore with relevant statistics of the 
aptamer candidates obtained.   
 
Aptamer Model KD (nM) χ2* 
R3 Langmuir Binding 870  0,776 
S2 Langmuir Binding 630 0,943 
*The Chi2 value is a standard statistical measure of the closeness of fit of data to the model used for 
elucidation of the KD, where for good fitting to ideal data, χ2 is of the same order of magnitude as 
the noise in RU, typically <2. 
 
 
6.4.6 Development of apta-PCR assay  
 
A development of real-time apta-PCR for the ultrasensitive detection of 
thrombin has been reported previously [36]. In apta-PCR the aptamer acts not only 
as a biomolecular recognition element, but also as a label for amplification via real-
time PCR. The use of the aptamer itself as the reporter molecule eliminates the 
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necessity of laborious labeling, which is particularly atractive in the case of modified 
RNA aptamers.  
The aptamer candidates R3 and S2 were tested for their ability to bind to 
PSA adsorbed on a microtiter plate. Three different concentrations of PSA were 
immobilized on the microtiter plate and incubated with aptamer candidate S2 or 
R3, and the aptamer S2 was observed to be the ligand with the highest affinity and 
specificity (Figure 6.14).    
 
































Figure 6.14 Evaluation of binding affinities and specificities of selected aptamers in 
Apta PCR assay.  
 
 
Aptamer candidate S2 was thus used to develop a competitive apta-PCR 
assay. This assay is based on immobilization of PSA on the microtiter plate, which 
competes with PSA free in solution for the binding to the aptamer. After the 
incubation step, the captured RNA aptamer is reverse transcribed and amplified 
using qPCR. A calibration curve between 2.6 pM to 8.3 µM (80 pg/ml – 250 
µg/ml) was obtained, with r2   0.994 and EC50 value of 596 nM (Figure 6.15). The 
limit of detection (LOD) 11 nM (0,329 µg/ml) obtained from the apta-PCR assay is 
lower in comparison to the previously published DNA aptamer selected against 
PSA (pDNA aptamer) [37], which had a LOD above 40 nM (1.23 µg/ml). In 
comparison to anti PSA antibodies which can achieve LOD around 1-500 pg/ml 
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[38-40], the LOD of aptamer S2 is several order of magnitude higher and does not 
meet the requirement for diagnosing prostate cancer.   
 




































Figure 6.15 Detection of PSA by apta-PCR assay 
using aptamer candidate S2, with relevant statistics 
obtained (n=3).  
 
 
6.4.7 Clinical potential of 2´F modified RNA aptamers  
 
6.4.7.1 Stability of aptamers S2 and R3 in human serum 
 
A prerequisite for a potential therapeutic use of the aptamers is a reasonable 
stability in human serum. In contrast to unmodified RNA, which is easily degraded 
in biological fluids, 2´F modified RNA is much more stable. To test the stability of 
aptamer S2 in human serum, stability assays were carried out incubating the 
FIT VALUES 
LOD 11 nM (0,329  µg/ml) 
EC50 596  nM (17.88  µg/ml) 
R2 0,994 
Replicates 3 
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aptamer S2 and R3 in human serum for up to 48 hours (Figure 6.16, a, b). The 
starting 2´F modified RNA pool used for the SELEX was also tested (Figure 6.16, 
c) as well as pDNA aptamer (Figure 6.16, d) and unmodified RNA aptamer (pRNA 
aptamer) selected against active PSA [41]  (Figure 6.16, e).  
 
(a)              (b)  
         
 
(c)                 (d)  
                
 
        (e) 
      
 
Figure 6.16 Stability of aptamer S2 (a), R3 (b), starting pool of 2´F modified 
library (c), pDNA aptamer (d), pRNA aptamer (e) in human serum. 
 
 
The incubation of aptamer S2 and R3 in human serum showed no evidence of 
degradation after 6 hours of incubation. Only partial degradation was observed 
after 12 and 24 hours. Even after 48 hours of incubation, the aptamer could still be 
detected on the gel. Similarly, the starting pool of 2´F modified library showed 
comparable stability. The stability of pDNA aptamer was not as high as that of the 
2´F modified RNA aptamers, but was much higher than that of pRNA aptamer, 
which degraded rapidly in human serum.   
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6.4.7.2 Aptamers as modulators of PSA activity 
 
 
The effect of aptamers R3 and S2 and previously published PSA aptamers 
(pDNA[37], pRNA[41]) on the activity of PSA was studied using a synthetic PSA 
substrate (Figure 6.17). The activity of PSA was moderated in the presence of the 
selected RNA aptamers R3 and S2, whereas the starting RNA pool, pDNA, and 
pRNA had almost no effect at same concentrations. To analyze the potential of 
aptamer S2 to moderate the PSA activity, the activity of PSA was studied in the 
presence of increasing concentrations of aptamer S2 (Figure 6.18). PSA activity was 
moderated by aptamer S2 achieving 60% of the initial activity in high 
concentrations.  


















 0 µM       1 µM
 
Figure 6.17 Inhibition of PSA activity by aptamer candidates S2, R3 starting random RNA 
pool, and published PSA aptamers (pDNA, pRNA), n = 3. 
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RNA based SELEX for a PSA target was successfully performed on an 
automated Biomek 2000 workstation, achieving aptamers with dissociation 
constants in the nM range. Moreover, the final aptamers could distinguish PSA 
from other proteins, such as streptavidin or BSA highlighting their high specificity. 
The potential use of the selected aptamers in diagnostic and therapeutic 
applications was studied.  In order to demonstrate the functionality of the selected 
2´F modified aptamers, apta-PCR was developed for the quantitative detection of 
PSA. The limit of detection of aptamer S2 was found to be 11 nM, improving the 
limit of detection achieved by previously published DNA aptamer, but still several 
orders of magnitude higher than in case of anti PSA antibodies. Nevertheless, we 
have demonstrated the possibility of PSA detection using selected S2 2´F modified 
aptamer and with further investigation, the aptamer S2 may be applied to clinical 
diagnostics. An alternative application is for therapeutics, to this end stability of 
selected aptamers S2 and R3 was carried out incubating aptamers in human serum 
up to 48 hours. The results demonstrated that 2´F modified aptamers are 
significantly more stable in human serum than the previously published unmodified 
RNA aptamer and slightly more stable than the previously published DNA 
aptamer. The potential use of RNA aptamers S2 and R3 in therapeutics was 
validated in PSA activity assays, where the activity of PSA was moderated in the 
presence of selected aptamers R3 and S2, whereas the starting RNA pool, pDNA, 
and pRNA had almost no effect at the same concentrations. Although the effect of 
the aptamer S2 on the activity of PSA was moderate, it may be significant for 
potential treatment of prostate cancer, as prostate cancer generally grows very 
slowly, and even a modest reduction in tumor growth rate can play some role in the 
prevention of the development of prostate cancer in diagnosed patients.  
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7 5  
7.1 Overall conclusions and outlook 
 
 
 This work overviews the selection of aptamers against prostate specific 
antigen (PSA). Fundamental aspects such as the characterization of PSA, evaluation 
of immobilization strategies, the preparation of the oligonucleotide library and 
single stranded DNA (ssDNA) have been evaluated. Finally, the selection of DNA 
and RNA based aptamers against PSA and their potential use in diagnostic and 
therapeutic applications have been described. 
The selection of aptamers depends highly on the target properties, 
therefore the characterization of PSA obtained from seminal fluid was performed 
using sodium dodecyl sulphate-polyacrylmide gel electrophoresis (SDS-PAGE) and 
Mass spectrometry (MS). A high heterogeneity of PSA was found, indicating the 
presence of different PSA isoforms comprising proPSA, intact PSA and nicked 
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form of PSA as described previously [1]. Moreover, these multiple forms of PSA 
can vary more, due to differences in carbohydrate structure [2]. The complex 
distribution of PSA leads to uncertainties in the immunological measurement of 
PSA [3] and can also cause difficulties during the selection process. A comparison 
of two different lots of PSA showed a high consistency in the proportion of PSA 
isoforms in both samples, confirming previously published results [2].  
In order to determine the best strategy for PSA immobilization, different 
techniques were evaluated, including covalent immobilization using amine, 
carboxyl, and epoxy modified beads, as well as bioaffinity immobilization with 
avidin-biotin interaction. These were studied using competitive enzyme-linked 
immunosorbent assay (ELISA) and peptide mass fingerprinting (p.m.f). The 
amount of immobilized PSA per miligram of beads was found to be similar in the 
cases of carboxyl and epoxy modified beads. Although a higher number of 
aminoacids containing carboxyl groups are available as compared to aminoacids 
containing lysines, the lowest amount of immobilized PSA was found on amine 
modified beads, probably due to the lower exposure on the surface of PSA. 
Bioaffinity immobilization with avidin-biotin was absolutely unrivaled in terms of 
the amount of immobilized PSA, achieving a two times higher PSA immobilization. 
The stability of immobilized PSA on the surface of magnetic beads was studied 
after 4 weeks of storage. In most cases, ≥ 80 % of the amount of PSA was 
obtained, indicating that the PSA coupled beads are relatively resistant to storage 
conditions. Only PSA immobilized on the epoxy beads showed a severe reduction 
of PSA to 57%. After considering all the pros and cons of the methods studied, 
two strategies including (i) amine coupling using carboxyl modified beads and (ii) 
the use of bioaffinity technique with biotin – streptavidin interaction were selected 
for their use in SELEX. Moreover, both methods had been previously used for 
immobilization of other proteins in SELEX achieving high affinity aptamers [4-6].  
Another critical point of SELEX is an oligonucleotide random library 
consisting of a multitude of ssDNA. The heterogeneity of the random library can 
cause non-uniform amplification during the PCR amplification [7], therefore the 
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choice of library, and efficient PCR amplification of the selected library can 
contribute to the success of aptamer selection. The optimisation of three different 
libraries with specific features was carried out to ensure high purity and yield of 
amplified libraries. The composition of random libraries changes during SELEX, 
therefore optimisation of the enriched libraries was also required. It was found that 
the addition of single stranded binding protein (SSB protein) to the PCR master 
mix with optimized PCR conditions could prevent smearing into a multi-sized 
population. The addition of SSB protein was previously used to increase 
amplification efficiency with a number of diverse targets achieving comparable 
results [8]. In the case of production of smaller bands that can appear during the 
SELEX process, PCR amplification performed with 3% of DMSO and 500 mM of 
Betaine helped to decrease the amount of these undesired products. These two 
substances are often used to improve PCR amplification and our results are 
consistent with those previously published [9-10].    
Aptamers can be selected from single stranded DNA (ss-DNA) or RNA 
libraries and in the case of DNA based SELEX, each round is completed by the 
generation of single stranded DNA, available for target binding in the subsequent 
round. The generation of the ss-DNA is a critical step in SELEX as the purity and 
yield can have a significant impact on the successful evolution throughout the 
SELEX process. We compared several techniques generally used for ssDNA 
generation including asymmetric PCR, lambda exonuclease digestion and magnetic 
separation, as well as a new technique which combines the highly efficient 
asymmetric PCR with enzyme digestion. Moreover, generation of ssDNA is very 
time-consuming in methods such as enzyme digestion and magnetic separation due 
to the several purification steps, including purification of PCR product and 
purification of ssDNA at the end of process. We hypothesized that yield obtained 
from unpurified PCR product should be similar to those obtained from purified 
PCR product. The efficiency of each system for the generation of ss-DNA was 
quantitatively evaluated using an enzyme linked oligonucleotide assay (ELONA) 
and the quality of the PCR product was assessed using agarose gel electrophoresis. 
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According to the results obtained from our comparison studies, all reported 
methods can be used for the generation of ss-DNA, once their disadvantages are 
clearly taken into consideration. Asymmetric PCR followed by T7 Exonuclease 
digestion was demonstrated to have the highest efficiency, achieving a final yield of 
ss-DNA around 85%. Furthermore, we have demonstrated that in methods such as 
enzyme digestion and magnetic separation with streptavidin beads when 
purification of PCR product is usually used, the yield of ssDNA obtained from 
unpurified PCR product is comparable to those obtained from purified PCR 
product, overcoming a loss of dsDNA during purification step, and thus decreasing 
the time required for each SELEX cycle.  
Having all fundamental aspects of SELEX evaluated and optimised, in vitro 
selection of DNA aptamers against PSA was performed. Variations of SELEX 
protocols were used to identify aptamers against this enzyme, as aptamer selection 
against PSA presented significant difficulties. Partitioning of bound nucleic acids 
from the unbound ones was one of these problems. Two methods, one focused on 
the use of nitrocellulose filters with the target free in solution, and another focused 
on target immobilization with modified beads were used.  The latter one was 
observed to be more effective with minimum losses of target bound sequences. 
Another problem found during the selection process was associated with the 
amplification of random libraries, and as we discussed in Chapter 3, optimization of 
enriched library with the use of specific additives could prevent incorrect 
amplification. Diverse methods of single stranded DNA generation and selected 
buffers were not observed to be critical for aptamer selection. Finally, several 
aptamer candidates that exhibited an ability to bind to PSA were identified. 
However, all the aptamer candidates showed high cross-reactivity with control 
proteins (BSA, streptavidin). Aptamer I1 and I4, with a dissociation constant in the 
low µM range, showed the lowest cross reactivity with control proteins. For the 
evaluation of the functionality of aptamer I1, a competitive RLAA with different 
concentrations of PSA was used achieving a limit of detection of 268 nM. 
Nevertheless, the low specificity of selected aptamer does not permit its use for 
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analysis. Despite the great number of publications related to the selection of 
aptamers, showing that aptamers can be routinely obtained for almost every desired 
target [11], one of the true problems of SELEX is the uncertainty of the success of 
the selection, as it impossible to judge the ability of a target molecule to be suitable 
for the selection process [12], with the success rate for homogenous targets being 
around 50% [13].  
Finally, selection of an RNA based aptamer against PSA using an automated 
SELEX process was carried out. Aptamers with dissociation constants in the nM 
range with high specificity were developed. The potential use of the selected 
aptamers for diagnostics was studied using apta-PCR, achieving a limit of detection 
of around 11 nM for aptamer S2, improving the limit of detection achieved by the 
previously published DNA aptamer for PSA, but still several orders of magnitude 
higher than the anti PSA antibodies generally used in diagnostics. Although the 
limit of detection does not meet the requirement for the use of selected aptamers 
for PSA detection in diagnostics, we have demonstrated the functionality of the 
selected aptamers. Another promising application of selected aptamer in diagnosis 
could be in vivo imaging of prostate cancer, due to the discrimination and targeting 
capacities of aptamers making them suitable imaging agents for non-invasive 
diagnostic procedures [14].  
One major hindrance to the clinical use of aptamers is their instability in 
body fluids due to the high levels of nuclease activity. However, the selected 2´F 
modified aptamers remained stable in human serum for dozens of hours, indicating 
their high resistance to nucleases. 
 Finally, the potential use of the selected RNA aptamers in therapeutics was 
evaluated in activity assays, demonstrating an inhibiting effect on the PSA activity. 
Due to the inhibition of PSA activity, the amount of several substrates related to 
cancer cell invasion and tumor growth which are cleaved by PSA could be limited 
in the early development of cancer. Recently, peptides that bind specifically to 
enzymatic active PSA and stimulate its activity was reported [15]. The stimulation 
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of PSA activity by these peptides reduced angiogenesis and could be potentially 
used at later stages of cancer therapy.  
In addition, anti PSA aptamers could be used in targeted therapy. Aptamers 
are suitable to serve as escort ligands in which the aptamer may be used to deliver 
an active drug, radionucline, toxin, or cytotoxic agent to the desired sites for 
targeted therapies [16-17]. In respect to prostate cancer, there is another well 
established and characterized aptamer A 10 selected against the prostate-specific 
membrane antigen (PSMA) [18], which is already used as a drug-delivery vehicle 
with an efficient targeting of solid tumors, leading to the reduction in the size of 
tumor  and significant reduction of prostate tumor proliferation [19-22]. Small 
interfering RNA (siRNA) has also been used to conjugate with aptamer A10 
obtaining cell specific siRNA-mediated reduction of the corresponding mRNA and 
protein levels [12, 23-24]. 
 To conclude, since the first description of aptamers in 1990, considerable 
progress has been made in the field of aptamer technology. The characteristics of 
aptamers make them promising tools for diagnostic applications, where aptamers 
could be an alternative to antibodies. Recently, new technology platform using 
SOMAmers (Slow Off-rate Modified Aptamers) to accurately screen dozens of 
patient samples simultaneously has been reported [29], allowing quantification of 
many specific proteins in a multiplexed, high-throughput manner. The company 
SomaLogic has thus far validated SOMAmers to a broad array of over 1000 
different protein targets for use in biomarker discovery, diagnostics, and drug 
discovery and development. In therapeutics, there are many aptamers selected 
against a large variety of targets that play crucial roles in several diseases showing 
the potential use of aptamers in therapy. Aptamers have been used to deliver 
therapeutic agents to cells or tissues, showing their inmense potential as they are 
relatively small and can easily penetrate tissues [25]. However, the in case of 
intracellular target proteins, the application of aptamers is limited due to their 
negative charge that will not easily cross cellular membranes [11]. However, recent 
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developments have demonstrated the possibility to transfer the functional 
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  For the potential use of the selected aptamers in further applications, there 
are still several parameters and issues that need to be investigated, starting with the 
elucidation of the two and three-dimensional structures of the selected RNA 
aptamers, and truncation studies, which often leads to an improvement in detection 
limits. A selection experiment employing a partially randomized pool based on the 
already selected aptamers could also be used in order to improve the affinity of 
aptamers towards the low nanomolar or even picomolar range [28]. Another 
possibility would be use of new alternative SELEX strategies with higher 
partitioning efficiency which could lead to higher affinity aptamers. In case of a 
complicated target, where selection of “normal” aptamers is not successful, there 
exists the possibility to use libraries which bear dU residues that are uniformly 
functionalized at the 5-position with moieties (e.g. benzyl, 2-napthyl, or 3-indolyl-
carboxamide) and can participate in interactions with target molecules, as well as 
form novel secondary and tertiary motifs [29]. Selection of aptamers immobilizing 
the PSA via amine groups could be another option to see whether the orientation 
of immobilized PSA can affect the selection of aptamers.  
The evaluation of external factors that can affect aptamer-PSA interaction 
should be assessed to see if the limit of detection could be improved as well as the 
use of aptamers in different assay formats to test the flexibility, adaptability and 
limitations of the selected aptamers. Among other factors, the effect of changes in 
temperature, pH, and composition of ions as well as immobilisation/modification 
strategy and binding efficiency should be studied. This information will be of 
immense importance in the development of for example, a molecular beacon 
format.  
The specificity of the DNA aptamers could be improved by incorporating 
counter SELEX, which is established in order to obtain aptamers with stronger 
specificity. The aptamers´ selectivity could be improved by excluding ssDNA with 
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coaffinity to BSA, Streptavidin. In the case of the selected 2´F modified RNA 
aptamers, the specificity of selected aptamers should be further investigated using 
proteins with higher similarities to PSA such as human kallikrein 2 (hK2) or 
proteins present in human serum to be sure that the selected aptamers do not 
interact with other serum proteins. Human kallikrein 2 with approximately 80% of 
sequence homology is particularly important as hK2 activates and regulates the 
activity of PSA.  
  Moreover, the effect of 2´F modified RNA aptamers on the activity of PSA 
should be investigated in more detail using different PSA substrates and 
combination of selected aptamers, or a combination of anti-PSA aptamers with 
anti-PSA antibodies to see if the inhibitory effect can be improved. The effect of 
aptamers on the PSA activity will be also studied using human serum as the 
inhibition effect that the selected aptamers exhibit may be different in other buffer 
conditions.   
 It would be also interesting to study which specific sites on the target surface 
(aptatopes) are recognized by the selected aptamers. The similar secondary 
structures of the 2´F modified aptamers S2 and R3 suggest that both aptamers bind 
to one single aptatope on PSA. Analysis of numerous protein SELEX experiments 
shows that during the selection, one aptatope of a protein is dominant even in the 
presence of many other potential sites for aptamer binding [30]. However, the 
existence of a dominant aptatope of a protein target does not exclude selection of 
ligands that bind to other sites [31].  Competition assays with different types of 
anti-PSA antibodies that recognize different epitopes on the surface of PSA could 
be used to determine binding site specific for selected aptamers. 
To conclude, the main contribution of this thesis is the optimization of 
several critical points in the aptamer selection process. The comparison between 
different methods showing the benefits as well as limitations of many protocols 
described in the literature will serve to guide future research that would improve the 
knowledge gained in the field of aptamer selection. 
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